htgc-10q_20200930.htm

Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter periods that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§ 232.405 of this Chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☐ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer”, “smaller reporting company,” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

On October 22, 2020, there were 114,616,652 shares outstanding of the Registrant’s common stock, $0.001 par value.

In this Quarterly Report, the “Company,” “Hercules,” “we,” “us” and “our” refer to Hercules Capital, Inc. and its wholly owned subsidiaries and its affiliated securitization trusts, unless the context otherwise requires.

	September 30, 2020			December 31, 2019
Assets
Investments:
Non-control/Non-affiliate investments (cost of $2,352,003 and $2,248,524, respectively)	$	2,355,935		$	2,232,972
Control investments (cost of $65,242 and $65,333, respectively)		55,092			59,746
Affiliate investments (cost of $88,584 and $88,175, respectively)		9,800			21,808
Total investments in securities, at value (cost of $2,505,829 and $2,402,032, respectively)		2,420,827			2,314,526
Cash and cash equivalents		27,554			64,393
Restricted cash		20,507			50,603
Interest receivable		19,506			20,207
Right of use asset		9,884			11,659
Other assets		5,723			580
Total assets	$	2,504,001		$	2,461,968

Liabilities
Accounts payable and accrued liabilities	$	28,782		$	30,306
Operating lease liability		9,753			11,538
SBA Debentures, net (principal of $99,000 and $149,000, respectively) ⁽¹⁾		98,668			148,165
2022 Notes, net (principal of $150,000 and $150,000, respectively) ⁽¹⁾		148,907			148,514
July 2024 Notes, net (principal of $105,000 and $105,000, respectively) ⁽¹⁾		103,869			103,685
February 2025 Notes, net (principal of $50,000 and $0, respectively) ⁽¹⁾		49,493			—
2025 Notes, net (principal of $75,000 and $75,000, respectively) ⁽¹⁾		73,256			72,970
June 2025 Notes, net (principal of $70,000 and $0, respectively) ⁽¹⁾		69,233			—
2033 Notes, net (principal of $40,000 and $40,000, respectively) ⁽¹⁾		38,582			38,501
2027 Asset-Backed Notes, net (principal of $200,000 and $200,000, respectively) ⁽¹⁾		197,521			197,312
2028 Asset-Backed Notes, net (principal of $250,000 and $250,000, respectively) ⁽¹⁾		247,579			247,395
2022 Convertible Notes, net (principal of $230,000 and $230,000, respectively) ⁽¹⁾		227,786			226,614
Credit Facilities		37,492			103,919
Total liabilities	$	1,330,921		$	1,328,919

Net assets consist of:
Common stock, par value		115			108
Capital in excess of par value		1,225,823			1,145,106
Total distributable earnings (loss)		(52,858	)		(12,165	)
Total net assets	$	1,173,080		$	1,133,049
Total liabilities and net assets	$	2,504,001		$	2,461,968

Shares of common stock outstanding ($0.001 par value and 200,000,000 authorized)		114,317			107,364
Net asset value per share	$	10.26		$	10.55

The following table presents the assets and liabilities of our consolidated securitization trusts for the 2027 Asset-Backed Notes and the 2028 Asset-Backed Notes (see “Note 4 - Borrowings”), which are variable interest entities, or VIEs. The assets of our securitization VIEs can only be used to settle obligations of our consolidated securitization VIEs, these liabilities are only the obligations of our consolidated securitization VIEs, and the creditors (or beneficial interest holders) do not have recourse to our general credit. These assets and liabilities are included in the Consolidated Statements of Assets and Liabilities above.

	Three Months Ended September 30,						Nine Months Ended September 30,
	2020			2019			2020			2019
Investment income:
Interest income
Non-control/Non-affiliate investments	$	64,403		$	62,696		$	192,408		$	176,568
Control investments		740			1,055			2,117			3,119
Affiliate investments		232			493			609			1,740
Total interest income		65,375			64,244			195,134			181,427
Fee income
Commitment, facility and loan fee income
Non-control/Non-affiliate investments		2,985			3,591			10,692			11,069
Control investments		5			5			15			13
Affiliate investments		—			26			—			186
Total commitment, facility and loan fee income		2,990			3,622			10,707			11,268
One-time fee income
Non-control/Non-affiliate investments		1,974			1,372			6,085			4,602
Total one-time fee income		1,974			1,372			6,085			4,602
Total fee income		4,964			4,994			16,792			15,870
Total investment income		70,339			69,238			211,926			197,297
Operating expenses:
Interest		14,807			13,857			44,415			39,927
Loan fees		1,824			1,138			5,268			5,793
General and administrative
Legal expenses		673			1,586			2,563			4,212
Tax expenses		994			815			3,028			1,706
Other expenses		3,624			3,967			11,622			10,398
Total general and administrative		5,291			6,368			17,213			16,316
Employee compensation
Compensation and benefits		7,181			7,559			22,575			23,372
Stock-based compensation		2,522			1,443			7,477			8,716
Total employee compensation		9,703			9,002			30,052			32,088
Total operating expenses		31,625			30,365			96,948			94,124
Net investment income		38,714			38,873			114,978			103,173
Net realized gain (loss) on investments
Non-control/Non-affiliate investments		(48,501	)		4,807			(41,393	)		13,633
Total net realized gain (loss) on investments		(48,501	)		4,807			(41,393	)		13,633
Net change in unrealized appreciation (depreciation) on investments
Non-control/Non-affiliate investments		54,299			(26,351	)		19,483			15,533
Control investments		646			2,489			(4,563	)		421
Affiliate investments		(2,111	)		(547	)		(12,416	)		(3,773	)
Total net unrealized appreciation (depreciation) on investments		52,834			(24,409	)		2,504			12,181
Total net realized and unrealized gain (loss)		4,333			(19,602	)		(38,889	)		25,814
Net increase (decrease) in net assets resulting from operations	$	43,047		$	19,271		$	76,089		$	128,987

Net investment income before investment gains and losses per common share:
Basic	$	0.34		$	0.37		$	1.03		$	1.03
Change in net assets resulting from operations per common share:
Basic	$	0.38		$	0.18		$	0.68		$	1.29
Diluted	$	0.38		$	0.18		$	0.67		$	1.29
Weighted average shares outstanding
Basic		113,489			104,314			111,342			99,615
Diluted		113,744			104,655			111,590			100,043
Distributions paid per common share:
Basic	$	0.32		$	0.34		$	1.04		$	0.98



						Capital in			Distributable
	Common Stock					excess			Earnings			Net
For the Three Months Ended September 30, 2020	Shares			Par Value		of par value			(loss)			Assets
Balance at June 30, 2020		114,230		$	115	$	1,223,263		$	(59,348	)	$	1,164,030
Net increase (decrease) in net assets resulting from operations		—			—		—			43,047			43,047
Public offering, net of offering expenses		—			—		(96	)		—			(96	)
Issuance of common stock under restricted stock plan		34			—		—			—			—
Retired shares for restricted stock vesting		(24	)		—		(391	)		—			(391	)
Distributions reinvested in common stock		77			—		923			—			923
Distributions		—			—		—			(36,557	)		(36,557	)
Stock-based compensation⁽¹⁾		—			—		2,124			—			2,124
Balance at September 30, 2020		114,317		$	115	$	1,225,823		$	(52,858	)	$	1,173,080

For the Nine Months Ended September 30, 2020
Balance at December 31, 2019		107,364		$	108	$	1,145,106		$	(12,165	)	$	1,133,049
Net increase (decrease) in net assets resulting from operations		—			—		—			76,089			76,089
Public offering, net of offering expenses		5,966			6		73,560			—			73,566
Issuance of common stock due to stock option exercises		29			—		362			—			362
Retired shares from net issuance		(24	)		—		(376	)		—			(376	)
Issuance of common stock under restricted stock plan		835			1		(1	)		—			—
Retired shares for restricted stock vesting		(51	)		—		(1,553	)		—			(1,553	)
Distributions reinvested in common stock		198			—		2,393			—			2,393
Distributions		—			—		—			(116,782	)		(116,782	)
Stock-based compensation ⁽¹⁾		—			—		6,332			—			6,332
Balance at September 30, 2020		114,317		$	115	$	1,225,823		$	(52,858	)	$	1,173,080



						Capital in			Distributable
	Common Stock					excess			Earnings			Treasury			Net
For the Three Months Ended September 30, 2019	Shares			Par Value		of par value			(loss)⁽²⁾			Stock			Assets
Balance at June 30, 2019		104,282		$	104	$	1,149,774		$	(45,194	)	$	—		$	1,104,684
Net increase (decrease) in net assets resulting from operations		—			—		—			19,271			—			19,271
Public offering, net of offering expenses		—			—		(331	)		—			—			(331	)
Issuance of common stock due to stock option exercises		23			—		300			—			—			300
Issuance of common stock under restricted stock plan		770			1		(1	)		—			—			—
Retired shares for restricted stock vesting		(482	)		—		(4,471	)		—			—			(4,471	)
Distributions reinvested in common stock		43			—		544			—			—			544
Distributions		—			—		—			(35,555	)		—			(35,555	)
Stock-based compensation ⁽²⁾		—			—		1,239			—			—			1,239
Balance at September 30, 2019		104,636		$	105	$	1,147,054		$	(61,478	)	$	—		$	1,085,681

For the Nine Months Ended September 30, 2019
Balance at December 31, 2018		96,501		$	96	$	1,052,269		$	(92,859	)	$	(4,062	)	$	955,444
Net increase (decrease) in net assets resulting from operations		—			—		—			128,987			—			128,987
Public offering, net of offering expenses		7,700			8		95,084			—			—			95,092
Issuance of common stock due to stock option exercises		37			—		461			—			—			461
Retired shares from net issuance		(12	)		—		(166	)		—			—			(166	)
Issuance of common stock under restricted stock plan		828			1		(1	)		—			—			—
Retirement of common stock under repurchase plan		—			—		(4,062	)		—			4,062			—
Retired shares for restricted stock vesting		(550	)		—		(5,358	)		—			—			(5,358	)
Distributions reinvested in common stock		132			—		1,733			—			—			1,733
Distributions		—			—		—			(97,606	)		—			(97,606	)
Stock-based compensation ⁽²⁾		—			—		7,094			—			—			7,094
Balance at September 30, 2019		104,636		$	105	$	1,147,054		$	(61,478	)	$	—		$	1,085,681

	For the Nine Months Ended September 30,
	2020			2019
Cash flows from operating activities:
Net increase (decrease) in net assets resulting from operations	$	76,089		$	128,987
Adjustments to reconcile net increase in net assets resulting from operations to net cash provided by (used in) operating activities:
Purchase of investments		(631,431	)		(784,858	)
Principal and fee payments received on investments		480,709			424,479
Proceeds from the sale of investments		22,057			31,664
Net unrealized depreciation (appreciation) on investments		(2,504	)		(12,181	)
Net realized loss (gain) on investments		41,393			(13,633	)
Accretion of paid-in-kind principal		(6,481	)		(6,571	)
Accretion of loan discounts		(3,028	)		(2,435	)
Accretion of loan discount on convertible notes		504			504
Accretion of loan exit fees		(19,178	)		(17,598	)
Change in deferred loan origination revenue		11,986			13,617
Unearned fees related to unfunded commitments		30			1,896
Amortization of debt fees and issuance costs		3,640			4,714
Depreciation		319			175
Stock-based compensation and amortization of restricted stock grants ⁽¹⁾		6,332			7,094
Change in operating assets and liabilities:
Interest and fees receivable		701			(2,887	)
Prepaid expenses and other assets		(1,844	)		(12,286	)
Accounts payable		(17	)		(196	)
Accrued liabilities		(3,292	)		12,763
Net cash used in operating activities		(24,015	)		(226,752	)

Cash flows from investing activities:
Purchases of capital equipment		(115	)		(484	)
Net cash used in investing activities		(115	)		(484	)

Cash flows from financing activities:
Issuance of common stock, net		73,566			95,091
Retirement of employee shares		(1,567	)		(5,063	)
Distributions paid		(114,389	)		(95,873	)
Issuance of July 2024 Notes		—			105,000
Issuance of 2028 Asset-Backed Notes		—			250,000
Issuance of February 2025 Notes		50,000			—
Issuance of June 2025 Notes		70,000
Repayments of 2024 Notes		—			(83,510	)
Repayments of Long-Term SBA Debentures		(50,000	)		—
Borrowings of credit facilities		494,082			480,834
Repayments of credit facilities		(560,509	)		(522,205	)
Cash paid for debt issuance costs		(1,419	)		(4,131	)
Fees paid for credit facilities and debentures		(2,569	)		(2,833	)
Net cash (used in) provided by financing activities		(42,805	)		217,310
Net increase (decrease) in cash, cash equivalents, and restricted cash		(66,935	)		(9,926	)
Cash, cash equivalents, and restricted cash at beginning of period		114,996			45,857
Cash, cash equivalents, and restricted cash at end of period	$	48,061		$	35,931

Supplemental disclosures of cash flow information and non-cash investing and financing activities:
Interest paid	$	46,209		$	40,984
Income tax, including excise tax, paid	$	2,478		$	1,371
Distributions reinvested	$	2,393		$	1,733

The following table presents a reconciliation of cash, cash equivalents and restricted cash reported within the Consolidated Statements of Assets and Liabilities that sum to the total of the same such amounts in the Consolidated Statements of Cash Flows:

See “Note 2 – Summary of Significant Accounting Policies” for a description of restricted cash and cash equivalents.

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Debt investments
Communications & Networking
1-5 Years Maturity
Cytracom Holdings LLC^(11)(17)(18)	Communications & Networking	Senior Secured	February 2025	Interest rate 3-month LIBOR + 9.25% or Floor rate of 10.25%	$	7,000	$	6,810	$	6,805
Subtotal: 1-5 Years Maturity								6,810		6,805
Subtotal: Communications & Networking (0.58%)*								6,810		6,805
Diversified Financial Services
1-5 Years Maturity
Gibraltar Business Capital, LLC⁽⁷⁾	Diversified Financial Services	Unsecured	March 2023	Interest rate FIXED 14.50%	$	15,000		14,823		14,947
Subtotal: 1-5 Years Maturity								14,823		14,947
Subtotal: Diversified Financial Services (1.27%)*								14,823		14,947
Drug Delivery
1-5 Years Maturity
Antares Pharma Inc.^{(10)(11)(15)(17)}	Drug Delivery	Senior Secured	July 2022	Interest rate PRIME + 4.50% or Floor rate of 4.50%, 4.14% Exit Fee	$	40,000		40,979		40,740
Subtotal: 1-5 Years Maturity								40,979		40,740
Subtotal: Drug Delivery (3.47%)*								40,979		40,740
Drug Discovery & Development
Under 1 Year Maturity
Genocea Biosciences, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	May 2021	Interest rate PRIME + 3.00% or Floor rate of 8.00%, 13.43% Exit Fee	$	12,922		13,790		13,816
Metuchen Pharmaceuticals LLC	Drug Discovery & Development	Senior Secured	April 2021	Interest rate PRIME + 7.25% or Floor rate of 11.50%, 3.05% Exit Fee	$	8,195		9,219		9,181
Stealth Bio Therapeutics Corp.^(5)(10)(11)	Drug Discovery & Development	Senior Secured	July 2021	Interest rate PRIME + 5.50% or Floor rate of 9.50%, 7.69% Exit Fee	$	9,027		10,359		10,359
Subtotal: Under 1 Year Maturity								33,368		33,356
1-5 Years Maturity
Acacia Pharma Inc.^(5)(10)(11)	Drug Discovery & Development	Senior Secured	January 2022	Interest rate PRIME + 4.50% or Floor rate of 9.25%, 3.95% Exit Fee	$	6,630		6,907		6,893
Albireo Pharma, Inc.^{(5)(10)(11)(17)}	Drug Discovery & Development	Senior Secured	January 2024	Interest rate PRIME + 5.90% or Floor rate of 9.15%, 6.95% Exit Fee	$	10,000		9,924		9,924
Aldeyra Therapeutics, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	October 2023	Interest rate PRIME + 3.10% or Floor rate of 9.10%, 6.95% Exit Fee	$	15,000		15,249		15,358
Applied Genetic Technologies Corporation⁽¹¹⁾	Drug Discovery & Development	Senior Secured	December 2023	Interest rate PRIME + 6.50% or Floor rate of 9.75%, 6.95% Exit Fee	$	10,000		9,952		9,952
Aveo Pharmaceuticals, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	September 2023	Interest rate PRIME + 6.40% or Floor rate of 9.65%, 6.95% Exit Fee	$	15,000		14,945		14,945
Bicycle Therapeutics PLC^(5)(10)(17)	Drug Discovery & Development	Senior Secured	October 2024	Interest rate PRIME + 5.60% or Floor rate of 8.85%, 5.00% Exit Fee	$	15,000		14,926		14,926
BridgeBio Pharma LLC^(12)(13)(16)	Drug Discovery & Development	Senior Secured	November 2023	Interest rate PRIME + 3.85% or Floor rate of 8.75%, 6.35% Exit Fee	$	35,000		36,055		36,231
	Drug Discovery & Development	Senior Secured	November 2023	Interest rate PRIME + 2.85% or Floor rate of 8.60%, 5.75% Exit Fee	$	20,000		20,478		20,578
	Drug Discovery & Development	Senior Secured	November 2023	Interest rate PRIME + 3.10% or Floor rate of 8.85%, 5.75% Exit Fee	$	20,000		20,324		20,414
Total BridgeBio Pharma LLC					$	75,000		76,857		77,223
Century Therapeutics, LLC	Drug Discovery & Development	Senior Secured	April 2024	Interest rate PRIME + 6.30% or Floor rate of 9.55%, 3.95% Exit Fee	$	10,000		9,855		9,855
Chemocentryx, Inc.^{(10)(11)(15)(17)}	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 3.30% or Floor rate of 8.05%, 6.25% Exit Fee	$	20,000		20,600		20,824
	Drug Discovery & Development	Senior Secured	February 2024	Interest rate PRIME + 3.25% or Floor rate of 8.50%, 7.15% Exit Fee	$	5,000		5,010		5,225
Total Chemocentryx, Inc.					$	25,000		25,610		26,049
Codiak Biosciences, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	October 2024	Interest rate PRIME + 3.75% or Floor rate of 9.00%, 5.50% Exit Fee	$	25,000		24,992		25,190
Constellation Pharmaceuticals, Inc.⁽¹²⁾	Drug Discovery & Development	Senior Secured	April 2023	Interest rate PRIME + 2.55% or Floor rate of 8.55%, 6.35% Exit Fee	$	30,000		30,663		31,249
Dermavant Sciences Ltd.^(5)(10)(13)	Drug Discovery & Development	Senior Secured	June 2023	Interest rate PRIME + 4.45% or Floor rate of 9.95%, 6.95% Exit Fee	$	20,000		20,515		20,322
Eidos Therapeutics, Inc.^(10)(13)(17)	Drug Discovery & Development	Senior Secured	October 2023	Interest rate PRIME + 3.25% or Floor rate of 8.50%, 5.95% Exit Fee	$	8,750		8,859		8,992
G1 Therapeutics, Inc.^(10)(11)(17)	Drug Discovery & Development	Senior Secured	June 2024	Interest rate PRIME + 6.40% or Floor rate of 9.65%, 6.95% Exit Fee	$	20,000		19,939		19,939

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Geron Corporation^(10)(17)	Drug Discovery & Development	Senior Secured	October 2024	Interest rate PRIME + 5.75% or Floor rate of 9.00%, 6.55% Exit Fee	$	16,250		16,072		16,072
Kaleido Biosciences, Inc.⁽¹³⁾	Drug Discovery & Development	Senior Secured	January 2024	Interest rate PRIME + 6.10% or Floor rate of 9.35%, 7.55% Exit Fee	$	22,500		22,760		22,668
Mesoblast^{(5)(10)(11)(13)}	Drug Discovery & Development	Senior Secured	March 2022	Interest rate PRIME + 4.95% or Floor rate of 9.70%, 8.70% Exit Fee	$	50,000		52,579		52,549
Nabriva Therapeutics^(5)(10)	Drug Discovery & Development	Senior Secured	June 2023	Interest rate PRIME + 4.30% or Floor rate of 9.80%, 9.95% Exit Fee	$	5,000		5,193		5,184
Paratek Pharmaceuticals, Inc.^{(11)(13)(14)(15)(16)}	Drug Discovery & Development	Senior Secured	September 2022	Interest rate PRIME + 5.35% or Floor rate of 8.85%, PIK Interest 1.55%, 1.95% Exit Fee	$	60,070		59,564		59,633
Replimune Group, Inc.^{(5)(10)(11)(17)}	Drug Discovery & Development	Senior Secured	August 2023	Interest rate PRIME + 2.75% or Floor rate of 8.75%, 4.95% Exit Fee	$	10,000		10,089		10,148
Seres Therapeutics, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	November 2023	Interest rate PRIME + 4.40% or Floor rate of 9.65%, 4.85% Exit Fee	$	25,000		25,124		25,556
Syndax Pharmaceutics Inc.⁽¹³⁾	Drug Discovery & Development	Senior Secured	September 2023	Interest rate PRIME + 5.10% or Floor rate of 9.85%, 4.99% Exit Fee	$	20,000		20,120		20,152
TG Therapeutics, Inc.^(10)(13)	Drug Discovery & Development	Senior Secured	March 2022	Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.25% Exit Fee	$	30,000		30,239		30,550
Tricida, Inc.^{(11)(13)(15)(16)}	Drug Discovery & Development	Senior Secured	April 2023	Interest rate PRIME + 2.35% or Floor rate of 8.35%, 11.04% Exit Fee	$	75,000		77,412		77,871
uniQure B.V.^(5)(10)(11)	Drug Discovery & Development	Senior Secured	June 2023	Interest rate PRIME + 3.35% or Floor rate of 8.85%, 7.72% Exit Fee	$	35,000		35,519		36,314
Unity Biotechnology, Inc.⁽¹⁰⁾	Drug Discovery & Development	Senior Secured	August 2024	Interest rate PRIME + 6.10% or Floor rate of 9.35%, 6.25% Exit Fee	$	25,000		24,808		24,808
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC)⁽¹¹⁾	Drug Discovery & Development	Senior Secured	May 2024	Interest rate PRIME + 6.45% or Floor rate of 9.70%, 3.85% Exit Fee	$	7,500		7,329		7,329
Verastem, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee	$	35,000		35,795		36,143
X4 Pharmaceuticals, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	July 2023	Interest rate PRIME + 3.75% or Floor rate of 8.75%, 7.18% Exit Fee	$	25,000		25,459		25,642
Yumanity Therapeutics, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	January 2024	Interest rate PRIME + 4.00% or Floor rate of 8.75%, 7.25% Exit Fee	$	15,000		15,012		14,968
Subtotal: 1-5 Years Maturity								752,267		756,404
Greater than 5 Years Maturity
Axsome Therapeutics, Inc.^(10)(17)	Drug Discovery & Development	Senior Secured	October 2025	Interest rate PRIME + 5.90% or Floor rate of 9.15%, 4.85% Exit Fee	$	50,000		48,831		48,831
Subtotal: Greater than 5 Years Maturity								48,831		48,831
Subtotal: Drug Discovery & Development (71.49%)*								834,466		838,591
Electronics & Computer Hardware
Under 1 Year Maturity
Glo AB^{(5)(8)(10)(13)(14)}	Electronics & Computer Hardware	Senior Secured	February 2021	Interest rate PRIME + 6.20% or Floor rate of 10.45%, PIK Interest 1.75%, 5.03% Exit Fee	$	3,343		3,858		2,761
Subtotal: Under 1 Year Maturity								3,858		2,761
Subtotal: Electronics & Computer Hardware (0.24%)*								3,858		2,761
Healthcare Services, Other
1-5 Years Maturity
The CM Group LLC⁽¹⁷⁾	Healthcare Services, Other	Senior Secured	June 2024	Interest rate 1-month LIBOR + 8.35% or Floor rate of 9.35%	$	9,381		9,244		9,064
	Healthcare Services, Other	Senior Secured	June 2024	Interest rate 3-month LIBOR + 8.35% or Floor rate of 9.35%	$	1,000		1,000		981
Total The CM Group LLC					$	10,381		10,244		10,045
Velocity Clinical Research, Inc.^(13)(18)	Healthcare Services, Other	Senior Secured	November 2024	Interest rate 1-month LIBOR + 9.08% or Floor rate of 10.08%	$	9,849		9,520		9,776
	Healthcare Services, Other	Senior Secured	November 2024	Interest rate 1-month LIBOR + 9.08% or Floor rate of 10.08%	$	750		750		742
Total Velocity Clinical Research, Inc.					$	10,599		10,270		10,518
Subtotal: 1-5 Years Maturity								20,514		20,563
Subtotal: Healthcare Services, Other (1.75%)*								20,514		20,563
Information Services
1-5 Years Maturity
Planet Labs, Inc.⁽¹¹⁾	Information Services	Senior Secured	June 2022	Interest rate PRIME + 5.50% or Floor rate of 11.00%, 3.00% Exit Fee	$	25,000		24,772		24,701
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.)^(14)(15)(19)	Information Services	Senior Secured	December 2021	Interest rate PRIME + 6.25% or Floor rate of 9.50%, PIK Interest 1.70%, 5.30% Exit Fee	$	15,757		16,147		16,147

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Yipit, LLC^(11)(17)(18)	Information Services	Senior Secured	May 2024	Interest rate 1-month LIBOR + 8.88% or Floor rate of 9.88%	$	12,000		11,768		11,800
Subtotal: 1-5 Years Maturity								52,687		52,648
Subtotal: Information Services (4.49%)*								52,687		52,648
Internet Consumer & Business Services
Under 1 Year Maturity
Greenphire, Inc.⁽¹⁷⁾	Internet Consumer & Business Services	Senior Secured	January 2021	Interest rate 3-month LIBOR + 8.00% or Floor rate of 9.00%	$	717		717		717
	Internet Consumer & Business Services	Senior Secured	January 2021	Interest rate PRIME + 3.75% or Floor rate of 8.75%	$	720		720		720
Total Greenphire, Inc.					$	1,437		1,437		1,437
Intent (p.k.a. Intent Media, Inc.)^(8)(14)	Internet Consumer & Business Services	Senior Secured	September 2021	Interest rate PRIME + 5.13% or Floor rate of 10.13%, 2.00% Exit Fee	$	4,200		4,267		2,685
	Internet Consumer & Business Services	Senior Secured	September 2021	PIK Interest 10.13%	$	5,130		5,110		3,216
Total Intent (p.k.a. Intent Media, Inc.)					$	9,330		9,377		5,901
Snagajob.com, Inc.⁽¹³⁾	Internet Consumer & Business Services	Senior Secured	June 2021	Interest rate PRIME + 6.90% or Floor rate of 10.15%, 3.05% Exit Fee	$	43,005		43,889		43,604
	Internet Consumer & Business Services	Senior Secured	June 2021	Interest rate PRIME + 7.80% or Floor rate of 11.05%, 3.05% Exit Fee	$	5,173		5,268		5,229
Total Snagajob.com, Inc.					$	48,178		49,157		48,833
Tectura Corporation^(7)(8)(14)	Internet Consumer & Business Services	Senior Secured	March 2021	PIK Interest 5.00%	$	10,680		240		-
	Internet Consumer & Business Services	Senior Secured	March 2021	Interest rate FIXED 8.25%	$	8,250		8,250		8,250
	Internet Consumer & Business Services	Senior Secured	March 2021	PIK Interest 5.00%	$	13,023		13,023		45
Total Tectura Corporation					$	31,953		21,513		8,295
Subtotal: Under 1 Year Maturity								81,484		64,466
1-5 Years Maturity
AppDirect, Inc.⁽¹¹⁾	Internet Consumer & Business Services	Senior Secured	August 2024	Interest rate PRIME + 5.90% or Floor rate of 9.15%, 7.95% Exit Fee	$	30,790		30,547		30,547
Contentful, Inc.^{(5)(10)(11)(14)}	Internet Consumer & Business Services	Senior Secured	July 2022	Interest rate PRIME + 2.95% or Floor rate of 7.95%, PIK Interest 1.25%, 3.55% Exit Fee	$	3,830		3,876		3,893
ePayPolicy Holdings, LLC^(11)(17)	Internet Consumer & Business Services	Senior Secured	December 2024	Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00%	$	8,000		7,789		8,135
EverFi, Inc.^(13)(14)(16)	Internet Consumer & Business Services	Senior Secured	May 2022	Interest rate PRIME + 3.90% or Floor rate of 9.15%, PIK Interest 2.30%	$	83,594		83,380		83,753
Houzz, Inc.^(13)(14)	Internet Consumer & Business Services	Senior Secured	November 2022	Interest rate PRIME + 3.20% or Floor rate of 8.45%, PIK Interest 2.50%, 4.50% Exit Fee	$	51,080		51,310		51,639
Nextroll, Inc.^(14)(17)(19)	Internet Consumer & Business Services	Senior Secured	June 2022	Interest rate PRIME + 3.85% or Floor rate of 9.35%, PIK Interest 2.95%, 3.50% Exit Fee	$	20,766		20,992		21,122
Postmates, Inc.⁽¹⁹⁾	Internet Consumer & Business Services	Senior Secured	September 2022	Interest rate PRIME + 3.85% or Floor rate of 8.85%, 8.05% Exit Fee	$	20,000		20,782		20,797
SeatGeek, Inc.^(14)(16)	Internet Consumer & Business Services	Senior Secured	June 2023	Interest rate PRIME + 5.00% or Floor rate of 10.50%, PIK Interest 0.50%	$	60,225		59,126		57,546
Skyword, Inc.⁽¹⁴⁾	Internet Consumer & Business Services	Senior Secured	September 2023	Interest rate PRIME + 3.88% or Floor rate of 9.38%, PIK Interest 1.25%, 4.00% Exit Fee	$	12,157		12,189		11,989
Thumbtack, Inc.^(13)(14)	Internet Consumer & Business Services	Senior Secured	September 2023	Interest rate PRIME + 3.45% or Floor rate of 8.95%, PIK Interest 1.50%, 3.95% Exit Fee	$	25,136		24,887		24,887
Varsity Tutors LLC^(13)(14)(17)	Internet Consumer & Business Services	Senior Secured	August 2023	Interest rate PRIME + 5.25% or Floor rate of 10.75%, PIK Interest 0.55%, 3.00% Exit Fee	$	39,210		39,263		39,849
Wheels Up Partners LLC⁽¹¹⁾	Internet Consumer & Business Services	Senior Secured	July 2022	Interest rate 3-month LIBOR + 8.55% or Floor rate of 9.55%	$	14,274		14,212		14,274
Xometry, Inc.⁽¹³⁾	Internet Consumer & Business Services	Senior Secured	May 2022	Interest rate PRIME + 3.95% or Floor rate of 8.70%, 6.25% Exit Fee	$	11,000		11,388		11,442
Xometry, Inc.⁽¹³⁾	Internet Consumer & Business Services	Senior Secured	May 2022	Interest rate PRIME + 3.95% or Floor rate of 8.70%, 6.25% Exit Fee	$	4,000		4,140		4,179
Subtotal: 1-5 Years Maturity								383,881		384,052
Subtotal: Internet Consumer & Business Services (38.23%)*								465,365		448,518
Media/Content/Info
1-5 Years Maturity

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Bustle^(14)(15)	Media/Content/Info	Senior Secured	June 2023	Interest rate PRIME + 4.35% or Floor rate of 9.35%, PIK Interest 1.95%, 4.34% Exit Fee	$	20,941		21,118		21,308
Subtotal: 1-5 Years Maturity								21,118		21,308
Subtotal: Media/Content/Info (1.82%)*								21,118		21,308
Medical Devices & Equipment
Under 1 Year Maturity
Intuity Medical, Inc.^(11)(15)	Medical Devices & Equipment	Senior Secured	June 2021	Interest rate PRIME + 5.00% or Floor rate of 9.25%, 6.95% Exit Fee	$	11,217		12,288		12,199
Optiscan Biomedical, Corp.^(6)(8)(9)	Medical Devices & Equipment	Convertible Debt	July 2021	Interest rate FIXED 8.00%	$	408		408		-
Sebacia, Inc.^(11)(15)	Medical Devices & Equipment	Senior Secured	January 2021	Interest rate PRIME + 4.35% or Floor rate of 8.85%, 6.05% Exit Fee	$	6,892		7,541		5,807
Subtotal: Under 1 Year Maturity								20,237		18,006
1-5 Years Maturity
Flowonix Medical Incorporated^(11)(14)	Medical Devices & Equipment	Senior Secured	October 2021	Interest rate PRIME + 4.25% or Floor rate of 9.25%, 7.95% Exit Fee	$	7,561		8,388		8,405
Quanterix Corporation⁽¹¹⁾	Medical Devices & Equipment	Senior Secured	October 2021	Interest rate PRIME + 2.75% or Floor rate of 8.00%, 0.96% Exit Fee	$	7,688		7,728		7,698
Subtotal: 1-5 Years Maturity								16,116		16,103
Subtotal: Medical Devices & Equipment (2.91%)*								36,353		34,109
Software
Under 1 Year Maturity
Pollen, Inc.⁽¹⁵⁾	Software	Senior Secured	November 2020	Interest rate PRIME + 4.25% or Floor rate of 8.50%, 5.95% Exit Fee	$	7,000		7,416		7,416
ZocDoc^(11)(19)	Software	Senior Secured	August 2021	Interest rate PRIME + 6.20% or Floor rate of 10.95%, 2.00% Exit Fee	$	30,000		30,440		30,574
Subtotal: Under 1 Year Maturity								37,856		37,990
1-5 Years Maturity
3GTMS, LLC.^(11)(17)(18)	Software	Senior Secured	February 2025	Interest rate 3-month LIBOR + 9.28% or Floor rate of 10.28%	$	10,000		9,750		9,754
Abrigo⁽¹⁸⁾	Software	Senior Secured	May 2023	Interest rate 3-month LIBOR + 7.88% or Floor rate of 8.88%	$	38,705		38,195		38,123
	Software	Senior Secured	May 2023	Interest rate 3-month LIBOR + 5.96% or Floor rate of 6.96%	$	2,327		2,283		2,284
Total Abrigo					$	41,032		40,478		40,407
Businessolver.com, Inc.^(11)(16)(17)	Software	Senior Secured	May 2023	Interest rate 6-month LIBOR + 7.50% or Floor rate of 8.50%	$	58,650		57,951		57,976
	Software	Senior Secured	May 2023	Interest rate 6-month LIBOR + 7.50% or Floor rate of 8.50%	$	7,650		7,521		7,421
Total Businessolver.com, Inc.					$	66,300		65,472		65,397
Clarabridge, Inc.^{(12)(13)(14)(17)}	Software	Senior Secured	May 2024	Interest rate PRIME + 5.30% or Floor rate of 8.55%, PIK Interest 2.25%	$	55,507		55,013		55,176
Cloud 9 Software⁽¹³⁾	Software	Senior Secured	April 2024	Interest rate 3-month LIBOR + 8.20% or Floor rate of 9.20%	$	9,500		9,358		9,067
	Software	Senior Secured	April 2024	Interest rate 3-month LIBOR + 8.20% or Floor rate of 9.20%	$	500		500		495
Total Cloud 9 Software					$	10,000		9,858		9,562
CloudBolt Software Inc.^(17)(19)	Software	Senior Secured	October 2024	Interest rate PRIME + 6.70% or Floor rate of 9.95%, 2.95% Exit Fee	$	5,000		4,846		4,846
Cloudian, Inc.⁽¹¹⁾	Software	Senior Secured	November 2022	Interest rate PRIME + 3.25% or Floor rate of 8.25%, 9.75% Exit Fee	$	15,000		15,754		15,558
Couchbase, Inc.^(11)(15)(19)	Software	Senior Secured	June 2024	Interest rate PRIME + 5.25% or Floor rate of 10.75%, 3.75% Exit Fee	$	25,000		25,131		25,131
Dashlane, Inc.^{(11)(14)(17)(19)}	Software	Senior Secured	April 2022	Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 8.50% Exit Fee	$	10,266		10,717		10,707
	Software	Senior Secured	March 2023	Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 4.95% Exit Fee	$	10,166		10,165		10,105
Total Dashlane, Inc.					$	20,432		20,882		20,812
Delphix Corp.^(13)(16)(19)	Software	Senior Secured	February 2023	Interest rate PRIME + 5.50% or Floor rate of 10.25%, 5.00% Exit Fee	$	60,000		59,515		59,777
Envisage Technologies, LLC^(13)(18)	Software	Senior Secured	March 2025	Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00%	$	9,750		9,514		9,750
Evernote Corporation^{(11)(14)(15)(19)}	Software	Senior Secured	July 2022	Interest rate PRIME + 5.45% or Floor rate of 8.95%	$	5,549		5,527		5,428
	Software	Senior Secured	July 2022	Interest rate PRIME + 6.00% or Floor rate of 9.50%, PIK Interest 1.25%	$	9,292		9,226		9,264
Total Evernote Corporation					$	14,841		14,753		14,692

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
ExtraHop Networks, Inc.⁽¹⁹⁾	Software	Senior Secured	September 2023	Interest rate PRIME + 7.00% or Floor rate of 10.25%, 2.50% Exit Fee	$	15,000		14,674		14,674
FreedomPay, Inc.^(13)(19)	Software	Senior Secured	June 2023	Interest rate PRIME + 7.70% or Floor rate of 10.95%, 3.55% Exit Fee	$	10,000		9,929		9,929
Ikon Science Limited^{(5)(10)(11)(17)(18)}	Software	Senior Secured	October 2024	Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00%	$	7,000		6,730		6,650

Insurance Technologies Corporation^(11)(18)	Software	Senior Secured	January 2025	Interest rate 3-month LIBOR + 8.27% or Floor rate of 9.27%	$	17,000		16,578		16,537
Jolt Software, Inc.⁽¹⁴⁾	Software	Senior Secured	October 2022	Interest rate PRIME + 3.00% or Floor rate of 8.50%, PIK Interest 1.75%, 4.50% Exit Fee	$	7,605		7,659		7,760
Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.)^(11)(18)	Software	Senior Secured	July 2023	Interest rate 6-month LIBOR + 10.15% or Floor rate of 11.15%	$	8,718		8,481		8,349
Khoros (p.k.a Lithium Technologies)⁽¹¹⁾	Software	Senior Secured	October 2022	Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00%	$	55,000		54,297		54,850
	Software	Senior Secured	October 2022	Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00%	$	604		604		601
Total Khoros (p.k.a Lithium Technologies)					$	55,604		54,901		55,451
Lightbend, Inc.^(14)(15)	Software	Senior Secured	February 2022	Interest rate PRIME + 4.25% or Floor rate of 9.25%, PIK Interest 2.00%, 3.00% Exit Fee	$	13,937		14,140		14,114
memsql, Inc.^(11)(14)(17)	Software	Senior Secured	May 2023	Interest rate PRIME + 4.70% or Floor rate of 7.95%, PIK Interest 0.75%, 3.95% Exit Fee	$	5,011		4,983		4,983
Mixpanel, Inc.	Software	Senior Secured	August 2024	Interest rate PRIME + 4.70% or Floor rate of 7.95%, PIK Interest 1.80%, 3.00% Exit Fee	$	20,000		19,574		19,574
Mobile Solutions Services^(17)(18)	Software	Senior Secured	October 2024	Interest rate 6-month LIBOR + 8.80% or Floor rate of 9.80%	$	5,500		5,351		5,352
Nuvolo Technologies Corporation^(13)(17)(19)	Software	Senior Secured	April 2023	Interest rate PRIME + 7.25% or Floor rate of 11.50%	$	15,000		14,848		14,778
OrthoFi, Inc.^(13)(18)	Software	Senior Secured	April 2024	Interest rate 6-month LIBOR + 8.28% or Floor rate of 9.28%	$	17,853		17,481		17,331
	Software	Senior Secured	April 2024	Interest rate 6-month LIBOR + 8.28% or Floor rate of 9.28%	$	1,667		1,667		1,667
Total OrthoFi, Inc.					$	19,520		19,148		18,998
Pymetrics, Inc.	Software	Senior Secured	October 2022	Interest rate PRIME + 5.50% or Floor rate of 8.75%, PIK Interest 1.75%, 4.00% Exit Fee	$	10,000		9,818		9,818
Regent Education⁽¹⁴⁾	Software	Senior Secured	January 2022	Interest rate FIXED 10.00%, PIK Interest 2.00%, 7.94% Exit Fee	$	3,203		3,290		3,253
Reltio, Inc.^{(13)(14)(17)(19)}	Software	Senior Secured	July 2023	Interest rate PRIME + 5.70% or Floor rate of 8.95%, PIK Interest 1.70%, 4.95% Exit Fee	$	10,030		9,830		9,830
Salsa Labs, Inc.⁽¹¹⁾	Software	Senior Secured	April 2023	Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15%	$	5,985		5,917		5,929
	Software	Senior Secured	April 2023	Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15%	$	500		500		500
Total Salsa Labs, Inc.					$	6,485		6,417		6,429
Tact.ai Technologies, Inc.^(11)(14)	Software	Senior Secured	February 2023	Interest rate PRIME + 4.00% or Floor rate of 8.75%, PIK Interest 2.00%, 5.50% Exit Fee	$	5,056		4,911		4,855
ThreatConnect, Inc.^(13)(17)(18)	Software	Senior Secured	May 2024	Interest rate 3-month LIBOR + 8.26% or Floor rate of 9.26%	$	4,500		4,384		4,449
Udacity, Inc.⁽¹⁷⁾	Software	Senior Secured	September 2024	Interest rate PRIME + 4.50% or Floor rate of 7.75%, PIK Interest 2.00%, 3.00% Exit Fee	$	35,000		34,486		34,486
Vela Trading Technologies^(11)(18)	Software	Senior Secured	July 2022	Interest rate 3-month LIBOR + 10.50% or Floor rate of 11.50%, PIK Interest 0.50%	$	18,345		17,990		17,754
ZeroFox, Inc.⁽¹³⁾	Software	Senior Secured	January 2023	Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.00% Exit Fee	$	20,000		20,033		19,987
Subtotal: 1-5 Years Maturity								639,121		638,872
Greater than 5 Years Maturity

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Campaign Monitor Limited^(11)(17)(19)	Software	Senior Secured	November 2025	Interest rate 6-month LIBOR + 8.50% or Floor rate of 9.50%	$	30,021		29,415		29,310
Imperva, Inc.⁽¹⁹⁾	Software	Senior Secured	January 2027	Interest rate 3-month LIBOR + 7.75% or Floor rate of 8.75%	$	20,000		19,822		19,502
Subtotal: Greater than 5 Years Maturity								49,237		48,812
Subtotal: Software (61.86%)*								726,214		725,674
Sustainable and Renewable Technology
Under 1 Year Maturity
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)^(6)(8)(14)	Sustainable and Renewable Technology	Senior Secured	January 2021	Interest rate FIXED 6.48%, PIK Interest 6.48%, 6.67% Exit Fee	$	10,000		10,775		8,308
	Sustainable and Renewable Technology	Senior Secured	January 2021	PIK Interest 10.00%	$	683		683		-
	Sustainable and Renewable Technology	Senior Secured	January 2021	Interest rate FIXED 8.85%, PIK Interest 8.85%	$	1,492		1,492		1,492
Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)					$	12,175	$	12,950	$	9,800
Subtotal: Under 1 Year Maturity								12,950.00		9,800.00
1-5 Years Maturity
Impossible Foods, Inc.^(12)(13)	Sustainable and Renewable Technology	Senior Secured	July 2022	Interest rate PRIME + 3.95% or Floor rate of 8.95%, 9.00% Exit Fee	$	44,502		47,562.00		47,983.00
Subtotal: 1-5 Years Maturity								47,562		47,983
Subtotal: Sustainable and Renewable Technology (4.93%)*								60,512		57,783
Total: Debt Investments (193.03%)*								2,283,699		2,264,447

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
Equity Investments
Communications & Networking
Peerless Network Holdings, Inc.	Communications & Networking	Equity	Preferred Series A		1,135,000	$	1,230	$	5,717
Subtotal: Communications & Networking (0.49%)*							1,230		5,717
Consumer & Business Products
Intelligent Beauty, Inc.	Consumer & Business Products	Equity	Preferred Series B		111,156	$	230	$	654
Subtotal: Consumer & Business Products (0.06%)*							230		654
Diversified Financial Services
Gibraltar Business Capital, LLC⁽⁷⁾	Diversified Financial Services	Equity	Common Stock		830,000		1,884		2,143
	Diversified Financial Services	Equity	Preferred Series A		10,602,752		26,122		29,707
Total Gibraltar Business Capital, LLC					11,432,752		28,006		31,850
Subtotal: Diversified Financial Services (2.72%)*							28,006		31,850
Drug Delivery
AcelRx Pharmaceuticals, Inc.⁽⁴⁾	Drug Delivery	Equity	Common Stock		176,730		1,329		251
BioQ Pharma Incorporated⁽¹⁵⁾	Drug Delivery	Equity	Preferred Series D		165,000		500		733
Kaleo, Inc.	Drug Delivery	Equity	Preferred Series B		82,500		1,007		2,681
Neos Therapeutics, Inc.^(4)(15)	Drug Delivery	Equity	Common Stock		125,000		1,500		66
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.)⁽⁴⁾	Drug Delivery	Equity	Common Stock		2,498		309		6
Subtotal: Drug Delivery (0.32%)*							4,645		3,737
Drug Discovery & Development
Albireo Pharma, Inc.^(4)(5)(10)	Drug Discovery & Development	Equity	Common Stock		25,000		1,000		834
Aveo Pharmaceuticals, Inc.^(4)(15)	Drug Discovery & Development	Equity	Common Stock		190,175		1,715		1,129
Axovant Gene Therapies Ltd. (p.k.a. Axovant Sciences Ltd.)^(4)(5)(10)	Drug Discovery & Development	Equity	Common Stock		16,228		1,269		75
BridgeBio Pharma LLC^(4)(16)	Drug Discovery & Development	Equity	Common Stock		203,579		2,000		7,638
Cerecor, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		119,087		1,000		271
Chemocentryx, Inc.^(4)(10)(15)	Drug Discovery & Development	Equity	Common Stock		17,241		1,000		945
Concert Pharmaceuticals, Inc.^(4)(10)	Drug Discovery & Development	Equity	Common Stock		70,796		1,367		695
Dare Biosciences, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		13,550		1,000		14
Dynavax Technologies^(4)(10)	Drug Discovery & Development	Equity	Common Stock		20,000		550		86
Eidos Therapeutics, Inc.^(4)(10)	Drug Discovery & Development	Equity	Common Stock		15,000		255		758
Genocea Biosciences, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		27,932		2,000		64
Paratek Pharmaceuticals, Inc.^(4)(16)	Drug Discovery & Development	Equity	Common Stock		76,362		2,744		413
Rocket Pharmaceuticals, Ltd.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		944		1,500		22
Savara, Inc.^(4)(15)	Drug Discovery & Development	Equity	Common Stock		11,119		203		12
Tricida, Inc.^(4)(15)(16)	Drug Discovery & Development	Equity	Common Stock		68,816		863		624
uniQure B.V.^(4)(5)(10)	Drug Discovery & Development	Equity	Common Stock		17,175		332		633
X4 Pharmaceuticals, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		83,334		641		564
Subtotal: Drug Discovery & Development (1.26%)*							19,439		14,777
Healthcare Services, Other
23andMe, Inc.	Healthcare Services, Other	Equity	Common Stock		360,000		5,094		6,583
Chromadex Corporation⁽⁴⁾	Healthcare Services, Other	Equity	Common Stock		31,183		110		125
Subtotal: Healthcare Services, Other (0.57%)*							5,204		6,708
Internet Consumer & Business Services
Contentful, Inc.^(5)(10)	Internet Consumer & Business Services	Equity	Preferred Series D		217		500		738
Countable Corporation (p.k.a. Brigade Group, Inc.)	Internet Consumer & Business Services	Equity	Common Stock		9,023		93		—
DoorDash, Inc.	Internet Consumer & Business Services	Equity	Common Stock		105,000		6,051		20,503
Fastly, Inc.⁽⁴⁾	Internet Consumer & Business Services	Equity	Common Stock		6,238		8		584
Lyft, Inc.⁽⁴⁾	Internet Consumer & Business Services	Equity	Common Stock		200,738		10,487		5,530
Nextdoor.com, Inc.	Internet Consumer & Business Services	Equity	Common Stock		328,190		4,854		7,936
OfferUp, Inc.	Internet Consumer & Business Services	Equity	Preferred Series A		286,080		1,663		1,527
	Internet Consumer & Business Services	Equity	Preferred Series A-1		108,710		632		580
Total OfferUp, Inc.					394,790		2,295		2,107
Oportun⁽⁴⁾	Internet Consumer & Business Services	Equity	Common Stock		48,365		577		570
Reischling Press, Inc. (p.k.a. Blurb, Inc.)	Internet Consumer & Business Services	Equity	Preferred Series B		1,163		15		—

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
Tectura Corporation⁽⁷⁾	Internet Consumer & Business Services	Equity	Common Stock		414,994,863		900		—
	Internet Consumer & Business Services	Equity	Preferred Series BB		1,000,000		—		—
Total Tectura Corporation					415,994,863		900		—
Subtotal: Internet Consumer & Business Services (3.24%)*							25,780		37,968
Medical Devices & Equipment
Flowonix Medical Incorporated	Medical Devices & Equipment	Equity	Preferred Series AA		221,893		1,500		—
Gelesis, Inc.	Medical Devices & Equipment	Equity	Common Stock		227,013		—		441
	Medical Devices & Equipment	Equity	Preferred Series A-1		191,210		425		392
	Medical Devices & Equipment	Equity	Preferred Series A-2		191,626		500		381
Total Gelesis, Inc.					609,849		925		1,214
Medrobotics Corporation⁽¹⁵⁾	Medical Devices & Equipment	Equity	Preferred Series E		136,798		250		—
	Medical Devices & Equipment	Equity	Preferred Series F		73,971		155		—
	Medical Devices & Equipment	Equity	Preferred Series G		163,934		500		—
Total Medrobotics Corporation					374,703		905		—
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Devices & Equipment	Equity	Preferred Series B		61,855		3,000		—
	Medical Devices & Equipment	Equity	Preferred Series C		19,273		655		—
	Medical Devices & Equipment	Equity	Preferred Series D		551,038		5,257		—
	Medical Devices & Equipment	Equity	Preferred Series E		507,103		4,240		—
Total Optiscan Biomedical, Corp.					1,139,269		13,152		—
Outset Medical, Inc.⁽⁴⁾	Medical Devices & Equipment	Equity	Common Stock		38,243		527		1,474
ViewRay, Inc.^(4)(15)	Medical Devices & Equipment	Equity	Common Stock		36,457		333		128
Subtotal: Medical Devices & Equipment (0.24%)*							17,342		2,816
Software
CapLinked, Inc.	Software	Equity	Preferred Series A-3		53,614		51		75
Docker, Inc.	Software	Equity	Common Stock		20,000		4,284		27
Druva Holdings, Inc. (p.k.a. Druva, Inc.)	Software	Equity	Preferred Series 2		458,841		1,000		3,090
	Software	Equity	Preferred Series 3		93,620		300		665
Total Druva Holdings, Inc. (p.k.a. Druva, Inc.)					552,461		1,300		3,755
HighRoads, Inc.	Software	Equity	Common Stock		190		307		—
Palantir Technologies⁽⁴⁾	Software	Equity	Common Stock		2,085,421		12,747		15,893
Sprinklr, Inc.	Software	Equity	Common Stock		700,000		3,749		4,291
Subtotal: Software (2.05%)*							22,438		24,041
Surgical Devices
Gynesonics, Inc.⁽¹⁵⁾	Surgical Devices	Equity	Preferred Series B		219,298		250		10
	Surgical Devices	Equity	Preferred Series C		656,538		282		32
	Surgical Devices	Equity	Preferred Series D		1,991,157		712		101
	Surgical Devices	Equity	Preferred Series E		2,786,367		429		163
	Surgical Devices	Equity	Preferred Series F		1,523,693		118		157
	Surgical Devices	Equity	Preferred Series F-1		2,418,125		150		220
Total Gynesonics, Inc.					9,595,178		1,941		683
TransMedics Group, Inc. (p.k.a Transmedics, Inc.)⁽⁴⁾	Surgical Devices	Equity	Common Stock		162,617		2,550		2,241
Subtotal: Surgical Devices (0.25%)*							4,491		2,924
Sustainable and Renewable Technology
Impossible Foods, Inc.	Sustainable and Renewable Technology	Equity	Preferred Series E-1		188,611		2,000		2,356
Modumetal, Inc.	Sustainable and Renewable Technology	Equity	Preferred Series A-1		103,584		500		—
Proterra, Inc.	Sustainable and Renewable Technology	Equity	Preferred Series 5		99,280		500		301
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)⁽⁶⁾	Sustainable and Renewable Technology	Equity	Common Stock		488		61,502		—
Subtotal: Sustainable and Renewable Technology (0.23%)*							64,502		2,657
Total: Equity Investments (11.41%)*							193,307		133,849
Warrant Investments
Communications & Networking
Peerless Network Holdings, Inc.	Communications & Networking	Warrant	Common Stock		3,328		—		12
Spring Mobile Solutions, Inc.	Communications & Networking	Warrant	Common Stock		2,834,375		418		—
Subtotal: Communications & Networking (0.00%)*							418		12
Consumer & Business Products
Gadget Guard⁽¹⁵⁾	Consumer & Business Products	Warrant	Common Stock		1,662,441		228		—
The Neat Company	Consumer & Business Products	Warrant	Common Stock		54,054		365		—
Whoop, Inc.	Consumer & Business Products	Warrant	Preferred Series C		68,627		18		54
Subtotal: Consumer & Business Products (0.00%)*							611		54

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
Drug Delivery
Aerami Therapeutics (p.k.a. Dance Biopharm, Inc.)⁽¹⁵⁾	Drug Delivery	Warrant	Common Stock		110,882		74		—
BioQ Pharma Incorporated	Drug Delivery	Warrant	Common Stock		459,183		1		1,004
Neos Therapeutics, Inc.^(4)(15)	Drug Delivery	Warrant	Common Stock		70,833		285		—
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.)⁽⁴⁾	Drug Delivery	Warrant	Common Stock		3,929		390		—
Subtotal: Drug Delivery (0.09%)*							750		1,004
Drug Discovery & Development
Acacia Pharma Inc.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		201,330		304		149
ADMA Biologics, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		89,750		295		15
Albireo Pharma, Inc.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		5,310		61		85
Axsome Therapeutics, Inc.^(4)(10)	Drug Discovery & Development	Warrant	Common Stock		15,541		681		620
Brickell Biotech, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		9,005		119		—
Century Therapeutics, LLC	Drug Discovery & Development	Warrant	Common Units		40,540		37		37
Cerecor, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		22,328		70		1
Concert Pharmaceuticals, Inc.^(4)(10)(15)	Drug Discovery & Development	Warrant	Common Stock		61,273		178		105
CytRx Corporation⁽⁴⁾⁽¹⁵⁾	Drug Discovery & Development	Warrant	Common Stock		105,694		160		—
Dermavant Sciences Ltd.^(5)(10)	Drug Discovery & Development	Warrant	Common Stock		223,642		101		343
Evofem Biosciences, Inc.^(4)(15)	Drug Discovery & Development	Warrant	Common Stock		7,806		266		3
Genocea Biosciences, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		41,176		165		21
Motif BioSciences Inc.⁽⁴⁾^(5)(10)	Drug Discovery & Development	Warrant	Common Stock		121,337,041		282		—
Myovant Sciences, Ltd.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		73,710		460		347
Ology Bioservices, Inc.⁽¹⁵⁾	Drug Discovery & Development	Warrant	Common Stock		171,389		838		—
Paratek Pharmaceuticals, Inc.^(4)(15)(16)	Drug Discovery & Development	Warrant	Common Stock		469,388		644		756
Stealth Bio Therapeutics Corp.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		500,000		158		203
TG Therapeutics, Inc.^(4)(10)	Drug Discovery & Development	Warrant	Common Stock		147,058		563		2,558
Tricida, Inc.^(4)(15)(16)	Drug Discovery & Development	Warrant	Common Stock		31,353		280		13
Urovant Sciences, Ltd.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		99,777		383		315
Valo Health, LLC (p.k.a. Integral Health Holdings, LLC)	Drug Discovery & Development	Warrant	Common Units		75,000		177		176
X4 Pharmaceuticals, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		108,334		673		108
Yumanity Therapeutics, Inc.	Drug Discovery & Development	Warrant	Class C Preferred Units		73,110		110		148
Subtotal: Drug Discovery & Development (0.51%)*							7,005		6,003
Electronics & Computer Hardware
908 Devices, Inc.⁽¹⁵⁾	Electronics & Computer Hardware	Warrant	Preferred Series D		79,856		101		48
Subtotal: Electronics & Computer Hardware (0.00%)*							101		48
Information Services
InMobi Inc.^(5)(10)	Information Services	Warrant	Common Stock		65,587		82		—
NetBase Solutions, Inc.	Information Services	Warrant	Preferred Series 1		60,000		356		243
Planet Labs, Inc.	Information Services	Warrant	Common Stock		357,752		615		131
RichRelevance, Inc.	Information Services	Warrant	Preferred Series E		112,612		98		—
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.)⁽¹⁵⁾	Information Services	Warrant	Common Stock		2,812,500		283		341
Subtotal: Information Services (0.06%)*							1,434		715
Internet Consumer & Business Services
Aria Systems, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series G		231,535		74		—
Cloudpay, Inc.^(5)(10)	Internet Consumer & Business Services	Warrant	Preferred Series B		6,763		54		78
Contentful, Inc.^(5)(10)	Internet Consumer & Business Services	Warrant	Preferred Series C		82		1		135
First Insight, Inc.⁽¹⁵⁾	Internet Consumer & Business Services	Warrant	Preferred Series B		75,917		96		105
Houzz, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		529,661		20		53
Intent (p.k.a. Intent Media, Inc.)	Internet Consumer & Business Services	Warrant	Common Stock		140,077		168		—
Interactions Corporation	Internet Consumer & Business Services	Warrant	Preferred Series G-3		68,187		204		485
Just Fabulous, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series B		206,184		1,102		1,992
Lendio, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series D		127,032		39		18
LogicSource	Internet Consumer & Business Services	Warrant	Preferred Series C		79,625		30		98
Postmates, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		189,865		317		610
RumbleON, Inc.⁽⁴⁾	Internet Consumer & Business Services	Warrant	Common Stock		5,139		87		32
SeatGeek, Inc.⁽¹⁶⁾	Internet Consumer & Business Services	Warrant	Common Stock		1,379,761		842		1,134

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
ShareThis, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series C		493,502		547		—
Skyword, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series B		444,444		83		93
Snagajob.com, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		600,000		16		32
	Internet Consumer & Business Services	Warrant	Preferred Series A		1,800,000		782		26
	Internet Consumer & Business Services	Warrant	Preferred Series B		1,211,537		62		10
Total Snagajob.com, Inc.					3,611,537		860		68
Tapjoy, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series D		748,670		316		4
The Faction Group LLC	Internet Consumer & Business Services	Warrant	Preferred Series AA		8,076		234		769
Thumbtack, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		190,953		553		208
Xometry, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series B		87,784		47		328
Subtotal: Internet Consumer & Business Services (0.53%)*							5,674		6,210
Media/Content/Info
Napster	Media/Content/Info	Warrant	Common Stock		715,755		384		—
WP Technology, Inc. (Wattpad, Inc.)^(5)(10)	Media/Content/Info	Warrant	Common Stock		255,818		4		—
Zoom Media Group, Inc.	Media/Content/Info	Warrant	Preferred Series A		1,204		348		—
Subtotal: Media/Content/Info (0.00%)*							736		—
Medical Devices & Equipment
Aspire Bariatrics, Inc.⁽¹⁵⁾	Medical Devices & Equipment	Warrant	Preferred Series B-1		112,858		455		—
Flowonix Medical Incorporated	Medical Devices & Equipment	Warrant	Preferred Series AA		155,325		362		—
	Medical Devices & Equipment	Warrant	Preferred Series BB		725,806		351		—
Total Flowonix Medical Incorporated					881,131		713		—
Gelesis, Inc.	Medical Devices & Equipment	Warrant	Preferred Series A-1		74,784	78			109
InspireMD, Inc.^(4)(5)(10)	Medical Devices & Equipment	Warrant	Common Stock		23	0			—
Intuity Medical, Inc.⁽¹⁵⁾	Medical Devices & Equipment	Warrant	Common Stock		1,819,078	294			127
Medrobotics Corporation⁽¹⁵⁾	Medical Devices & Equipment	Warrant	Preferred Series E		455,539	370			—
NinePoint Medical, Inc.	Medical Devices & Equipment	Warrant	Preferred Series A-1		587,840	170			—
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Devices & Equipment	Warrant	Preferred Series E		74,424	572			—
Outset Medical, Inc.⁽⁴⁾	Medical Devices & Equipment	Warrant	Common Stock		62,794	402			1,371
Sebacia, Inc.	Medical Devices & Equipment	Warrant	Preferred Series D		778,301	133			—
SonaCare Medical, LLC	Medical Devices & Equipment	Warrant	Preferred Series A		6,464		188		—
Tela Bio, Inc.⁽⁴⁾	Medical Devices & Equipment	Warrant	Common Stock		15,712		61		11
Subtotal: Medical Devices & Equipment (0.14%)*							3,436		1,618
Semiconductors
Achronix Semiconductor Corporation	Semiconductors	Warrant	Preferred Series C		360,000		160		43
	Semiconductors	Warrant	Preferred Series D-2		750,000		99		389
Total Achronix Semiconductor Corporation					1,110,000		259		432
Subtotal: Semiconductors (0.04%)*							259		432
Software
Actifio, Inc.	Software	Warrant	Common Stock		73,584		249		19
	Software	Warrant	Preferred Series F		31,673		343		28
Total Actifio, Inc.					105,257		592		47
CloudBolt Software Inc.	Software	Warrant	Common Stock		158,506		91		91
Cloudian, Inc.	Software	Warrant	Common Stock		477,454		72		25
Couchbase, Inc.	Software	Warrant	Common Stock		263,377		462		832
Dashlane, Inc.	Software	Warrant	Common Stock		346,747		303		236
Delphix Corp.⁽¹⁶⁾	Software	Warrant	Common Stock		718,898		1,594		1,354
DNAnexus, Inc.	Software	Warrant	Preferred Series C		909,091		97		99
Evernote Corporation	Software	Warrant	Common Stock		62,500		106		47
ExtraHop Networks, Inc.	Software	Warrant	Common Stock		154,784		191		191
Fuze, Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series F		256,158		89		—
Lightbend, Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series C-1		854,787		130		152
memsql, Inc.	Software	Warrant	Preferred Series D		312,596		103		150
Message Systems, Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series C		503,718		334		218
Mixpanel, Inc.	Software	Warrant	Common Stock		82,362		252		252
Nuvolo Technologies Corporation	Software	Warrant	Common Stock		30,000		43		67

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
OneLogin, Inc.⁽¹⁵⁾	Software	Warrant	Common Stock		381,620		305		486
Poplicus, Inc.	Software	Warrant	Common Stock		132,168		—		—
Pymetrics, Inc.	Software	Warrant	Common Stock		150,943		77		77
RapidMiner, Inc.	Software	Warrant	Preferred Series C-1		4,982		24		19
Reltio, Inc.	Software	Warrant	Common Stock		69,120		215		202
SignPost, Inc.	Software	Warrant	Series Junior 1 Preferred		474,019		314		—
Tact.ai Technologies, Inc.	Software	Warrant	Common Stock		1,041,667		206		157
Udacity, Inc.	Software	Warrant	Common Stock		486,359		218		218
ZeroFox, Inc.	Software	Warrant	Preferred Series C-1		648,350		100		375
Subtotal: Software (0.45%)*							5,918		5,295
Specialty Pharmaceuticals
Alimera Sciences, Inc.⁽⁴⁾	Specialty Pharmaceuticals	Warrant	Common Stock		114,513		861		17
Subtotal: Specialty Pharmaceuticals (0.00%)*							861		17
Surgical Devices
Gynesonics, Inc.⁽¹⁵⁾	Surgical Devices	Warrant	Preferred Series C		151,123		67		7
	Surgical Devices	Warrant	Preferred Series D		1,575,965		320		25
Total Gynesonics, Inc.					1,727,088		387		32
TransMedics Group, Inc. (p.k.a Transmedics, Inc.)⁽⁴⁾	Surgical Devices	Warrant	Common Stock		64,441		139		234
Subtotal: Surgical Devices (0.02%)*							526		266
Sustainable and Renewable Technology
Agrivida, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series D		471,327		120		—
Fulcrum Bioenergy, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series C-1		280,897		274		533
Kinestral Technologies, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series A		325,000		155		167
	Sustainable and Renewable Technology	Warrant	Preferred Series B		131,883		63		55
Total Kinestral Technologies, Inc.					456,883		218		222
NantEnergy, Inc. (p.k.a. Fluidic, Inc.)	Sustainable and Renewable Technology	Warrant	Preferred Series D		61,804		102		—
Polyera Corporation⁽¹⁵⁾	Sustainable and Renewable Technology	Warrant	Preferred Series C		311,609		338		—
Proterra, Inc.	Sustainable and Renewable Technology	Warrant	Common Stock		36,630		1		3
	Sustainable and Renewable Technology	Warrant	Preferred Series 4		477,517		41		99
Total Proterra, Inc.					514,147		42		102
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)⁽⁶⁾	Sustainable and Renewable Technology	Warrant	Class A Units		1		—		—
Subtotal: Sustainable and Renewable Technology (0.07%)*							1,094		857
Total: Warrant Investments (1.92%)*						$	28,823	$	22,531
Total: Investments in Securities (206.37%)*						$	2,505,829	$	2,420,827

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Debt Investments
Biotechnology Tools
Under 1 Year Maturity
Exicure, Inc.⁽¹¹⁾	Biotechnology Tools	Senior Secured	March 2020	Interest rate PRIME + 6.45% or Floor rate of 9.95%, 5.52% Exit Fee	$	4,999	$	5,067	$	5,067
Subtotal: Under 1 Year Maturity								5,067		5,067
Subtotal: Biotechnology Tools (0.45%)*								5,067		5,067
Diversified Financial Services
1-5 Years Maturity
Gibraltar Business Capital, LLC⁽⁷⁾	Diversified Financial Services	Unsecured	March 2023	Interest rate FIXED 14.50%	$	15,000		14,780		14,780
Pico Quantitative Trading LLC⁽¹⁸⁾	Diversified Financial Services	Senior Secured	June 2024	Interest rate 1-month LIBOR + 8.60% or Floor rate of 9.60%	$	30,000		29,556		28,773
Subtotal: 1-5 Years Maturity								44,336		43,553
Subtotal: Diversified Financial Services (3.84%)*								44,336		43,553
Drug Delivery
1-5 Years Maturity
Antares Pharma Inc.^(10)(11)(15)	Drug Delivery	Senior Secured	July 2022	Interest rate PRIME + 4.50% or Floor rate of 4.50%, 4.14% Exit Fee	$	40,000		40,626		40,773
Subtotal: 1-5 Years Maturity								40,626		40,773
Subtotal: Drug Delivery (3.60%)*								40,626		40,773
Drug Discovery & Development
Under 1 Year Maturity
Metuchen Pharmaceuticals LLC⁽¹⁴⁾	Drug Discovery & Development	Senior Secured	October 2020	Interest rate PRIME + 7.25% or Floor rate of 10.75%, PIK Interest 1.35%, 2.25% Exit Fee	$	12,775		13,730		13,731
Subtotal: Under 1 Year Maturity								13,730		13,731
1-5 Years Maturity
Acacia Pharma Inc.^(5)(10)(11)	Drug Discovery & Development	Senior Secured	January 2022	Interest rate PRIME + 4.50% or Floor rate of 9.25%, 3.95% Exit Fee	$	10,000		10,115		10,043
Aldeyra Therapeutics, Inc	Drug Discovery & Development	Senior Secured	October 2023	Interest rate PRIME + 3.10% or Floor rate of 9.10%, 6.95% Exit Fee	$	15,000		14,969		14,969
Aveo Pharmaceuticals, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	July 2021	Interest rate PRIME + 4.70% or Floor rate of 9.45%, 5.40% Exit Fee	$	8,084		8,404		8,340
	Drug Discovery & Development	Senior Secured	July 2021	Interest rate PRIME + 4.70% or Floor rate of 9.45%, 3.00% Exit Fee	$	8,084		8,280		8,274
Total Aveo Pharmaceuticals, Inc.					$	16,168		16,684		16,614
Axovant Gene Therapies Ltd. (p.k.a. Axovant Sciences Ltd.)^(5)(10)(11)	Drug Discovery & Development	Senior Secured	March 2021	Interest rate PRIME + 6.80% or Floor rate of 11.55%	$	15,731		15,608		15,608
BridgeBio Pharma LLC^(12)(13)(16)	Drug Discovery & Development	Senior Secured	January 2023	Interest rate PRIME + 3.85% or Floor rate of 8.85%, 6.35% Exit Fee	$	35,000		35,684		35,721
	Drug Discovery & Development	Senior Secured	January 2023	Interest rate PRIME + 2.85% or Floor rate of 8.60%, 5.75% Exit Fee	$	20,000		20,264		20,495
	Drug Discovery & Development	Senior Secured	January 2023	Interest rate PRIME + 3.10% or Floor rate of 9.10%, 5.75% Exit Fee	$	20,000		20,062		20,284
Total BridgeBio Pharma LLC					$	75,000		76,010		76,500
Chemocentryx, Inc.^(10)(15)	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 3.30% or Floor rate of 8.05%, 6.25% Exit Fee	$	20,000		20,306		20,501
Codiak Biosciences, Inc.^(11)(17)	Drug Discovery & Development	Senior Secured	October 2024	Interest rate PRIME + 3.75% or Floor rate of 9.00%, 5.50% Exit Fee	$	10,000		9,955		9,955
Constellation Pharmaceuticals, Inc.^(12)(17)	Drug Discovery & Development	Senior Secured	April 2023	Interest rate PRIME + 2.55% or Floor rate of 8.55%, 6.35% Exit Fee	$	30,000		30,139		30,636
Dermavant Sciences Ltd.^(5)(10)(13)	Drug Discovery & Development	Senior Secured	June 2022	Interest rate PRIME + 4.45% or Floor rate of 9.95%, 6.95% Exit Fee	$	20,000		20,085		20,113
Eidos Therapeutics, Inc.^(10)(17)	Drug Discovery & Development	Senior Secured	October 2023	Interest rate PRIME + 3.25% or Floor rate of 8.50%, 5.95% Exit Fee	$	8,750		8,728		8,728
Genocea Biosciences, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	May 2021	Interest rate PRIME + 3.00% or Floor rate of 8.00%, 13.43% Exit Fee	$	12,922		13,502		13,542
Kaleido Biosciences, Inc.	Drug Discovery & Development	Senior Secured	January 2024	Interest rate PRIME + 4.20% or Floor rate of 8.95%, 7.55% Exit Fee	$	22,500		22,372		22,373
Mesoblast⁽^5)(10)(11)	Drug Discovery & Development	Senior Secured	March 2022	Interest rate PRIME + 4.95% or Floor rate of 9.45%, 6.95% Exit Fee	$	50,000		51,552		51,547
Motif BioSciences Inc.^(5)(8)(10)	Drug Discovery & Development	Senior Secured	September 2021	Interest rate PRIME + 5.50% or Floor rate of 10.00%, 2.87% Exit Fee	$	6,738		6,732		—
Nabriva Therapeutics^(5)(10)	Drug Discovery & Development	Senior Secured	June 2023	Interest rate PRIME + 4.30% or Floor rate of 9.80%, 6.95% Exit Fee	$	35,000		35,259		35,536

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Paratek Pharmaceuticals, Inc.^(11)(15)(16)	Drug Discovery & Development	Senior Secured	September 2021	Interest rate PRIME + 2.75% or Floor rate of 8.50%, 4.13% Exit Fee	$	60,000		61,905		62,131
	Drug Discovery & Development	Senior Secured	August 2022	Interest rate PRIME + 2.10% or Floor rate of 7.85%, 6.95% Exit Fee	$	10,000		10,241		10,295
Total Paratek Pharmaceuticals, Inc.					$	70,000		72,146		72,426
Replimune Group, Inc.^(5)(10)(11)	Drug Discovery & Development	Senior Secured	August 2023	Interest rate PRIME + 2.75% or Floor rate of 8.75%, 4.95% Exit Fee	$	10,000	$	9,974	$	9,974
Seres Therapeutics, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	November 2023	Interest rate PRIME + 4.40% or Floor rate of 9.65%, 4.85% Exit Fee	$	25,000		24,804		24,804
Stealth Bio Therapeutics Corp.^(5)(10)(11)	Drug Discovery & Development	Senior Secured	January 2021	Interest rate PRIME + 5.50% or Floor rate of 9.50%, 6.68% Exit Fee	$	16,509		17,502		17,501
TG Therapeutics, Inc.^(10)(13)	Drug Discovery & Development	Senior Secured	March 2022	Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.25% Exit Fee	$	30,000		29,726		29,849
Tricida, Inc.^{(11)(15)(16)(17)}	Drug Discovery & Development	Senior Secured	April 2023	Interest rate PRIME + 2.35% or Floor rate of 8.35%, 11.92% Exit Fee	$	60,000		60,442		61,193
uniQure B.V.^(5)(10)(11)	Drug Discovery & Development	Senior Secured	June 2023	Interest rate PRIME + 3.35% or Floor rate of 8.85%, 7.72% Exit Fee	$	35,000		36,090		36,419
Urovant Sciences, Ltd.^(5)(10)(13)	Drug Discovery & Development	Senior Secured	March 2023	Interest rate PRIME + 4.65% or Floor rate of 10.15%, 4.25% Exit Fee	$	45,000		44,622		44,622
Verastem, Inc.⁽¹¹⁾	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee	$	5,000		5,028		5,073
	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee	$	5,000		5,048		5,094
	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee	$	5,000		5,060		5,083
	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee	$	10,000		10,066		10,157
	Drug Discovery & Development	Senior Secured	December 2022	Interest rate PRIME + 4.25% or Floor rate of 9.75%, 5.25% Exit Fee	$	10,000		10,035		10,125
Total Verastem, Inc.					$	35,000		35,237		35,532
X4 Pharmaceuticals, Inc.^(11)(17)	Drug Discovery & Development	Senior Secured	July 2023	Interest rate PRIME + 2.75% or Floor rate of 8.75%, 7.98% Exit Fee	$	20,000		20,088		20,165
Yumanity Therapeutics, Inc.	Drug Discovery & Development	Senior Secured	January 2024	Interest rate PRIME + 4.00% or Floor rate of 8.75%, 5.25% Exit Fee	$	15,000		14,732		14,732
Subtotal: 1-5 Years Maturity								717,379		713,882
Subtotal: Drug Discovery & Development (64.22%)*								731,109		727,613
Electronics & Computer Hardware
1-5 Years Maturity
Glo AB⁽⁵⁾⁽^10)(13)(14)	Electronics & Computer Hardware	Senior Secured	February 2021	Interest rate PRIME + 6.20% or Floor rate of 10.45%, PIK Interest 1.75%, 5.03% Exit Fee	$	8,215		8,730		4,410
Subtotal: 1-5 Years Maturity								8,730		4,410
Subtotal: Electronics & Computer Hardware (0.39%)*								8,730		4,410
Healthcare Services, Other
1-5 Years Maturity
Oak Street Health^(11)(16)	Healthcare Services, Other	Senior Secured	June 2022	Interest rate PRIME + 5.00% or Floor rate of 9.75%, 5.95% Exit Fee	$	80,000		81,190		81,270
The CM Group LLC⁽¹⁷⁾	Healthcare Services, Other	Senior Secured	June 2024	Interest rate 1-month LIBOR + 8.35% or Floor rate of 9.35%	$	9,429		9,268		9,114
Velocity Clinical Research, Inc.⁽¹⁸⁾	Healthcare Services, Other	Senior Secured	November 2024	Interest rate 3-month LIBOR + 9.08% or Floor rate of 10.08%	$	7,500		7,226		7,226
Subtotal: 1-5 Years Maturity								97,684		97,610
Subtotal: Healthcare Services, Other (8.61%)*								97,684		97,610
Information Services
1-5 Years Maturity
Planet Labs, Inc.⁽¹¹⁾	Information Services	Senior Secured	June 2022	Interest rate PRIME + 5.50% or Floor rate of 11.00%, 3.00% Exit Fee	$	20,000		19,526		19,583
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.)^(14)(15)(19)	Information Services	Senior Secured	June 2021	Interest rate PRIME + 2.75% or Floor rate of 9.50%, PIK Interest 1.70%, 2.80% Exit Fee	$	15,554		15,647		15,682
Yipit, LLC^(17)(18)	Information Services	Senior Secured	May 2024	Interest rate 3-month LIBOR + 7.99% or Floor rate of 8.99%	$	10,625		10,415		10,272
Subtotal: 1-5 Years Maturity								45,588		45,537
Subtotal: Information Services (4.02%)*								45,588		45,537
Internet Consumer & Business Services
Under 1 Year Maturity
Snagajob.com, Inc.^(13)(14)	Internet Consumer & Business Services	Senior Secured	August 2020	Interest rate PRIME + 5.15% or Floor rate of 9.15%, PIK Interest 1.95%, 2.55% Exit Fee	$	42,676		43,344		43,344

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
	Internet Consumer & Business Services	Senior Secured	August 2020	Interest rate PRIME + 5.65% or Floor rate of 10.65%, PIK Interest 1.95%, 2.55% Exit Fee	$	5,134		5,127		5,127
Total Snagajob.com, Inc.					$	47,810		48,471		48,471
Subtotal: Under 1 Year Maturity								48,471		48,471
1-5 Years Maturity
AppDirect, Inc.^(11)(19)	Internet Consumer & Business Services	Senior Secured	January 2022	Interest rate PRIME + 5.70% or Floor rate of 9.95%, 3.45% Exit Fee	$	20,000	$	20,288	$	20,239
Arctic Wolf Networks, Inc.^(13)(19)	Internet Consumer & Business Services	Senior Secured	April 2023	Interest rate 3-month LIBOR + 7.75% or Floor rate of 10.10%, 7.55% Exit Fee	$	30,000		30,214		30,280
Cloudpay, Inc.^(5)(10)(11)	Internet Consumer & Business Services	Senior Secured	April 2022	Interest rate PRIME + 4.05% or Floor rate of 8.55%, 6.95% Exit Fee	$	15,000		15,304		15,169
Contentful, Inc.^{(5)(10)(11)(14)}	Internet Consumer & Business Services	Senior Secured	July 2022	Interest rate PRIME + 2.95% or Floor rate of 7.95%, PIK Interest 1.25%, 3.55% Exit Fee	$	3,794		3,793		3,786
ePayPolicy Holdings, LLC⁽¹⁷⁾	Internet Consumer & Business Services	Senior Secured	December 2024	Interest rate 3-month LIBOR + 9.00% or Floor rate of 10.00%	$	8,000		7,758		7,758
EverFi, Inc.^(11)(14)(16)	Internet Consumer & Business Services	Senior Secured	May 2022	Interest rate PRIME + 3.90% or Floor rate of 9.15%, PIK Interest 2.30%	$	72,208		71,905		72,277
Greenphire, Inc.	Internet Consumer & Business Services	Senior Secured	January 2021	Interest rate 3-month LIBOR + 8.00% or Floor rate of 9.00%	$	1,612		1,612		1,610
	Internet Consumer & Business Services	Senior Secured	January 2021	Interest rate PRIME + 3.75% or Floor rate of 8.75%	$	2,000		2,000		2,000
Total Greenphire, Inc.					$	3,612		3,612		3,610
Houzz, Inc.⁽¹⁴⁾	Internet Consumer & Business Services	Senior Secured	November 2022	Interest rate PRIME + 3.20% or Floor rate of 8.45%, PIK Interest 2.50%, 4.50% Exit Fee	$	50,115		49,720		49,720
Intent (p.k.a. Intent Media, Inc.)⁽¹²⁾	Internet Consumer & Business Services	Senior Secured	September 2021	Interest rate PRIME + 5.13% or Floor rate of 10.13%, 2.00% Exit Fee	$	15,200		15,141		15,034
Lendio, Inc.^(11)(19)	Internet Consumer & Business Services	Senior Secured	April 2023	Interest rate PRIME + 4.45% or Floor rate of 9.95%, 5.25% Exit Fee	$	5,000		4,985		4,999
Nextroll, Inc.^(14)(19)	Internet Consumer & Business Services	Senior Secured	June 2022	Interest rate PRIME + 3.85% or Floor rate of 9.35%, PIK Interest 2.95%, 3.50% Exit Fee	$	20,303		20,268		20,459
Patron Technology⁽¹⁸⁾	Internet Consumer & Business Services	Senior Secured	June 2024	Interest rate 3-month LIBOR + 8.30% or Floor rate of 9.30%	$	35,750		34,776		35,400
	Internet Consumer & Business Services	Senior Secured	June 2024	Interest rate 3-month LIBOR + 8.30% or Floor rate of 9.30%	$	1,500		1,500		1,500
Total Patron Technology					$	37,250		36,276		36,900
Postmates, Inc.⁽¹⁹⁾	Internet Consumer & Business Services	Senior Secured	September 2022	Interest rate PRIME + 3.85% or Floor rate of 8.85%, 8.05% Exit Fee	$	20,000		20,313		20,274
SeatGeek, Inc.^(14)(17)	Internet Consumer & Business Services	Senior Secured	June 2023	Interest rate PRIME + 5.00% or Floor rate of 10.50%, PIK Interest 0.50%	$	23,043		22,382		22,471
Skyword, Inc.⁽¹⁴⁾	Internet Consumer & Business Services	Senior Secured	September 2023	Interest rate PRIME + 3.88% or Floor rate of 9.38%, PIK Interest 1.25%, 2.75% Exit Fee	$	12,042		11,886		11,886
Tectura Corporation^{(7)(8)(9)(14)}	Internet Consumer & Business Services	Senior Secured	June 2021	Interest rate FIXED 6.00%, PIK Interest 3.00%	$	21,407		21,407		9,586
	Internet Consumer & Business Services	Senior Secured	June 2021	PIK Interest 8.00%	$	10,680		240		—
Total Tectura Corporation					$	32,087		21,647		9,586
Varsity Tutors LLC⁽¹⁴⁾	Internet Consumer & Business Services	Senior Secured	August 2023	Interest rate PRIME + 5.25% or Floor rate of 10.75%, PIK Interest 0.55%, 3.00% Exit Fee	$	35,052		34,822		34,822
Wheels Up Partners LLC⁽¹¹⁾	Internet Consumer & Business Services	Senior Secured	July 2022	Interest rate 3-month LIBOR + 8.55% or Floor rate of 9.55%	$	17,129		17,026		16,988
Xometry, Inc.^(13)(19)	Internet Consumer & Business Services	Senior Secured	November 2021	Interest rate PRIME + 3.95% or Floor rate of 8.45%, 7.09% Exit Fee	$	11,000		11,345		11,401
Subtotal: 1-5 Years Maturity								418,685		407,659
Subtotal: Internet Consumer & Business Services (40.26%)*								467,156		456,130
Media/Content/Info
1-5 Years Maturity
Bustle⁽¹⁴⁾⁽¹⁵⁾	Media/Content/Info	Senior Secured	June 2023	Interest rate PRIME + 4.35% or Floor rate of 9.35%, PIK Interest 1.95%, 4.34% Exit Fee	$	20,632		20,647		20,786
Subtotal: 1-5 Years Maturity								20,647		20,786
Subtotal: Media/Content/Info (1.83%)*								20,647		20,786
Medical Devices & Equipment
1-5 Years Maturity

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Flowonix Medical Incorporated⁽¹¹⁾	Medical Devices & Equipment	Senior Secured	October 2021	Interest rate PRIME + 4.00% or Floor rate of 9.00%, 7.95% Exit Fee	$	7,561		8,178		8,158
Intuity Medical, Inc.^(11)(15)	Medical Devices & Equipment	Senior Secured	June 2021	Interest rate PRIME + 5.00% or Floor rate of 9.25%, 6.95% Exit Fee	$	14,188		14,906		14,810
Quanterix Corporation⁽¹¹⁾	Medical Devices & Equipment	Senior Secured	October 2021	Interest rate PRIME + 2.75% or Floor rate of 8.00%, 0.96% Exit Fee	$	7,688		7,683		7,728
Rapid Micro Biosystems, Inc.^(11)(15)	Medical Devices & Equipment	Senior Secured	April 2022	Interest rate PRIME + 5.15% or Floor rate of 9.65%, 7.25% Exit Fee	$	18,000		18,586		18,454
Sebacia, Inc.^(11)(15)	Medical Devices & Equipment	Senior Secured	January 2021	Interest rate PRIME + 4.35% or Floor rate of 8.85%, 6.05% Exit Fee	$	11,000	$	11,503	$	11,426
Subtotal: 1-5 Years Maturity								60,856		60,576
Subtotal: Medical Devices & Equipment (5.35%)*								60,856		60,576
Semiconductors
1-5 Years Maturity
Elenion Technologies Corporation^(13)(14)	Semiconductors	Senior Secured	February 2022	Interest rate PRIME + 4.25% or Floor rate of 9.75%, PIK Interest 2.25%, 5.00% Exit Fee	$	10,187		10,316		10,316
Subtotal: 1-5 Years Maturity								10,316		10,316
Subtotal: Semiconductors (0.91%)*								10,316		10,316
Software
Under 1 Year Maturity
Delphix Corp.⁽¹⁹⁾	Software	Senior Secured	September 2020	Interest rate PRIME + 5.25% or Floor rate of 10.25%, 7.00% Exit Fee	$	10,000		9,878		9,878
Evernote Corporation^{(11)(14)(15)(19)}	Software	Senior Secured	October 2020	Interest rate PRIME + 5.45% or Floor rate of 8.95%	$	5,549		5,494		5,494
Lightbend, Inc.^(14)(15)	Software	Senior Secured	June 2020	Interest rate PRIME + 4.25% or Floor rate of 9.25%, PIK Interest 2.00%, 12.95% Exit Fee	$	2,026		2,026		2,026
Pollen, Inc.⁽¹⁵⁾	Software	Senior Secured	October 2020	Interest rate PRIME + 4.25% or Floor rate of 8.50%, 5.95% Exit Fee	$	7,000		7,339		7,339
Subtotal: Under 1 Year Maturity								24,737		24,737
1-5 Years Maturity
Abrigo⁽¹⁸⁾	Software	Senior Secured	March 2023	Interest rate 3-month LIBOR + 7.88% or Floor rate of 8.88%	$	39,303		38,649		38,826
	Software	Senior Secured	March 2023	Interest rate 3-month LIBOR + 5.92% or Floor rate of 6.92%	$	2,362		2,304		2,304
Total Abrigo					$	41,665		40,953		41,130
Businessolver.com, Inc.^(11)(16)	Software	Senior Secured	May 2023	Interest rate 3-month LIBOR + 7.50% or Floor rate of 8.50%	$	58,650		57,776		57,760
	Software	Senior Secured	May 2023	Interest rate 3-month LIBOR + 7.50% or Floor rate of 8.50% and Interest rate PRIME + 6.5% or Floor rate of 8.50%	$	2,550		2,550		2,550
Total Businessolver.com, Inc.					$	61,200		60,326		60,310
Clarabridge, Inc.^{(12)(13)(14)(17)}	Software	Senior Secured	April 2022	Interest rate PRIME + 4.80% or Floor rate of 8.55%, PIK Interest 2.25%	$	48,268		47,907		48,006
Cloud 9 Software^(13)(17)	Software	Senior Secured	April 2024	Interest rate 3-month LIBOR + 8.20% or Floor rate of 9.20%	$	9,500		9,332		9,374
Cloudian, Inc.⁽¹¹⁾	Software	Senior Secured	November 2022	Interest rate PRIME + 3.25% or Floor rate of 8.25%, 9.75% Exit Fee	$	15,000		15,323		15,211
Couchbase, Inc.^(11)(15)(19)	Software	Senior Secured	May 2023	Interest rate PRIME + 5.25% or Floor rate of 10.75%, 3.75% Exit Fee	$	50,000		49,575		49,932
Dashlane, Inc.^{(11)(14)(17)(19)}	Software	Senior Secured	April 2022	Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 8.50% Exit Fee	$	10,180		10,457		10,481
	Software	Senior Secured	March 2023	Interest rate PRIME + 4.05% or Floor rate of 8.55%, PIK Interest 1.10%, 4.95% Exit Fee	$	10,081		9,920		9,899
Total Dashlane, Inc.					$	20,261		20,377		20,380
Evernote Corporation^{(11)(14)(15)(19)}	Software	Senior Secured	July 2021	Interest rate PRIME + 6.00% or Floor rate of 9.50%, PIK Interest 1.25%	$	4,126		4,055		4,038
	Software	Senior Secured	July 2022	Interest rate PRIME + 6.00% or Floor rate of 9.50%, PIK Interest 1.25%	$	5,077		5,012		5,065
Total Evernote Corporation					$	9,203		9,067		9,103
Ikon Science Limited^(5)(10)(18)	Software	Senior Secured	October 2024	Interest rate LIBOR + 9.00% or Floor rate of 10.00%	$	7,000		6,688		6,688
Insurance Technologies Corporation^(11)(18)	Software	Senior Secured	March 2023	Interest rate 3-month LIBOR + 7.90% or Floor rate of 8.90%	$	13,750		13,526		13,330

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor ⁽²⁾	Principal Amount		Cost ⁽³⁾		Value ⁽⁴⁾
Jolt Software, Inc.⁽¹⁴⁾	Software	Senior Secured	October 2022	Interest rate PRIME + 3.00% or Floor rate of 8.50%, PIK Interest 1.75%, 4.50% Exit Fee	$	5,017		5,004		5,004
Kazoo, Inc. (p.k.a. YouEarnedIt, Inc.)^(11)(18)	Software	Senior Secured	July 2023	Interest rate 1-month LIBOR + 8.65% or Floor rate of 9.65%	$	8,785		8,589		8,531
Khoros (p.k.a Lithium Technologies)⁽¹¹⁾	Software	Senior Secured	October 2022	Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00%	$	12,000		11,835		11,825
	Software	Senior Secured	October 2022	Interest rate 6-month LIBOR + 8.00% or Floor rate of 9.00%	$	43,000		42,233		42,049
Total Khoros (p.k.a Lithium Technologies)					$	55,000		54,068		53,874
Lastline, Inc.⁽¹⁹⁾	Software	Senior Secured	July 2022	Interest rate PRIME + 5.45% or Floor rate of 10.95%	$	6,000		5,834		5,844
Lightbend, Inc.^(14)(15)	Software	Senior Secured	February 2022	Interest rate PRIME + 4.25% or Floor rate of 9.25%, PIK Interest 2.00%, 3.00% Exit Fee	$	16,509	$	16,384	$	16,333
Mobile Solutions Services^(17)(18)	Software	Senior Secured	October 2024	Interest rate 3-month LIBOR + 8.80% or Floor rate of 9.80%	$	5,500		5,329		5,329
Nuvolo Technologies Corporation⁽¹⁹⁾	Software	Senior Secured	October 2022	Interest rate PRIME + 6.25% or Floor rate of 11.75%	$	13,000		12,815		12,877
OrthoFi, Inc.^(13)(18)	Software	Senior Secured	April 2024	Interest rate 3-month LIBOR + 8.28% or Floor rate of 9.28%	$	17,853		17,417		17,283
Quid, Inc.^(11)(14)(15)	Software	Senior Secured	November 2022	Interest rate PRIME + 4.45% or Floor rate of 9.95%, PIK Interest 2.25%, 3.61% Exit Fee	$	13,251		13,235		13,235
Regent Education⁽¹⁴⁾	Software	Senior Secured	January 2022	Interest rate FIXED 10.00%, PIK Interest 2.00%, 7.94% Exit Fee	$	3,155		3,214		1,773
Salsa Labs, Inc.^(11)(17)	Software	Senior Secured	April 2023	Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15%	$	6,000		5,915		5,959
	Software	Senior Secured	April 2023	Interest rate 3-month LIBOR + 8.15% or Floor rate of 9.15%	$	150		150		151
Total Salsa Labs, Inc.					$	6,150		6,065		6,110
ThreatConnect, Inc.^(13)(17)(18)	Software	Senior Secured	May 2024	Interest rate 3-month LIBOR + 8.26% or Floor rate of 9.26%	$	4,500		4,365		4,387
Vela Trading Technologies^(11)(18)	Software	Senior Secured	July 2022	Interest rate 3-month LIBOR + 10.50% or Floor rate of 11.50%	$	19,095		18,721		18,721
ZeroFox, Inc.	Software	Senior Secured	January 2023	Interest rate PRIME + 4.75% or Floor rate of 10.25%, 3.00% Exit Fee	$	15,000		14,927		14,948
ZocDoc⁽¹¹⁾⁽¹⁹⁾	Software	Senior Secured	August 2021	Interest rate PRIME + 6.20% or Floor rate of 10.95%, 2.00% Exit Fee	$	30,000		30,241		30,287
Subtotal: 1-5 Years Maturity								489,282		488,000
Greater than 5 Years Maturity
Campaign Monitor Limited^(11)(17)(19)	Software	Senior Secured	November 2025	Interest rate 1-month LIBOR + 8.50% or Floor rate of 9.50%	$	29,333		28,676		28,511
	Software	Senior Secured	November 2025	Interest rate 1-month LIBOR + 8.50% or Floor rate of 9.50%	$	688		672		672
Total Campaign Monitor Limited					$	30,021		29,348		29,183
Imperva, Inc.⁽¹⁹⁾	Software	Senior Secured	January 2027	Interest rate 3-month LIBOR + 7.75% or Floor rate of 8.75%	$	20,000		19,806		19,806
Subtotal: Greater than 5 Years Maturity								49,154		48,989
Subtotal: Software (49.58%)*								563,173		561,726
Sustainable and Renewable Technology
1-5 Years Maturity
Impossible Foods, Inc.^(12)(13)	Sustainable and Renewable Technology	Senior Secured	January 2022	Interest rate PRIME + 3.95% or Floor rate of 8.95%, 9.00% Exit Fee	$	50,000		51,843		51,780
Proterra, Inc.^(11)(14)(19)	Sustainable and Renewable Technology	Senior Secured	May 2021	Interest rate PRIME + 5.05% or Floor rate of 10.55%, PIK Interest 1.75%	$	10,101		10,059		10,100
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)^{(6)(8)(14)(19)}	Sustainable and Renewable Technology	Senior Secured	December 2020	Interest rate FIXED 6.73%, PIK Interest 6.73%, 6.67% Exit Fee	$	10,000		10,775		10,512
	Sustainable and Renewable Technology	Senior Secured	December 2020	PIK Interest 10.00%	$	683		683		664
	Sustainable and Renewable Technology	Senior Secured	December 2020	Interest rate FIXED 8.85%, PIK Interest 8.85%	$	1,492		1,492		1,439
Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)					$	12,175		12,950		12,615
Subtotal: 1-5 Years Maturity								74,852		74,495
Subtotal: Sustainable and Renewable Technology (6.57%)*								74,852		74,495
Total: Debt Investments (189.63%)*								2,170,140		2,148,592

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
Equity Investments
Communications & Networking
Peerless Network Holdings, Inc.	Communications & Networking	Equity	Preferred Series A		1,135,000	$	1,230	$	3,955
Subtotal: Communications & Networking (0.35%)*							1,230		3,955
Diversified Financial Services
Gibraltar Business Capital, LLC⁽⁷⁾	Diversified Financial Services	Equity	Common Stock		830,000		1,884		2,380
	Diversified Financial Services	Equity	Preferred Series A		10,602,752		26,122		33,000
Total Gibraltar Business Capital, LLC					11,432,752		28,006		35,380
Subtotal: Diversified Financial Services (3.11%)*							28,006		35,380
Drug Delivery
AcelRx Pharmaceuticals, Inc.⁽⁴⁾	Drug Delivery	Equity	Common Stock		176,730		1,329		373
BioQ Pharma Incorporated⁽¹⁵⁾	Drug Delivery	Equity	Preferred Series D		165,000		500		768
Kaleo, Inc.	Drug Delivery	Equity	Preferred Series B		82,500		1,007		3,067
Neos Therapeutics, Inc.^(4)(15)	Drug Delivery	Equity	Common Stock		125,000		1,500		189
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.)⁽⁴⁾	Drug Delivery	Equity	Common Stock		2,498		309		7
Subtotal: Drug Delivery (0.39%)*							4,645		4,404
Drug Discovery & Development
Aveo Pharmaceuticals, Inc.^(4)(15)	Drug Discovery & Development	Equity	Common Stock		1,901,791		1,715		1,189
Axovant Gene Therapies Ltd. (p.k.a. Axovant Sciences Ltd.)^(4)(5)(10)	Drug Discovery & Development	Equity	Common Stock		16,228		1,269		83
BridgeBio Pharma LLC^(4)(16)	Drug Discovery & Development	Equity	Common Stock		203,579		2,000		7,135
Cerecor, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		119,087		1,000		642
Concert Pharmaceuticals, Inc.^(4)(10)	Drug Discovery & Development	Equity	Common Stock		70,796		1,367		653
Dare Biosciences, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		13,550		1,000		11
Dynavax Technologies^(4)(10)	Drug Discovery & Development	Equity	Common Stock		20,000		550		114
Eidos Therapeutics, Inc.^(4)(10)	Drug Discovery & Development	Equity	Common Stock		15,000		255		861
Genocea Biosciences, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		27,932		2,000		58
Insmed, Incorporated⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		50,771		717		1,212
Melinta Therapeutics⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		10,364		2,000		6
Paratek Pharmaceuticals, Inc.^(4)(16)	Drug Discovery & Development	Equity	Common Stock		76,362		2,744		307
Rocket Pharmaceuticals, Ltd.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		944		1,500		21
Savara, Inc.^(4)(15)	Drug Discovery & Development	Equity	Common Stock		11,119		203		50
uniQure B.V.^(4)(5)(10)	Drug Discovery & Development	Equity	Common Stock		17,175		332		1,231
X4 Pharmaceuticals, Inc.⁽⁴⁾	Drug Discovery & Development	Equity	Common Stock		83,334		640		891
Subtotal: Drug Discovery & Development (1.28%)*							19,292		14,464
Healthcare Services, Other
23andMe, Inc.	Healthcare Services, Other	Equity	Common Stock		360,000		5,094		5,196
Chromadex Corporation⁽⁴⁾	Healthcare Services, Other	Equity	Common Stock		44,264		157		191
Subtotal: Healthcare Services, Other (0.48%)*							5,251		5,387
Information Services
DocuSign, Inc.⁽⁴⁾	Information Services	Equity	Common Stock		251,000		3,871		13,795
Subtotal: Information Services (1.22%)*							3,871		13,795
Internet Consumer & Business Services
Blurb, Inc.	Internet Consumer & Business Services	Equity	Preferred Series B		220,653		175		46
Contentful, Inc.^(5)(10)	Internet Consumer & Business Services	Equity	Preferred Series D		217		500		443
Countable Corporation (p.k.a. Brigade Group, Inc.)	Internet Consumer & Business Services	Equity	Common Stock		9,023		93		—
DoorDash, Inc.	Internet Consumer & Business Services	Equity	Common Stock		105,000		6,051		14,422
Lyft, Inc.⁽⁴⁾	Internet Consumer & Business Services	Equity	Common Stock		200,738		10,487		8,636
Nextdoor.com, Inc.	Internet Consumer & Business Services	Equity	Common Stock		328,190		4,854		6,692
OfferUp, Inc.	Internet Consumer & Business Services	Equity	Preferred Series A		286,080		1,663		1,470
	Internet Consumer & Business Services	Equity	Preferred Series A-1		108,710		632		559
Total OfferUp, Inc.					394,790		2,295		2,029
Oportun⁽⁴⁾	Internet Consumer & Business Services	Equity	Common Stock		37,393		500		890
Tectura Corporation⁽⁷⁾	Internet Consumer & Business Services	Equity	Common Stock		414,994,863		900		—
	Internet Consumer & Business Services	Equity	Preferred Series BB		1,000,000		—		—
Total Tectura Corporation					415,994,863		900		—
Subtotal: Internet Consumer & Business Services (2.92%)*							25,855		33,158
Medical Devices & Equipment
Flowonix Medical Incorporated	Medical Devices & Equipment	Equity	Preferred Series AA		221,893		1,500		—
Gelesis, Inc.	Medical Devices & Equipment	Equity	Common Stock		227,013		—		679
	Medical Devices & Equipment	Equity	Preferred Series A-1		191,210		425		598
	Medical Devices & Equipment	Equity	Preferred Series A-2		191,626		500		584
Total Gelesis, Inc.					609,849		925		1,861
Medrobotics Corporation⁽¹⁵⁾	Medical Devices & Equipment	Equity	Preferred Series E		136,798		250		—
	Medical Devices & Equipment	Equity	Preferred Series F		73,971		155		—
	Medical Devices & Equipment	Equity	Preferred Series G		163,934		500		—
Total Medrobotics Corporation					374,703		905		—

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Devices & Equipment	Equity	Preferred Series B		61,855	$	3,000	$	463
	Medical Devices & Equipment	Equity	Preferred Series C		19,273		655		127
	Medical Devices & Equipment	Equity	Preferred Series D		551,038		5,257		3,784
	Medical Devices & Equipment	Equity	Preferred Series E		507,103		4,239		4,610
Total Optiscan Biomedical, Corp.					1,139,269		13,151		8,984
Outset Medical, Inc.	Medical Devices & Equipment	Equity	Preferred Series B		232,061		527		615
ViewRay, Inc.^(4)(15)	Medical Devices & Equipment	Equity	Common Stock		36,457		333		154
Subtotal: Medical Devices & Equipment (1.03%)*							17,341		11,614
Software
CapLinked, Inc.	Software	Equity	Preferred Series A-3		53,614		51		95
Docker, Inc.	Software	Equity	Common Stock		20,000		4,284		22
Druva Holdings, Inc. (p.k.a. Druva, Inc.)	Software	Equity	Preferred Series 2		458,841		1,000		1,883
	Software	Equity	Preferred Series 3		93,620		300		432
Total Druva Holdings, Inc. (p.k.a. Druva, Inc.)					552,461		1,300		2,315
HighRoads, Inc.	Software	Equity	Common Stock		190		307		—
Palantir Technologies	Software	Equity	Preferred Series D		9,535		47		49
	Software	Equity	Preferred Series E		1,749,089		10,489		8,932
	Software	Equity	Preferred Series G		326,797		2,211		1,668
Total Palantir Technologies					2,085,421		12,747		10,649
Sprinklr, Inc.	Software	Equity	Common Stock		700,000		3,749		4,159
Subtotal: Software (1.52%)*							22,438		17,240
Surgical Devices
Gynesonics, Inc.⁽¹⁵⁾	Surgical Devices	Equity	Preferred Series B		219,298		250		7
	Surgical Devices	Equity	Preferred Series C		656,538		282		21
	Surgical Devices	Equity	Preferred Series D		1,991,157		712		70
	Surgical Devices	Equity	Preferred Series E		2,786,367		429		121
	Surgical Devices	Equity	Preferred Series F		1,523,693		118		148
	Surgical Devices	Equity	Preferred Series F-1		2,418,125		150		201
Total Gynesonics, Inc.					9,595,178		1,941		568
TransMedics Group, Inc. (p.k.a Transmedics, Inc.)⁽⁴⁾	Surgical Devices	Equity	Common Stock		162,617		2,550		3,091
Subtotal: Surgical Devices (0.32%)*							4,491		3,659
Sustainable and Renewable Technology
Impossible Foods, Inc.	Sustainable and Renewable Technology	Equity	Preferred Series E-1		188,611		2,000		1,496
Modumetal, Inc.	Sustainable and Renewable Technology	Equity	Preferred Series A-1		103,584		500		8
Proterra, Inc.	Sustainable and Renewable Technology	Equity	Preferred Series 5		99,280		500		493
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)⁽⁶⁾	Sustainable and Renewable Technology	Equity	Common Stock		488		61,502		—
Subtotal: Sustainable and Renewable Technology (0.18%)*							64,502		1,997
Total: Equity Investments (12.80%)*							196,922		145,053

Communications & Networking
Peerless Network Holdings, Inc.	Communications & Networking	Warrant	Common Stock		3,328		—		7
Spring Mobile Solutions, Inc.	Communications & Networking	Warrant	Common Stock		2,834,375		418		—
Subtotal: Communications & Networking (0.00%)*							418		7
Consumer & Business Products
Gadget Guard⁽¹⁵⁾	Consumer & Business Products	Warrant	Common Stock		1,662,441		228		—
Intelligent Beauty, Inc.	Consumer & Business Products	Warrant	Preferred Series B		190,234		230		475
The Neat Company	Consumer & Business Products	Warrant	Common Stock		54,054		365		—
Whoop, Inc.	Consumer & Business Products	Warrant	Preferred Series C		68,627		18		55
Subtotal: Consumer & Business Products (0.05%)*							841		530
Drug Delivery
Aerami Therapeutics (p.k.a. Dance Biopharm, Inc.)⁽¹⁵⁾	Drug Delivery	Warrant	Common Stock		110,882		74		—
Agile Therapeutics, Inc.⁽⁴⁾	Drug Delivery	Warrant	Common Stock		180,274		730		113
BioQ Pharma Incorporated	Drug Delivery	Warrant	Common Stock		459,183		1		928
Neos Therapeutics, Inc.^(4)(15)	Drug Delivery	Warrant	Common Stock		70,833		285		—
PDS Biotechnology Corporation (p.k.a. Edge Therapeutics, Inc.)⁽⁴⁾	Drug Delivery	Warrant	Common Stock		3,929		390		—
Pulmatrix Inc.⁽⁴⁾	Drug Delivery	Warrant	Common Stock		2,515		116		—
ZP Opco, Inc.⁽⁴⁾	Drug Delivery	Warrant	Common Stock		3,618		265		—
Subtotal: Drug Delivery (0.09%)*							1,861		1,041
Drug Discovery & Development
Acacia Pharma Inc.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		201,330		304		109
ADMA Biologics, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		89,750		295		39
Brickell Biotech, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		9,005		119		—
Cerecor, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		22,328		70		12
Concert Pharmaceuticals, Inc.^(4)(10)(15)	Drug Discovery & Development	Warrant	Common Stock		61,273		178		75

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
CTI BioPharma Corp.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		29,239	$	165	$	—
CytRx Corporation^(4)(15)	Drug Discovery & Development	Warrant	Common Stock		105,694		160		—
Dare Biosciences, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		17,190		369		—
Dermavant Sciences Ltd.^(5)(10)	Drug Discovery & Development	Warrant	Common Stock		223,642		101		108
Dicerna Pharmaceuticals, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		200		28		—
Evofem Biosciences, Inc.^(4)(15)	Drug Discovery & Development	Warrant	Common Stock		7,806		266		19
Genocea Biosciences, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		41,176		165		15
Immune Pharmaceuticals⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		10,742		164		—
Melinta Therapeutics⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		8,109		625		—
Motif BioSciences Inc.^{(4)(5)(10)(15)}	Drug Discovery & Development	Warrant	Common Stock		73,452		282		—
Myovant Sciences, Ltd.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		73,710		460		485
Ology Bioservices, Inc.⁽¹⁵⁾	Drug Discovery & Development	Warrant	Common Stock		171,389		838		—
Paratek Pharmaceuticals, Inc.^(4)(15)(16)	Drug Discovery & Development	Warrant	Common Stock		94,841		204		20
Sorrento Therapeutics, Inc.^(4)(10)	Drug Discovery & Development	Warrant	Common Stock		306,748		889		270
Stealth Bio Therapeutics Corp.^(4)(5)(10)	Drug Discovery & Development	Warrant	American Depositary Shares		41,667		158		2
TG Therapeutics, Inc.^(4)(10)	Drug Discovery & Development	Warrant	Common Stock		147,058		564		920
Tricida, Inc.^(4)(15)(16)	Drug Discovery & Development	Warrant	Common Stock		131,998		1,102		2,667
Urovant Sciences, Ltd.^(4)(5)(10)	Drug Discovery & Development	Warrant	Common Stock		99,777		383		715
X4 Pharmaceuticals, Inc.⁽⁴⁾	Drug Discovery & Development	Warrant	Common Stock		108,334		673		302
XOMA Corporation^(4)(10)(15)	Drug Discovery & Development	Warrant	Common Stock		9,063		279		6
Yumanity Therapeutics, Inc.	Drug Discovery & Development	Warrant	Class B Preferred Units		34,946		110		114
Subtotal: Drug Discovery & Development (0.51%)*							8,951		5,878
Electronics & Computer Hardware
908 Devices, Inc.⁽¹⁵⁾	Electronics & Computer Hardware	Warrant	Preferred Series D		79,856		101		52
Subtotal: Electronics & Computer Hardware (0.00%)*							101		52
Information Services
InMobi Inc.^(5)(10)	Information Services	Warrant	Common Stock		65,587		82		—
Netbase Solutions, Inc.	Information Services	Warrant	Preferred Series 1		60,000		356		416
Planet Labs, Inc.	Information Services	Warrant	Common Stock		274,160		565		224
RichRelevance, Inc.	Information Services	Warrant	Preferred Series E		112,612		98		—
Sapphire Digital, Inc. (p.k.a. MDX Medical, Inc.)⁽¹⁵⁾	Information Services	Warrant	Common Stock		2,812,500		283		122
Subtotal: Information Services (0.07%)*							1,384		762
Internet Consumer & Business Services
Aria Systems, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series G		231,535		73		—
Blurb, Inc.⁽¹⁵⁾	Internet Consumer & Business Services	Warrant	Preferred Series C		234,280		636		13
Cloudpay, Inc.^(5)(10)	Internet Consumer & Business Services	Warrant	Preferred Series B		6,763		54		18
Contentful, Inc.^(5)(10)	Internet Consumer & Business Services	Warrant	Preferred Series C		82		1		17
Fastly, Inc.⁽⁴⁾	Internet Consumer & Business Services	Warrant	Common Stock		76,098		71		617
First Insight, Inc.⁽¹⁵⁾	Internet Consumer & Business Services	Warrant	Preferred Series B		75,917		96		151
Houzz, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		529,661		20		14
Intent (p.k.a. Intent Media, Inc.)	Internet Consumer & Business Services	Warrant	Common Stock		140,077		168		214
Interactions Corporation	Internet Consumer & Business Services	Warrant	Preferred Series G-3		68,187		204		445
Just Fabulous, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series B		206,184		1,102		1,622
Lendio, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series D		127,032		39		14
LogicSource	Internet Consumer & Business Services	Warrant	Preferred Series C		79,625		30		122
Oportun⁽⁴⁾	Internet Consumer & Business Services	Warrant	Common Stock		23,514		78		279
Postmates, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		189,865		317		83
RumbleON, Inc.⁽⁴⁾	Internet Consumer & Business Services	Warrant	Common Stock		102,768		87		6
SeatGeek, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		689,880		662		596
ShareThis, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series C		493,502		547		—
Skyword, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series A		444,444		83		43
Snagajob.com, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series A		1,800,000		782		40
	Internet Consumer & Business Services	Warrant	Preferred Series B		1,211,537		62		15
Total Snagajob.com, Inc.					3,011,537		844		55
Tapjoy, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series D		748,670		316		2
The Faction Group LLC	Internet Consumer & Business Services	Warrant	Preferred Series AA		8,076		234		395
Thumbtack, Inc.	Internet Consumer & Business Services	Warrant	Common Stock		190,953		553		958
Xometry, Inc.	Internet Consumer & Business Services	Warrant	Preferred Series B		87,784		47		180
Subtotal: Internet Consumer & Business Services (0.52%)*							6,262		5,844
Media/Content/Info
Machine Zone, Inc.	Media/Content/Info	Warrant	Common Stock		1,552,710		1,960		285
Napster	Media/Content/Info	Warrant	Common Stock		715,755		384		—
WP Technology, Inc. (Wattpad, Inc.)^(5)(10)	Media/Content/Info	Warrant	Common Stock		255,818		3		—
Zoom Media Group, Inc.	Media/Content/Info	Warrant	Preferred Series A		1,204		348		—
Subtotal: Media/Content/Info (0.03%)*							2,695		285

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
Medical Devices & Equipment
Aspire Bariatrics, Inc.⁽¹⁵⁾	Medical Devices & Equipment	Warrant	Preferred Series B-1		112,858	$	455	$	—
Flowonix Medical Incorporated	Medical Devices & Equipment	Warrant	Preferred Series AA		155,325		362		—
	Medical Devices & Equipment	Warrant	Preferred Series BB		725,806		351		—
Total Flowonix Medical Incorporated					881,131		713		—
Gelesis, Inc.	Medical Devices & Equipment	Warrant	Preferred Series A-1		74,784		78		172
InspireMD, Inc.^(4)(5)(10)	Medical Devices & Equipment	Warrant	Common Stock		1,105		—		—
Intuity Medical, Inc.⁽¹⁵⁾	Medical Devices & Equipment	Warrant	Preferred Series 5		1,819,078		294		338
Medrobotics Corporation⁽¹⁵⁾	Medical Devices & Equipment	Warrant	Preferred Series E		455,539		370		—
NinePoint Medical, Inc.	Medical Devices & Equipment	Warrant	Preferred Series A-1		587,840		170		38
Optiscan Biomedical, Corp.⁽⁶⁾	Medical Devices & Equipment	Warrant	Preferred Series E		74,424		572		209
Outset Medical, Inc.	Medical Devices & Equipment	Warrant	Preferred Series A		500,000		402		382
Sebacia, Inc.	Medical Devices & Equipment	Warrant	Preferred Series D		778,301		133		4
SonaCare Medical, LLC	Medical Devices & Equipment	Warrant	Preferred Series A		6,464		188		—
Tela Bio, Inc.⁽⁴⁾	Medical Devices & Equipment	Warrant	Common Stock		15,712		61		8
Subtotal: Medical Devices & Equipment (0.10%)*							3,436		1,151
Semiconductors
Achronix Semiconductor Corporation	Semiconductors	Warrant	Preferred Series C		360,000		160		6
	Semiconductors	Warrant	Preferred Series D-2		750,000		99		330
Total Achronix Semiconductor Corporation					1,110,000		259		336
Elenion Technologies Corporation	Semiconductors	Warrant	Preferred Series C		225		8		6
Subtotal: Semiconductors (0.03%)*							267		342
Software
Actifio, Inc.	Software	Warrant	Common Stock		73,584		249		93
	Software	Warrant	Preferred Series F		31,673		343		91
Total Actifio, Inc.					105,257		592		184
BryterCX, Inc. (p.k.a. ClickFox, Inc.)⁽¹⁵⁾	Software	Warrant	Preferred Series B		492,877		152		—
	Software	Warrant	Preferred Series C		592,019		730		—
	Software	Warrant	Preferred Series C-A		2,218,214		230		1
Total BryterCX, Inc. (p.k.a. ClickFox, Inc.)					3,303,110		1,112		1
CareCloud Corporation⁽¹⁵⁾	Software	Warrant	Common Stock		13,499		258		—
Cloudian, Inc.	Software	Warrant	Common Stock		477,454		71		24
Couchbase, Inc.	Software	Warrant	Common Stock		263,377		462		409
Dashlane, Inc.	Software	Warrant	Common Stock		346,747		303		424
Delphix Corp.	Software	Warrant	Common Stock		203,541		407		529
DNAnexus, Inc.	Software	Warrant	Preferred Series C		909,091		97		68
Evernote Corporation	Software	Warrant	Common Stock		62,500		106		67
Fuze, Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series F		256,158		89		—
Lastline, Inc.	Software	Warrant	Common Stock		363,636		133		136
Lightbend, Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series C-1		854,787		130		122
Message Systems, Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series C		503,718		334		731
Nuvolo Technologies Corporation	Software	Warrant	Common Stock		30,000		43		73
OneLogin, Inc.⁽¹⁵⁾	Software	Warrant	Common Stock		381,620		305		602
Poplicus, Inc.	Software	Warrant	Common Stock		132,168		—		—
Quid, Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series D		71,576		1		—
	Software	Warrant	Preferred Series E		40,261		1		—
Total Quid, Inc.					111,837		2		—
RapidMiner, Inc.	Software	Warrant	Preferred Series C-1		4,982		24		20
RedSeal Inc.⁽¹⁵⁾	Software	Warrant	Preferred Series C-Prime		640,603		66		2
Signpost, Inc.	Software	Warrant	Series Junior 1 Preferred		474,019		314		—
ZeroFox, Inc.	Software	Warrant	Preferred Series C-1		486,263		57		87
Subtotal: Software (0.31%)*							4,905		3,479
Specialty Pharmaceuticals
Alimera Sciences, Inc.⁽⁴⁾	Specialty Pharmaceuticals	Warrant	Common Stock		114,513		861		36
Subtotal: Specialty Pharmaceuticals (0.00%)*							861		36
Surgical Devices
Gynesonics, Inc.⁽¹⁵⁾	Surgical Devices	Warrant	Preferred Series C		180,480		74		4
	Surgical Devices	Warrant	Preferred Series D		1,575,965		320		13
Total Gynesonics, Inc.					1,756,445		394		17
TransMedics Group, Inc. (p.k.a Transmedics, Inc.)⁽⁴⁾	Surgical Devices	Warrant	Common Stock		64,441		139		444
Subtotal: Surgical Devices (0.04%)*							533		461
Sustainable and Renewable Technology
Agrivida, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series D		471,327		120		—
Calera, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series C		44,529		513		—
Fulcrum Bioenergy, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series C-1		280,897		275		537

Portfolio Company	Sub-Industry	Type of Investment ⁽¹⁾	Series	Shares		Cost ⁽³⁾		Value ⁽⁴⁾
GreatPoint Energy, Inc.⁽¹⁵⁾	Sustainable and Renewable Technology	Warrant	Preferred Series D-1		393,212		548		—
Kinestral Technologies, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series A		325,000		155		168
	Sustainable and Renewable Technology	Warrant	Preferred Series B		131,883	$	63	$	52
Total Kinestral Technologies, Inc.					456,883		218		220
NantEnergy, Inc. (p.k.a. Fluidic, Inc.)	Sustainable and Renewable Technology	Warrant	Preferred Series D		61,804		102		—
Polyera Corporation⁽¹⁵⁾	Sustainable and Renewable Technology	Warrant	Preferred Series C		311,609		338		—
Proterra, Inc.	Sustainable and Renewable Technology	Warrant	Common Stock		36,630		1		4
	Sustainable and Renewable Technology	Warrant	Preferred Series 4		477,517		41		252
Total Proterra, Inc.					514,147		42		256
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)⁽⁶⁾	Sustainable and Renewable Technology	Warrant	Class A Units		0.69		—		—
TAS Energy, Inc.	Sustainable and Renewable Technology	Warrant	Preferred Series AA		428,571		299		—
Subtotal: Sustainable and Renewable Technology (0.09%)*							2,455		1,013
Total: Warrant Investments (1.84%)*							34,970		20,881
Total Investments in Securities (204.27%)*						$	2,402,032	$	2,314,526

Hercules Capital, Inc. (the “Company”) is a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. The Company sources its investments through its principal office located in Palo Alto, CA, as well as through its additional offices in Boston, MA, New York, NY, Bethesda, MD, Hartford, CT, and San Diego, CA. The Company was incorporated under the General Corporation Law of the State of Maryland in December 2003.

The Company is an internally managed, non-diversified closed-end investment company that has elected to be regulated as a business development company (“BDC”) under the Investment Company Act of 1940, as amended (the “1940 Act”). From incorporation through December 31, 2005, the Company was subject to tax as a corporation under Subchapter C of the Internal Revenue Code of 1986, as amended (the “Code”). Effective January 1, 2006, the Company elected to be treated for tax purposes as a regulated investment company (“RIC”) under Subchapter M of the Code (see “Note 5 - Income Taxes”).

The Company does not currently use Commodity Futures Trading Commission (“CFTC”) derivatives, however, to the extent that it uses CFTC derivatives in the future, it intends to do so below prescribed levels and will not market itself as a “commodity pool” or a vehicle for trading such instruments. The Company has claimed an exclusion from the definition of the term “commodity pool operator” pursuant to Rule 4.5 under the Commodity Exchange Act (“CEA”). The Company is not, therefore, subject to registration or regulation as a “commodity pool operator” under the CEA.

Hercules Technology III, L.P. (“HT III”) and Hercules Technology IV, L.P. (“HT IV”) are Delaware limited partnerships that were formed in September 2009 and December 2010, respectively. On May 26, 2010, HT III was licensed to operate as a small business investment company (“SBIC”) under the authority of the Small Business Administration (“SBA”). Hercules Technology II, L.P. (“HT II”) was a Delaware limited partnership formed in January 2005 to operate as an SBIC. On July 13, 2018, the Company completed repayment of the remaining outstanding HT II debentures and subsequently surrendered the SBA license with respect to HT II and dissolved the entity.

As an SBIC, HT III is subject to a variety of regulations concerning, among other things, the size and nature of the companies in which it may invest and the structure of those investments. HT IV was formed in anticipation of receiving an additional SBIC license. As of September 30, 2020, HT IV has no material assets or liabilities. The Company received the SBIC license on October 27, 2020 (see “Note 12 - Subsequent Events”). The Company also formed Hercules Technology SBIC Management, LLC (“HTM”), a Delaware limited liability company, in November 2003. HTM is a wholly owned subsidiary of the Company and serves as the limited partner and general partner of HT III (see “Note 4 - Borrowings” to the Company’s consolidated financial statements).

The Company also established wholly owned subsidiaries, all of which are structured as Delaware corporations or limited liability companies (“LLCs”), to hold portfolio companies organized as LLCs (or other forms of pass-through entities). These subsidiaries are consolidated for financial reporting purposes and in accordance with generally accepted accounting principles in the United States of America (“U.S. GAAP”), and the portfolio investments held by these subsidiaries are included in the Company’s consolidated financial statements and recorded at fair value. These taxable subsidiaries are not consolidated with Hercules for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments.

The accompanying consolidated interim financial statements have been prepared in conformity with U.S. GAAP for interim financial information, and pursuant to the requirements for reporting on Form 10-Q and Articles 6, 10 and 12 of Regulation S-X. Accordingly, certain disclosures accompanying annual consolidated financial statements prepared in accordance with U.S. GAAP are omitted. In the opinion of management, all adjustments consisting solely of normal recurring accruals considered necessary for the fair presentation of consolidated financial statements for the interim periods have been included. The current period’s results of operations are not necessarily indicative of results that ultimately may be achieved for the full fiscal year. Therefore, the interim unaudited consolidated financial statements and notes should be read in conjunction with the audited consolidated financial statements and notes thereto for the year ended December 31, 2019. The year-end Consolidated Statements of Assets and Liabilities data was derived from audited financial statements but does not include all disclosures required by U.S. GAAP.

As an investment company, the Company follows accounting and reporting guidance as set forth in Topic 946 (“Financial Services – Investment Companies”) of the Financial Accounting Standards Board’s (“FASB”) Accounting Standards Codification, as amended (“ASC”). As provided under Regulation S-X and ASC Topic 946, the Company will not consolidate its investment in a portfolio company other than an investment company subsidiary or a controlled operating company whose business consists of providing services to the Company. Rather, an investment company’s interest in portfolio companies that are not investment companies should be measured at fair value in accordance with ASC Topic 946.

Financial statements prepared on a U.S. GAAP basis require management to make estimates and assumptions that affect the reported amounts of assets and liabilities at the date of the consolidated financial statements and the reported amounts of income, expenses, gains and losses during the reported periods. Changes in the economic and regulatory environment, financial markets, the credit worthiness of our portfolio companies, the global outbreak of the novel coronavirus (“COVID-19”) during the first quarter of 2020, and any other parameters used in determining these estimates and assumptions could cause actual results to differ from these estimates and assumptions.

The Consolidated Financial Statements include the accounts of the Company and its subsidiaries and all VIEs of which the Company is the primary beneficiary. All intercompany accounts and transactions have been eliminated in consolidation.

A VIE is an entity that either (i) has insufficient equity to permit the entity to finance its activities without additional subordinated financial support or (ii) has equity investors who lack the characteristics of a controlling financial interest. The primary beneficiary of a VIE is the party with both the power to direct the activities of the VIE that most significantly impact the VIE’s economic performance and the obligation to absorb the losses or the right to receive benefits that could be significant to the VIE.

To assess whether the Company has the power to direct the activities of a VIE that most significantly impact its economic performance, the Company considers all the facts and circumstances including its role in establishing the VIE and its ongoing rights and responsibilities. This assessment includes identifying the activities that most significantly impact the VIE’s economic performance and identifying which party, if any, has power over those activities. In general, the party that makes the most significant decisions affecting the VIE is determined to have the power to direct the activities of a VIE. To assess whether the Company has the obligation to absorb the losses or the right to receive benefits that could potentially be significant to the VIE, the Company considers all of its economic interests, including debt and equity interests, servicing rights and fee arrangements, and any other variable interests in the VIE. If the Company determines that it is the party with the power to make the most significant decisions affecting the VIE, and the Company has a potentially significant interest in the VIE, then it consolidates the VIE.

The Company performs periodic reassessments, usually quarterly, of whether it is the primary beneficiary of a VIE. The reassessment process considers whether the Company has acquired or divested the power to direct the activities of the VIE through changes in governing documents or other circumstances. The Company also reconsiders whether entities previously determined not to be VIEs have become VIEs, based on certain events, and therefore are subject to the VIE consolidation framework.

As of September 30, 2020, the VIEs consolidated by the Company are its securitization VIEs formed in conjunction with the issuance of the 2027 Asset-Backed Notes and the 2028 Asset-Backed Notes (as defined herein). See “Note 4 – Borrowings”.

The most significant estimate inherent in the preparation of the Company’s consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At September 30, 2020, approximately 96.7% of the Company’s total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. The Company’s investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820 (“Fair Value Measurements”). The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, the Company values substantially all of its investments at fair value as determined in good faith pursuant to a consistent valuation policy approved by the Board of Directors in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of the Company’s investments determined in good faith by its Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

The Company intends to continue to engage one or more independent valuation firm(s) to provide management with assistance regarding the Company’s determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. Specifically, on a quarterly basis, the Company will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. The Company selects these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, size, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of services rendered by the independent valuation firm is at the discretion of the Board of Directors. The Board of Directors are ultimately, and solely, responsible for determining the fair value of the Company’s investments in good faith.

ASC Topic 820 establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. ASC Topic 820 also requires disclosure for fair value measurements based on the level within the hierarchy of the information used in the valuation. ASC Topic 820 applies whenever other standards require (or permit) assets or liabilities to be measured at fair value. ASC Topic 820 defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date.

The Company has categorized all investments recorded at fair value in accordance with ASC Topic 820 based upon the level of judgment associated with the inputs used to measure their fair value. Hierarchical levels, defined by ASC Topic 820 and directly related to the amount of subjectivity associated with the inputs to fair valuation of these assets and liabilities, are as follows:

Level 1—Inputs are unadjusted, quoted prices in active markets for identical assets at the measurement date. The types of assets carried at Level 1 fair value generally are equities listed in active markets.

Level 2—Inputs (other than quoted prices included in Level 1) are either directly or indirectly observable for the asset in connection with market data at the measurement date and for the extent of the instrument’s anticipated life. Fair valued assets that are generally included in this category are publicly held debt investments and warrants held in a public company.

Level 3—Inputs reflect management’s best estimate of what market participants would use in pricing the asset at the measurement date. It includes prices or valuations that require inputs that are both significant to the fair value measurement and unobservable. Generally, assets carried at fair value and included in this category are the debt investments and warrants and equities held in a private company.

Investments measured at fair value on a recurring basis are categorized in the tables below based upon the lowest level of significant input to the valuations as of September 30, 2020 and December 31, 2019.

(in thousands)	Balance September 30,		Quoted Prices In Active Markets For Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2020		(Level 1)		(Level 2)		(Level 3)
Senior Secured Debt	$	2,249,500	$	—	$	—	$	2,249,500
Unsecured Debt		14,947		—		—		14,947
Preferred Stock		50,283		—		—		50,283
Common Stock		83,566		41,646		—		41,920
Warrants		22,531		—		6,963		15,568
Escrow Receivable		417		—		—		417
Total	$	2,421,244	$	41,646	$	6,963	$	2,372,635

(in thousands)	Balance December 31,		Quoted Prices In Active Markets For Identical Assets		Significant Other Observable Inputs		Significant Unobservable Inputs
Description	2019		(Level 1)		(Level 2)		(Level 3)
Senior Secured Debt	$	2,133,812	$	—	$	—	$	2,133,812
Unsecured Debt		14,780		—		—		14,780
Preferred Stock		69,717		—		—		69,717
Common Stock		75,336		41,789		—		33,547
Warrants		20,881		—		7,159		13,722
Escrow Receivable		955		—		—		955
Total	$	2,315,481	$	41,789	$	7,159	$	2,266,533

The table below presents a reconciliation for all financial assets and liabilities measured at fair value on a recurring basis, excluding accrued interest components, using significant unobservable inputs (Level 3) for the nine months ended September 30, 2020 and the year ended December 31, 2019.

(in thousands)	Balance January 1, 2020		Net Realized Gains (Losses) ⁽¹⁾			Net Change in Unrealized Appreciation (Depreciation) ⁽²⁾			Purchases ⁽⁵⁾		Sales			Repayments ⁽⁶⁾			Gross Transfers into Level 3 ⁽³⁾		Gross Transfers out of Level 3 ⁽³⁾			Balance September 30, 2020
Senior Debt	$	2,133,812	$	(47,346	)	$	2,579		$	649,886	$	—		$	(489,431	)	$	—	$	—		$	2,249,500
Unsecured Debt		14,780		—			(283	)		450		—			—			—		—			14,947
Preferred Stock		69,717		(134	)		(5,323	)		245		(40	)		—			—		(14,182	)		50,283
Common Stock		33,547		1,240			8,373			—		(1,240	)		—			—		—			41,920
Warrants		13,722		(5,129	)		4,911			3,327		(1,088	)		—			—		(175	)		15,568
Escrow Receivable		955		105			—			1,440		(2,083	)		—			—		—			417
Total	$	2,266,533	$	(51,264	)	$	10,257		$	655,348	$	(4,451	)	$	(489,431	)	$	—	$	(14,357	)	$	2,372,635

(in thousands)	Balance January 1, 2019		Net Realized Gains (Losses) ⁽¹⁾			Net Change in Unrealized Appreciation (Depreciation) ⁽²⁾			Purchases ⁽⁵⁾		Sales			Repayments ⁽⁶⁾			Gross Transfers into Level 3 ⁽⁴⁾		Gross Transfers out of Level 3 ⁽⁴⁾			Balance December 31, 2019
Senior Debt	$	1,719,091	$	(5,513	)	$	(2,424	)	$	1,031,832	$	—		$	(609,174	)	$	—	$	—		$	2,133,812
Unsecured Debt		14,401		—			329			50		—			—			—		—			14,780
Preferred Stock		68,625		(1,146	)		12,566			4,638		(16	)		—			—		(14,950	)		69,717
Common Stock		24,241		(750	)		4,962			5,094		—			—			—		—			33,547
Warrants		22,673		6,270			(7,922	)		3,532		(8,981	)		—			3		(1,853	)		13,722
Escrow Receivable		970		(875	)		—			897		(37	)		—			—		—			955
Total	$	1,850,001	$	(2,014	)	$	7,511		$	1,046,043	$	(9,034	)	$	(609,174	)	$	3	$	(16,803	)	$	2,266,533

For the nine months ended September 30, 2020, approximately $5.5 million in net unrealized depreciation and $8.4 million in net unrealized appreciation were recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the nine months ended September 30, 2020, approximately $4.5 million and $0.4 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

For the year ended December 31, 2019, approximately $11.6 million and $4.6 million in net unrealized appreciation was recorded for preferred stock and common stock Level 3 investments, respectively, relating to assets still held at the reporting date. For the year ended December 31, 2019, approximately $5.9 million and $1.5 million in net unrealized depreciation was recorded for debt and warrant Level 3 investments, respectively, relating to assets still held at the reporting date.

The following tables provide quantitative information about the Company’s Level 3 fair value measurements as of September 30, 2020 and December 31, 2019. In addition to the techniques and inputs noted in the tables below, according to the Company’s valuation policy, the Company may also use other valuation techniques and methodologies when determining the Company’s fair value measurements. The tables below are not intended to be all-inclusive, but rather provide information on the significant Level 3 inputs as they relate to the Company’s fair value measurements.

The significant unobservable input used in the fair value measurement of the Company’s escrow receivables is the amount recoverable at the contractual maturity date of the escrow receivable.

Investment Type - Level Three Debt Investments	Fair Value at September 30, 2020 (in thousands)		Valuation Techniques/Methodologies	Unobservable Input⁽¹⁾	Range	Weighted Average ⁽²⁾
Pharmaceuticals	$	47,143	Originated Within 4-6 Months	Origination Yield	12.78% - 13.57%	13.30%
		662,170	Market Comparable Companies	Hypothetical Market Yield	9.29% - 14.31%	11.43%
				Premium/(Discount)	(0.50%) - 1.00%
Technology		49,629	Originated Within 4-6 Months	Origination Yield	10.91% - 13.94%	13.37%
		982,286	Market Comparable Companies	Hypothetical Market Yield	7.08% - 17.51%	12.32%
				Premium/(Discount)	(0.25%) - 1.00%
		5,901	Liquidation ⁽³⁾	Probability weighting of alternative outcomes	40.00% - 60.00%
Sustainable and Renewable Technology		15,622	Market Comparable Companies	Hypothetical Market Yield	10.18% - 10.60%	10.29%
				Premium/(Discount)	0.00% - 0.00%
		12,561	Liquidation ⁽³⁾	Probability weighting of alternative outcomes	30.00% - 100.00%
Medical Devices		69,042	Market Comparable Companies	Hypothetical Market Yield	9.01% - 14.61%	11.32%
				Premium/(Discount)	(0.25%) - 0.50%
		5,807	Liquidation (3)	Probability weighting of alternative outcomes	25.00% - 40.00%
Lower Middle Market		143,397	Market Comparable Companies	Hypothetical Market Yield	8.46% - 15.94%	11.86%
				Premium/(Discount)	(1.00%) - 0.5%
		8,295	Liquidation ⁽³⁾	Probability weighting of alternative outcomes	20.00% - 80.00%

			Debt Investments Where Fair Value Approximates Cost
		243,382	Debt Investments originated within 3 months
		-	Imminent Payoffs ⁽⁴⁾
		19,212	Debt Investments Maturing in Less than One Year
	$	2,264,447	Total Level Three Debt Investments

Investment Type - Level Three Debt Investments	Fair Value at December 31, 2019 (in thousands)		Valuation Techniques/Methodologies	Unobservable Input⁽¹⁾	Range	Weighted Average ⁽²⁾
Pharmaceuticals	$	34,898	Originated Within 4-6 Months	Origination Yield	10.87% - 12.01%	11.38%
		563,725	Market Comparable Companies	Hypothetical Market Yield	9.26% - 14.06%	11.43%
				Premium/(Discount)	(0.50%) - 0.50%
		—	Liquidation⁽³⁾	Probability weighting of alternative outcomes	0.00% - 100.00%
Technology		21,365	Originated Within 4-6 Months	Origination Yield	9.40% - 13.04%	12.33%
		844,169	Market Comparable Companies	Hypothetical Market Yield	10.56% - 16.13%	12.36%
				Premium/(Discount)	(0.50%) - 0.50%
		1,773	Liquidation⁽³⁾	Probability weighting of alternative outcomes	40.00% - 60.00%
Sustainable and Renewable Technology		34,115	Market Comparable Companies	Hypothetical Market Yield	11.49% - 21.59%	13.67%
				Premium/(Discount)	(0.50%) - 3.00%
		4,410	Liquidation⁽³⁾	Probability weighting of alternative outcomes	50.00%
Medical Devices		101,349	Market Comparable Companies	Hypothetical Market Yield	9.13% - 14.74%	12.07%
				Premium/(Discount)	(0.50%) - 0.50%
Lower Middle Market		34,822	Originated Within 4-6 Months	Origination Yield	13.24%	13.24%
		188,841	Market Comparable Companies	Hypothetical Market Yield	10.71% - 16.02%	13.09%
				Premium/(Discount)	(0.50%) - 0.00%
		9,587	Liquidation⁽³⁾	Probability weighting of alternative outcomes	20.00% - 80.00%

			Debt Investments Where Fair Value Approximates Cost
		149,358	Debt Investments originated within 3 months
		78,052	Imminent Payoffs ⁽⁴⁾
		82,128	Debt Investments Maturing in Less than One Year
	$	2,148,592	Total Level Three Debt Investments

Investment Type - Level Three Equity and Warrant Investments	Fair Value at September 30, 2020 (in thousands)		Valuation Techniques/ Methodologies	Unobservable Input ⁽¹⁾	Range	Weighted Average ⁽⁶⁾
Equity Investments	$	44,303	Market Comparable Companies	EBITDA Multiple ⁽²⁾	5.6x - 9.1x	8.0x
				Revenue Multiple ⁽²⁾	1.7x - 18.2x	1.9x
				Tangible Book Value Multiple ^(b)	3.9x - 3.9x	3.9x
				Discount for Lack of Marketability ⁽³⁾	20.66% - 31.28%	23.26%
				Average Industry Volatility⁽⁴⁾	49.92% - 124.93%	90.80%
				Risk-Free Interest Rate	0.12%	0.12%
				Estimated Time to Exit (in months)	10		10
		6,481	Market Adjusted OPM Backsolve	Market Equity Adjustment ⁽⁵⁾	(89.92%) - 32.29%	1.37%
				Average Industry Volatility ⁽⁴⁾	39.77% - 81.88%	75.75%
				Risk-Free Interest Rate	0.18% - 2.64%	0.59%
				Estimated Time to Exit (in months)	10 - 31		20
		—	Liquidation	Revenue Multiple ⁽²⁾	0.6x - 4.6x	2.6x
		41,419	Other ⁽⁷⁾
Warrant Investments		6,334	Market Comparable Companies	EBITDA Multiple ⁽²⁾	7.4x - 12.4x	7.5x
				Revenue Multiple ⁽²⁾	0.4x - 8.3x	4.9x
				Discount for Lack of Marketability ⁽³⁾	18.88% - 31.11%	24.97%
				Average Industry Volatility ⁽⁴⁾	36.85% - 78.99%	69.86%
				Risk-Free Interest Rate	0.11% - 0.22%	0.14%
				Estimated Time to Exit (in months)	10 - 49		25
		9,234	Market Adjusted OPM Backsolve	Market Equity Adjustment ⁽⁵⁾	(49.04%) - 32.29%	(1.50%)
				Average Industry Volatility ⁽⁴⁾	25.68% - 137.82%	72.47%
				Risk-Free Interest Rate	0.13% - 2.64%	0.51%
				Estimated Time to Exit (in months)	10 - 48		21
Total Level Three Warrant and Equity Investments	$	107,771

Investment Type - Level Three Equity and Warrant Investments	Fair Value at December 31, 2019 (in thousands)		Valuation Techniques/ Methodologies	Unobservable Input⁽¹⁾	Range	Weighted Average⁽⁶⁾
Equity Investments	$	45,205	Market Comparable Companies	EBITDA Multiple ⁽²⁾	5.4x	5.4x
				Revenue Multiple ⁽²⁾	0.5x - 13.6x	4.0x
				Discount for Lack of Marketability ⁽³⁾	15.92% - 25.07%	19.31%
				Average Industry Volatility⁽⁴⁾	54.15% - 106.47%	74.87%
				Risk-Free Interest Rate	1.59% - 1.60%	1.59%
				Estimated Time to Exit (in months)	11 - 31		11
		14,910	Market Adjusted OPM Backsolve	Market Equity Adjustment ⁽⁵⁾	(19.78%) - 26.70%	8.17%
				Average Industry Volatility ⁽⁴⁾	32.48% - 90.07%	79.18%
				Risk-Free Interest Rate	1.42% - 2.68%	1.94%
				Estimated Time to Exit (in months)	11 - 40		16
		—	Liquidation	Revenue Multiple ⁽²⁾	2.0x - 4.0x	3.0x
		43,149	Other ⁽⁷⁾
Warrant Investments		9,074	Market Comparable Companies	EBITDA Multiple ⁽²⁾	5.4x - 14.7x	14.6x
				Revenue Multiple ⁽²⁾	0.4x - 13.4x	9.9x
				Discount for Lack of Marketability ⁽³⁾	8.42% - 35.81%	19.46%
				Average Industry Volatility ⁽⁴⁾	35.81% - 97.06%	57.26%
				Risk-Free Interest Rate	1.57% - 1.66%	1.60%
				Estimated Time to Exit (in months)	4 - 48		21
		4,648	Market Adjusted OPM Backsolve	Market Equity Adjustment ⁽⁵⁾	(42.45%) - 23.22%	7.05%
				Average Industry Volatility ⁽⁴⁾	26.31% - 98.99%	62.78%
				Risk-Free Interest Rate	1.61% - 2.73%	1.78%
				Estimated Time to Exit (in months)	7 - 39		18
Total Level Three Warrant and Equity Investments	$	116,986

The Company follows the guidance set forth in ASC Topic 820 which establishes a framework for measuring the fair value of assets and liabilities and outlines a fair value hierarchy, which prioritizes the inputs used to measure fair value and the effect of fair value measures on earnings. The Company’s debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of the Company’s investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for debt instruments for these investment securities to be traded or exchanged. In addition, the Company may, from time to time, invest in public debt of companies that meet the Company’s investment objectives. These investments are considered Level 2 assets.

In making a good faith determination of the value of the Company’s investments, the Company generally starts with the cost basis of the investment, which includes the value attributed to the original issue discount (“OID”), if any, and payment-in-kind (“PIK”) interest or other receivables which have been accrued as earned. The Company then applies the valuation methods as set forth below.

The Company applies a procedure for debt investments that assumes the sale of each investment in a hypothetical market to a hypothetical market participant where buyers and sellers are willing participants. The hypothetical market does not include scenarios where the underlying security was simply repaid or extinguished, but does include an exit concept. The Company determines the yield at inception for each debt investment. The Company then uses senior secured, leveraged loan yields provided by third party providers to determine the change in market yields between the inception of the debt investment and the measurement date. Industry specific indices and other relevant market data are used to benchmark and assess market-based movements.

Under this process, the Company also evaluates the collateral for recoverability of the debt investments. The Company considers each portfolio company’s credit rating, security liens and other characteristics of the investment to adjust the baseline yield to derive a credit adjusted hypothetical yield for each investment as of the measurement date. The anticipated future cash flows from each investment are then discounted at the hypothetical yield to estimate each investment’s fair value as of the measurement date.

The Company’s process includes an analysis of, among other things, the underlying investment performance, the current portfolio company’s financial condition and market changing events that impact valuation, estimated remaining life, current market yield and interest rate spreads of similar securities as of the measurement date. The Company values its syndicated debt investments using broker quotes and bond indices amongst other factors. If there is a significant deterioration of the credit quality of a debt investment, the Company may consider other factors to estimate fair value, including the proceeds that would be received in a liquidation analysis.

The Company records unrealized depreciation on investments when it believes that an investment has decreased in value, including where collection of a debt investment is doubtful or, if under the in-exchange premise, when the value of a debt investment is less than amortized cost of the investment. Conversely, where appropriate, the Company records unrealized appreciation if it believes that the underlying portfolio company has appreciated in value and, therefore, that its investment has also appreciated in value or, if under the in-exchange premise, the value of a debt investment is greater than amortized cost.

When originating a debt instrument, the Company generally receives warrants or other equity-related securities from the borrower. The Company determines the cost basis of the warrants or other equity-related securities received based upon their respective fair values on the date of receipt in proportion to the total fair value of the debt and warrants or other equity-related securities received. Any resulting discount on the debt investments from recordation of the warrant or other equity instruments is accreted into interest income over the life of the debt investment.

Debt investments that are traded on a public exchange are valued at the prevailing market price as of the valuation date.

Securities that are traded in the over-the-counter markets or on a stock exchange will be valued at the prevailing bid price at period end. The Company has a limited amount of equity securities in public companies. In accordance with the 1940 Act, unrestricted publicly traded securities for which market quotations are readily available are valued at the closing market quote on the measurement date.

The Company estimates the fair value of warrants using a Black Scholes OPM. At each reporting date, privately held warrant and equity-related securities are valued based on an analysis of various factors including, but not limited to, the portfolio company’s operating performance and financial condition, general market conditions, price to enterprise value or price to equity ratios, discounted cash flow, valuation comparisons to comparable public companies and other industry benchmarks. When an external event occurs, such as a purchase transaction, public offering, or subsequent equity sale, the pricing indicated by that external event is utilized to corroborate the Company’s valuation of the warrant and equity-related securities. The Company periodically reviews the valuation of its portfolio companies that have not been involved in a qualifying external event to determine if the enterprise value of the portfolio company may have increased or decreased since the last valuation measurement date.

Cash and cash equivalents consist solely of funds deposited with financial institutions and short-term liquid investments in money market deposit accounts. Cash and cash equivalents are carried at cost, which approximates fair value. Restricted cash and cash equivalents include amounts that are collected and are held by trustees who have been appointed as custodians of the assets securing certain of the Company’s financing transactions.

Other assets generally consist of prepaid expenses, deferred financing costs net of accumulated amortization, fixed assets net of accumulated depreciation, deferred revenues and deposits and other assets, including escrow receivables.

Escrow receivables are collected in accordance with the terms and conditions of the escrow agreement. Escrow balances are typically distributed over a period greater than one year and may accrue interest during the escrow period. Escrow balances are measured for collectability on at least a quarterly basis and fair value is determined based on the amount of the estimated recoverable balances and the contractual maturity date. As of both September 30, 2020 and December 31, 2019, there were no material past due escrow receivables. The escrow receivable balance as of September 30, 2020 and December 31, 2019 was approximately $417,000 and $955,000, respectively, and was fair valued and held in accordance with ASC Topic 820.

The Company determines if an arrangement is a lease at inception. Operating leases are included in right-of-use (“ROU”) assets, and operating lease liability obligations in our Consolidated Statements of Assets and Liabilities. The Company recognizes a ROU asset and an operating lease liability for all leases, with the exception of short-term leases which have a term of 12 months or less. ROU assets represent the right to use an underlying asset for the lease term and operating lease liability obligations represent the obligation to make lease payments arising from the lease. ROU assets and liabilities are recognized at lease commencement date based on the present value of lease payments over the lease term. The Company has lease agreements with lease and non-lease components and has separated these components when determining the ROU assets and the related lease liabilities. As most of the Company’s leases do not provide an implicit rate, the Company estimated its incremental borrowing rate based on the information available at the lease commencement date in determining the present value of lease payments. The Company uses the implicit rate when readily determinable. The ROU asset also includes any lease payments made and excludes lease incentives and lease direct costs. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that we will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See “Note 10 – Commitments and Contingencies”.

As required by the 1940 Act, the Company classifies its investments by level of control. “Control investments” are defined in the 1940 Act as investments in those companies that the Company is deemed to “control”. Under the 1940 Act, the Company is generally deemed to “control” a company in which it has invested if it owns 25% or more of the voting securities of such company or has greater than 50% representation on its board. “Affiliate investments” are investments in those companies that are “affiliated companies” of the Company, as defined in the 1940 Act, which are not control investments. The Company is deemed to be an “affiliate” of a company in which it has invested if it owns 5% or more, but generally less than 25%, of the voting securities of such company. “Non-control/non-affiliate investments” are investments that are neither control investments nor affiliate investments.

The following table summarizes the Company’s realized gains and losses and changes in unrealized appreciation and depreciation on control and affiliate investments for the three and nine months ended September 30, 2020 and 2019.

(in thousands)				For the Three Months Ended September 30, 2020									For the Nine Months Ended September 30, 2020
Portfolio Company	Type	Fair Value at September 30, 2020		Interest Income		Fee Income		Net Change in Unrealized (Depreciation)/ Appreciation			Realized Gain/ (Loss)		Interest Income		Fee Income		Net Change in Unrealized (Depreciation)/ Appreciation			Realized Gain/ (Loss)
Control Investments
Gibraltar Business Capital, LLC	Control	$	46,797	$	565	$	5	$	154		$	—	$	1,683	$	15	$	(3,406	)	$	—
Tectura Corporation	Control		8,295		175		—		492			—		434		—		(1,157	)		—
Total Control Investments		$	55,092	$	740	$	5	$	646		$	—	$	2,117	$	15	$	(4,563	)	$	—

Affiliate Investments
Optiscan BioMedical, Corp.	Affiliate	$	—	$	—	$	—	$	(1,011	)	$	—	$	13	$	—	$	(9,601	)	$	—
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)	Affiliate		9,800		232		—		(1,100	)		—		596		—		(2,815	)		—
Total Affiliate Investments		$	9,800	$	232	$	—	$	(2,111	)	$	—	$	609	$	—	$	(12,416	)	$	—
Total Control & Affiliate Investments		$	64,892	$	972	$	5	$	(1,465	)	$	—	$	2,726	$	15	$	(16,979	)	$	—

(in thousands)				For the Three Months Ended September 30, 2019									For the Nine Months Ended September 30, 2019
Portfolio Company	Type	Fair Value at September 30, 2019		Interest Income		Fee Income		Net Change in Unrealized Appreciation/ (Depreciation)			Realized Gain/ (Loss)		Interest Income		Fee Income		Net Change in Unrealized (Depreciation)/ Appreciation			Realized Gain/ (Loss)
Control Investments
Gibraltar Business Capital, LLC	Control	$	48,955	$	564	$	5	$	2,719		$	—		1,673		13		9,427			—
Tectura Corporation	Control		9,605		491		—		(230	)		—		1,446		—		(9,006	)		—
Total Control Investments		$	58,560	$	1,055	$	5	$	2,489		$	—	$	3,119	$	13	$	421		$	—

Affiliate Investments
Optiscan BioMedical, Corp.	Affiliate	$	8,060	$	—	$	—	$	(312	)	$	—	$	—	$	—	$	(548	)	$	—
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)	Affiliate		12,904		493		26		(235	)		—		1,740		186		(3,225	)		—
Total Affiliate Investments		$	20,964	$	493	$	26	$	(547	)	$	—	$	1,740	$	186	$	(3,773	)	$	—
Total Control & Affiliate Investments		$	79,524	$	1,548	$	31	$	1,942		$	—	$	4,859	$	199	$	(3,352	)	$	—

The following table shows the fair value of the Company’s portfolio of investments by asset class as of September 30, 2020 and December 31, 2019:

The increase in senior secured debt and senior secured debt with warrants, as a percentage of the total portfolio, during the period is primarily due to an increase in debt investments that include detachable equity enhancement features.

A summary of the Company’s investment portfolio, at value, by geographic location as of September 30, 2020 and December 31, 2019 is shown as follows:

The following table shows the fair value of the Company’s portfolio by industry sector at September 30, 2020 and December 31, 2019:

	September 30, 2020					December 31, 2019
(in thousands)	Investments at Fair Value		Percentage of Total Portfolio			Investments at Fair Value		Percentage of Total Portfolio
Drug Discovery & Development	$	859,371		35.6	%	$	747,955		32.2	%
Software		755,010		31.2	%		582,445		25.2	%
Internet Consumer & Business Services		492,696		20.4	%		495,132		21.4	%
Sustainable and Renewable Technology		61,297		2.5	%		77,505		3.3	%
Information Services		53,363		2.2	%		60,094		2.6	%
Diversified Financial Services		46,797		1.9	%		78,933		3.4	%
Drug Delivery		45,481		1.9	%		46,218		2.0	%
Medical Devices & Equipment		38,543		1.6	%		73,341		3.2	%
Healthcare Services, Other		27,271		1.1	%		102,997		4.5	%
Media/Content/Info		21,308		0.9	%		21,071		0.9	%
Communications & Networking		12,534		0.5	%		3,962		0.2	%
Surgical Devices		3,190		0.1	%		4,120		0.2	%
Electronics & Computer Hardware		2,809		0.1	%		4,462		0.2	%
Consumer & Business Products		708		0.0	%		530		0.0	%
Semiconductors		432		0.0	%		10,658		0.5	%
Specialty Pharmaceuticals		17		0.0	%		36		0.0	%
Biotechnology Tools		—		0.0	%		5,067		0.2	%
Total	$	2,420,827		100.0	%	$	2,314,526		100.0	%

No single portfolio investment represents more than 10% of the fair value of the Company’s total investments as of September 30, 2020 and December 31, 2019.

In the majority of cases, the Company collateralizes its investments by obtaining a first priority security interest in a portfolio company’s assets, which may include its intellectual property. In other cases, the Company may obtain a negative pledge covering a company’s intellectual property. At September 30, 2020, approximately 85.5% of the Company’s debt investments were in a senior secured first lien position, with 43.3% secured by a first priority security in all of the assets of the portfolio company, including its intellectual property, 34.2% secured by a first priority security in all of the assets of the portfolio company other than intellectual property but the portfolio company was prohibited from pledging or encumbering its intellectual property, 0.6% of the Company’s debt investments were senior secured by the equipment of the portfolio company and 7.4% of the Company’s debt investments were in a first lien “last-out” senior secured position with a security interest in all of the assets of the portfolio company, whereby the “last-out” loans will be subordinated to the “first-out” portion of the unitranche loan in a liquidation, sale or other disposition. Another 13.8% of the Company’s debt investments were secured by a second priority security interest in the portfolio company’s assets, and 0.7% were unsecured.

In accordance with Rule 10-01(b)(1) of Regulation S-X, which applies for interim reports on Form 10-Q, the Company must determine if its unconsolidated subsidiaries are considered “significant subsidiaries”. As of September 30, 2020, there were no unconsolidated subsidiaries that are considered “significant subsidiaries”.

The Company records interest income on an accrual basis and recognizes it as earned in accordance with the contractual terms of the loan agreement, to the extent that such amounts are expected to be collected. OID initially represents the value of detachable equity warrants obtained in conjunction with the acquisition of debt securities and is accreted into interest income over the term of the loan as a yield enhancement. When a loan becomes 90 days or more past due, or if management otherwise does not expect that principal, interest, and other obligations due will be collected in full, the Company will generally place the loan on non-accrual status and cease recognizing interest income on that loan until all principal and interest due has been paid or the Company believes the portfolio company has demonstrated the ability to repay the Company’s current and future contractual obligations. Any uncollected interest related to prior periods is reversed from income in the period that collection of the interest receivable is determined to be doubtful. However, the Company may make exceptions to this policy if the investment has sufficient collateral value and is in the process of collection.

Fee income, generally collected in advance, includes loan commitment and facility fees for due diligence and structuring, as well as fees for transaction services and management services rendered by the Company to portfolio companies and other third parties. Loan commitment and facility fees are amortized into income over the contractual life of the loan. Management fees are generally recognized as income when the services are rendered. Loan origination fees are capitalized and then amortized into interest income using the effective interest rate method. In certain loan arrangements, warrants or other equity interests are received from the borrower as additional origination fees. The Company had approximately $41.5 million of unamortized fees at September 30, 2020, of which approximately $34.3 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $7.2 million was deferred contingent upon the occurrence of a funding or milestone. At December 31, 2019, the Company had approximately $42.0 million of unamortized fees, of which approximately $34.6 million was included as an offset to the cost basis of the Company’s current debt investments and approximately $7.4 million was deferred contingent upon the occurrence of a funding or milestone.

The Company recognizes nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. Certain fees may still be recognized as one-time fee income, including prepayment penalties, fees related to select covenant default, waiver fees and acceleration of previously deferred loan fees and OID related to early loan pay-off or material modification of the specific debt outstanding. The Company recorded approximately $2.0 million and $1.4 million in one-time fee income during the three months ended September 30, 2020 and 2019, respectively, and approximately $6.1 million and $4.6 million in one-time fee income during the nine months ended September 30, 2020 and 2019, respectively.

In addition, the Company may also be entitled to an exit fee that is amortized into income over the life of the loan. Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. At September 30, 2020, the Company had approximately $42.8 million in exit fees receivable, of which approximately $38.3 million was included as a component of the cost basis of the Company’s current debt investments and approximately $4.5 million was a deferred receivable related to expired commitments. At December 31, 2019, the Company had approximately $33.5 million in exit fees receivable, of which approximately $31.9 million was included as a component of the cost basis of its current debt investments and approximately $1.6 million was a deferred receivable related to expired commitments.

The Company has debt investments in its portfolio that contain a PIK provision. Contractual PIK interest, which represents contractually deferred interest added to the loan balance that is generally due at the end of the loan term, is generally recorded on an accrual basis to the extent such amounts are expected to be collected. The Company will generally cease accruing PIK interest if there is insufficient value to support the accrual or management does not expect the portfolio company to be able to pay all principal and interest due. The Company recorded approximately $2.3 million and $2.2 million in PIK income during the three months ended September 30, 2020 and 2019, respectively, and approximately $6.5 million and $6.6 million for the nine months ended September 30, 2020 and 2019, respectively.

To maintain the Company’s ability to be subject to tax as a RIC, PIK and exit fee income generally must be accrued and distributed to stockholders in the form of dividends for U.S. federal income tax purposes even though the cash has not yet been collected. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments.

In certain investment transactions, the Company may provide advisory services. For services that are separately identifiable and external evidence exists to substantiate fair value, income is recognized as earned, which is generally when the investment transaction closes. The Company had no income from advisory services in the three and nine months ended September 30, 2020 and 2019.

Fair value estimates are made at discrete points in time based on relevant information. These estimates may be subjective in nature and involve uncertainties and matters of significant judgment and, therefore, cannot be determined with precision. The Company believes that the carrying amounts of its financial instruments, consisting of cash and cash equivalents, receivables including escrow receivables, accounts payable and accrued liabilities, approximate the fair values of such items due to the short maturity of such instruments. The borrowings of the Company are recorded at amortized cost and not at fair value on the Consolidated Statements of Assets and Liabilities. The fair value of the Company’s outstanding borrowings is based on observable market trading prices or quotations and unobservable market rates as applicable for each instrument.

Based on market quotations on or around September 30, 2020, the 2022 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, and 2022 Convertible Notes were quoted for 1.012, 1.001, 1.006, and 1.004 per dollar at par value, respectively. At September 30, 2020, the 2025 Notes and 2033 Notes were trading on the New York Stock Exchange (“NYSE”) at $25.46 and $26.60 per unit at par value, respectively. The par value at underwriting for the 2025 Notes and 2033 Notes was $25.00 per unit. Calculated based on the net present value of payments over the term of the notes using estimated market rates for similar notes and remaining terms, the fair values of the SBA debentures, July 2024 Notes, February 2025 Notes and June 2025 Notes were approximately $102.8 million, $106.3 million, $49.7 million, and $69.7 million, respectively, compared to the principal amounts of $99.0 million, $105.0 million, $50.0 million, and $70.0 million, respectively, as of September 30, 2020. The fair value of the outstanding borrowings under the Union Bank Facility and the Wells Facility is equal to their principal outstanding balances as of September 30, 2020.

See the accompanying Consolidated Schedule of Investments for the fair value of the Company’s investments. The methodology for the determination of the fair value of the Company’s investments is discussed in “Note 2 - Summary of Significant Accounting Policies”.

The following tables provide additional information about the approximate fair value and level in the fair value hierarchy of the Company’s outstanding borrowings at September 30, 2020 and December 31, 2019:

(in thousands)			Identical Assets		Observable Inputs		Unobservable Inputs
Description	September 30, 2020		(Level 1)		(Level 2)		(Level 3)
SBA Debentures	$	102,815	$	—	$	—	$	102,815
2022 Notes		151,844		—		151,844		—
2025 Notes		76,380		—		76,380		—
2033 Notes		42,560		—		42,560		—
July 2024 Notes		106,294		—		—		106,294
February 2025 Notes		49,730		—		—		49,730
June 2025 Notes		69,681		—		—		69,681
2027 Asset-Backed Notes		200,219		—		200,219		—
2028 Asset-Backed Notes		251,475		—		251,475		—
2022 Convertible Notes		230,874		—		230,874		—
Wells Facility		—		—		—		—
Union Bank Facility		37,492		—		—		37,492
Total	$	1,319,364	$	—	$	953,352	$	366,012

At September 30, 2020 and December 31, 2019, the Company had the following available and outstanding borrowings:

	September 30, 2020						December 31, 2019
(in thousands)	Total Available		Principal		Carrying Value ⁽¹⁾		Total Available		Principal		Carrying Value ⁽¹⁾
SBA Debentures ⁽²⁾	$	99,000	$	99,000	$	98,668	$	149,000	$	149,000	$	148,165
2022 Notes		150,000		150,000		148,907		150,000		150,000		148,514
2025 Notes		75,000		75,000		73,256		75,000		75,000		72,970
2033 Notes		40,000		40,000		38,582		40,000		40,000		38,501
July 2024 Notes		105,000		105,000		103,869		105,000		105,000		103,685
February 2025 Notes		50,000		50,000		49,493		—		—		—
June 2025 Notes		70,000		70,000		69,233		—		—		—
2027 Asset-Backed Notes		200,000		200,000		197,521		200,000		200,000		197,312
2028 Asset-Backed Notes		250,000		250,000		247,579		250,000		250,000		247,395
2022 Convertible Notes		230,000		230,000		227,786		230,000		230,000		226,614
Wells Facility ⁽³⁾		75,000		—		—		75,000		—		—
Union Bank Facility ⁽³⁾		400,000		37,492		37,492		200,000		103,919		103,919
Total	$	1,744,000	$	1,306,492	$	1,292,386	$	1,474,000	$	1,302,919	$	1,287,075

Debt issuance costs are fees and other direct incremental costs incurred by the Company in obtaining debt financing and are recognized as prepaid expenses and amortized over the life of the related debt instrument using the effective yield method or the straight-line method, which closely approximates the effective yield method. In accordance with ASC Subtopic 835-30 (“Interest – Imputation of Interest”), debt issuance costs are presented as a reduction to the associated liability balance on the Consolidated Statements of Assets and Liabilities, except for debt issuance costs associated with line-of-credit arrangements. Debt issuance costs, net of accumulated amortization, were as follows as of September 30, 2020 and December 31, 2019:

On May 26, 2010, HT III received a license to operate as an SBIC under the SBIC program in which HT III can borrow funds from the SBA against eligible investments and additional contributions to regulatory capital. The Company paid down $38.7 million and $11.3 million of SBA debentures on March 1, 2020, and September 1, 2020, respectively. With the Company’s net investment of $74.5 million in HT III as of September 30, 2020, HT III has the approved capacity to issue a total of $99.0 million of SBA guaranteed debentures, of which $99.0 million was outstanding as of September 30, 2020. As the Company is past its investment period for HT III, it will no longer make any future commitments to new portfolio companies. The Company will only satisfy contractually agreed upon follow-on fundings to existing portfolio companies and may seek to pay-off a portion or all of the outstanding debentures early as per the available liquidity in HT III.

As of September 30, 2020, HT III has paid the SBA commitment fees and facility fees of approximately $1.5 million and $3.6 million, respectively. As of September 30, 2020, the Company held investments in HT III in 32 companies with a fair value of approximately $172.3 million, accounting for approximately 7.1% of the Company’s total investment portfolio at September 30, 2020. HT III held approximately $190.8 million in tangible assets which accounted for approximately 7.6% of the Company’s total assets at September 30, 2020.

SBICs are designed to stimulate the flow of private equity capital to eligible small businesses. SBICs are subject to a variety of regulations and oversight by the SBA concerning the size and nature of the companies in which they may invest as well as the structures of those investments.

HT III is periodically examined and audited by the SBA’s staff to determine its compliance with SBA regulations. HT III was in compliance with the terms of the SBIC’s leverage as of September 30, 2020 as a result of having sufficient capital as defined under the SBA regulations. The average amount of debentures outstanding for the three and nine months ended September 30, 2020 for HT III were approximately $106.6 million and $117.8 million, respectively, with an average interest rate of approximately 3.15% and 3.02% respectively.

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the SBA debentures were as follows:

The Company reported the following SBA debentures outstanding principal balances as of September 30, 2020 and December 31, 2019:

On October 23, 2017, the Company issued $150.0 million in aggregate principal amount of 4.625% Notes due 2022 (the “2022 Notes”). The 2022 Notes were issued pursuant to the Fourth Supplemental Indenture to the Base Indenture, dated October 23, 2017 (the “2022 Notes Indenture”), between the Company and U.S. Bank, National Association, as trustee (the “2022 Trustee”). The sale of the 2022 Notes generated net proceeds of approximately $147.4 million, including a public offering discount of $826,500. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discounts and commissions of approximately $975,000, were approximately $1.8 million.

The 2022 Notes mature on October 23, 2022, unless previously repurchased in accordance with their terms. The 2022 Notes bear interest at a rate of 4.625% per year payable semiannually in arrears on April 23 and October 23 of each year, commencing on April 23, 2018.

The 2022 Notes are unsecured obligations of the Company that rank senior in right of payment to all of the Company’s existing and future indebtedness that is expressly subordinated, or junior, in right of payment to the 2022 Notes. The 2022 Notes are not guaranteed by any of the Company’s current or future subsidiaries. The 2022 Notes rank pari passu, or equally, in right of payment with all of the Company’s existing and future liabilities that are not so subordinated, or junior. The 2022 Notes effectively rank subordinated, or junior, to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness. The 2022 Notes rank structurally subordinated, or junior, to all existing and future indebtedness (including trade payables) incurred by subsidiaries, financing vehicles or similar facilities of the Company.

The Company may redeem some or all of the 2022 Notes at any time, or from time to time, at the redemption price set forth under the terms of the indenture after September 23, 2022. No sinking fund is provided for the 2022 Notes. The 2022 Notes were issued in denominations of $2,000 and integral multiples of $1,000 thereof. As of September 30, 2020, the Company was in compliance with the terms of the 2022 Notes Indenture.

As of September 30, 2020 and December 31, 2019, the components of the carrying value of the 2022 Notes were as follows:

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2022 Notes were as follows:

On July 14, 2014, the Company and U.S. Bank, N.A. (the “2024 Trustee”), entered into the Third Supplemental Indenture to the Base Indenture between the Company and the 2024 Trustee, dated July 14, 2014, relating to the Company’s issuance, offer and sale of $100.0 million aggregate principal amount of 6.25% unsecured notes due 2024 (the “2024 Notes”).

On October 24, 2017, the Board of Directors approved a redemption of $75.0 million of outstanding aggregate principal amount of the 2024 Notes, which were redeemed on November 23, 2017. On February 9, 2018, the Board of Directors approved a redemption of $100.0 million of outstanding aggregate principal amount of the 2024 Notes, which were redeemed on April 2, 2018. Further, on December 7, 2018, the Board of Directors approved a full redemption, in two equal transactions, of $83.5 million of the outstanding aggregate principal amount of the 2024 Notes. The 2024 Notes were fully redeemed on January 14, 2019 and February 4, 2019.

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2024 Notes were as follows:

On July 16, 2019, the Company issued $105.0 million in aggregate principal amount of 4.77% notes due 2024 (the “July 2024 Notes”) to qualified institutional investors in a private placement pursuant to a note purchase agreement. The sale of the July 2024 Notes generated net proceeds of approximately $103.5 million. Aggregate estimated offering expenses in connection with the transaction, including fees and commissions, were approximately $1.5 million.

The July 2024 Notes have a fixed interest rate of 4.77% and are due on July 16, 2024, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the July 2024 Notes is due semiannually and the July 2024 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

As of September 30, 2020 and December 31, 2019, the components of the carrying value of the July 2024 Notes were as follows:

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the July 2024 Notes were as follows:

As of September 30, 2020, the Company was in compliance with the terms of the note purchase agreement governing the July 2024 Notes.

On February 5, 2020, the Company issued $50.0 million in aggregate principal amount of senior unsecured notes due February 2025 (the “February 2025 Notes”) to qualified institutional investors in a private placement pursuant to a note purchase agreement (“2025 Note Purchase Agreement”). The sale of the February 2025 Notes generated net proceeds of approximately $49.4 million. Aggregate estimated offering expenses in connection with the transaction, including fees and commissions, were approximately $581,000.

The February 2025 Notes have a fixed interest rate of 4.28% and are due February 2025, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the February 2025 Notes is due semiannually and the February 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

The 2025 Note Purchase Agreement also provided for the issuance of an additional $70.0 million aggregate principal amount of senior unsecured notes due June 2025 with a fixed interest rate of 4.31% per year that were issued in June 2020 and is described below.

As of September 30, 2020 and December 31, 2019, the components of the carrying value of the February 2025 Notes were as follows:

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the February 2025 Notes were as follows:

As of September 30, 2020, the Company was in compliance with the terms of the 2025 Note Purchase Agreement.

On June 3, 2020, the Company issued $70.0 million in aggregate principal amount of senior unsecured notes due June 2025 (the “June 2025 Notes”) to qualified institutional investors in a private placement pursuant to the 2025 Note Purchase Agreement. The sale of the June 2025 Notes generated net proceeds of approximately $69.2 million. Aggregate estimated offering expenses in connection with the transaction, including fees and commissions, were approximately $819,000.

The June 2025 Notes have a fixed interest rate of 4.31% and are due June 2025, unless redeemed, purchased or prepaid prior to such date by the Company or its affiliates in accordance with their terms. Interest on the June 2025 Notes is due semiannually and the June 2025 Notes are general unsecured obligations of the Company that rank pari passu with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

As of September 30, 2020 and December 31, 2019, the components of the carrying value of the June 2025 Notes were as follows:

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the June 2025 Notes were as follows:

As of September 30, 2020, the Company was in compliance with the terms of the 2025 Note Purchase Agreement.

On April 26, 2018, the Company issued $75.0 million in aggregate principal amount of 5.25% notes due 2025 (the “2025 Notes”). The 2025 Notes were issued pursuant to the Fifth Supplemental Indenture to the Base Indenture, dated April 26, 2018 (the “2025 Notes Indenture”), between the Company and U.S. Bank, National Association, as trustee. The sale of the 2025 Notes generated net proceeds of approximately $72.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $2.6 million.

The 2025 Notes will mature on April 30, 2025, unless previously repurchased in accordance with their terms. The 2025 Notes bear interest at a rate of 5.25% per year payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year, commencing on July 30, 2018 and trade on the NYSE under the symbol “HCXZ”. The 2025 Notes are the Company’s direct unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

The Company may redeem some or all of the 2025 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2025 Notes Indenture after April 30, 2021. No sinking fund is provided for the 2025 Notes. The 2025 Notes were issued in denominations of $25 and integral multiples of $25 thereof. As of September 30, 2020, the Company was in compliance with the terms of the 2025 Notes Indenture.

As of September 30, 2020 and December 31, 2019, the components of the carrying value of the 2025 Notes were as follows:

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2025 Notes were as follows:

On September 24, 2018, the Company issued $40.0 million in aggregate principal amount of 6.25% notes due 2033 (the “2033 Notes”). The 2033 Notes were issued pursuant to the Sixth Supplemental Indenture to the Base Indenture, dated September 24, 2018 (the “2033 Notes Indenture”), between the Company and U.S. Bank, National Association, as trustee. The sale of the 2033 Notes generated net proceeds of approximately $38.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $1.6 million.

The 2033 Notes will mature on October 30, 2033, unless previously repurchased in accordance with their terms. The 2033 Notes bear interest at a rate of 6.25% per year payable quarterly in arrears on January 30, April 30, July 30, and October 30 of each year, commencing on October 30, 2018 and trade on the NYSE under the symbol “HCXY.”

The 2033 Notes are the Company’s direct unsecured obligations and rank pari passu, or equally in right of payment, with all outstanding and future unsecured unsubordinated indebtedness issued by the Company.

The Company may redeem some or all of the 2033 Notes at any time, or from time to time, at the redemption price set forth under the terms of the 2033 Notes Indenture after October 30, 2023. No sinking fund is provided for the 2033 Notes. The 2033 Notes were issued in denominations of $25 and integral multiples of $25 thereof. As of September 30, 2020, the Company was in compliance with the terms of the 2033 Notes Indenture.

As of September 30, 2020 and December 31, 2019, the components of the carrying value of the 2033 Notes were as follows:

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2033 Notes were as follows:

On November 1, 2018, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of $200.0 million in aggregate principal amount of fixed rate asset-backed notes (the “2027 Asset-Backed Notes”).

The 2027 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2018-1 (the “2018 Securitization Issuer”) pursuant to a note purchase agreement, dated as of October 25, 2018, by and among the Company, Hercules Capital Funding 2018-1 LLC, as trust depositor, the 2018 Securitization Issuer, and Guggenheim Securities, LLC, as initial purchaser, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. The securitization has a reinvestment period which expired on October 20, 2020, and as a result, principal collections will not be reinvested into additional eligible loans going forward. Interest on the 2027 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.605% per annum. The 2027 Asset-Backed Notes have a stated maturity of November 22, 2027.

At both September 30, 2020 and December 31, 2019, the 2027 Asset-Backed Notes had an outstanding principal balance of $200.0 million.

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2027 Asset-Backed Notes were as follows:

Under the terms of the 2027 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2027 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2027 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. At September 30, 2020 and December 31, 2019, there was approximately $9.4 million and $20.9 million, respectively, of funds segregated as restricted cash related to the 2027 Asset-Backed Notes.

As of September 30, 2020, the Company was in compliance with the terms of the note purchase agreement governing the 2027 Asset-Backed Notes.

On January 22, 2019, the Company completed a term debt securitization in connection with which an affiliate of the Company made an offering of $250.0 million in aggregate principal amount of fixed rate asset-backed notes (the “2028 Asset-Backed Notes”).

The 2028 Asset-Backed Notes were issued by Hercules Capital Funding Trust 2019-1 (the “2019 Securitization Issuer”) pursuant to a note purchase agreement, dated as of January 14, 2019, by and among the Company, Hercules Capital Funding 2019-1 LLC, as trust depositor, the 2019 Securitization Issuer, and Guggenheim Securities, LLC, as initial purchaser, MUFG Securities Americas Inc., as a co-manager, and Wells Fargo Securities, LLC., as a co-manager, and are backed by a pool of senior loans made to certain portfolio companies of the Company and secured by certain assets of those portfolio companies and are to be serviced by the Company. The securitization has a reinvestment period with a scheduled termination date of January 2021 during which time principal collections may be reinvested into additional eligible loans. Interest on the 2028 Asset-Backed Notes will be paid, to the extent of funds available, at a fixed rate of 4.703% per annum. The 2028 Asset-Backed Notes have a stated maturity of February 22, 2028.

At both September 30, 2020 and December 31, 2019, the 2028 Asset-Backed Notes had an outstanding principal balance of $250.0 million.

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the 2028 Asset-Backed Notes were as follows:

Under the terms of the 2028 Asset-Backed Notes, the Company is required to maintain a reserve cash balance, funded through proceeds from the sale of the 2028 Asset-Backed Notes and through interest and principal collections from the underlying securitized debt portfolio, which may be used to pay monthly interest and principal payments on the 2028 Asset-Backed Notes. The Company has segregated these funds and classified them as restricted cash. At September 30, 2020 and December 31, 2019, there was approximately $11.1 million and $29.7 million, respectively, of funds segregated as restricted cash related to the 2028 Asset-Backed Notes.

As of September 30, 2020, the Company was in compliance with the terms of the note purchase agreement governing the 2028 Asset-Backed Notes.

On January 25, 2017, the Company issued $230.0 million in aggregate principal amount of 4.375% Convertible Notes due 2022 (the “2022 Convertible Notes”), which amount includes the additional $30.0 million aggregate principal amount of 2022 Convertible Notes issued pursuant to the initial purchaser’s exercise in full of its overallotment option. The 2022 Convertible Notes were issued pursuant to an Indenture, dated January 25, 2017 (the “2022 Convertible Notes Indenture”), between the Company and the 2022 Trustee. The sale of the 2022 Convertible Notes generated net proceeds of approximately $225.5 million, including $4.5 million of debt issuance costs.

The 2022 Convertible Notes mature on February 1, 2022, unless previously converted or repurchased in accordance with their terms. The 2022 Convertible Notes bear interest at a rate of 4.375% per year payable semiannually in arrears on February 1 and August 1 of each year, commencing on August 1, 2017.

The 2022 Convertible Notes are unsecured obligations of the Company and rank senior in right of payment to the Company’s future indebtedness that is expressly subordinated in right of payment to the 2022 Convertible Notes; equal in right of payment to the Company’s existing and future indebtedness that is not so subordinated; effectively junior in right of payment to any of the Company’s secured indebtedness (including unsecured indebtedness that the Company later secures) to the extent of the value of the assets securing such indebtedness; and structurally junior to all existing and future indebtedness (including trade payables) incurred by the Company’s subsidiaries, financing vehicles or similar facilities.

Prior to the close of business on the business day immediately preceding August 1, 2021, holders may convert their 2022 Convertible Notes only under certain circumstances set forth in the 2022 Convertible Notes Indenture. On or after August 1, 2021 until the close of business on the scheduled trading day immediately preceding the maturity date, holders may convert their 2022 Convertible Notes at any time. Upon conversion, the Company will pay or deliver, as the case may be, at its election, cash, shares of its common stock or a combination of cash and shares of its common stock. The conversion rate is initially 60.9366 shares of common stock per $1,000 principal amount of 2022 Convertible Notes (equivalent to an initial conversion price of approximately $16.41 per share of common stock). The conversion rate will be subject to adjustment in some events but will not be adjusted for any accrued and unpaid interest. In addition, if certain corporate events occur prior to the maturity date, the Company will increase the conversion rate for a holder who elects to convert its 2022 Convertible Notes in connection with such a corporate event in certain circumstances. As of September 30, 2020, the conversion rate was 60.9366 shares of common stock per $1,000 principal amount of Convertible Senior Notes (equivalent to an adjusted conversion price of approximately $16.41 per share of common stock).

The Company may not redeem the 2022 Convertible Notes at its option prior to maturity. No sinking fund is provided for the 2022 Convertible Notes. In addition, if certain corporate events occur, holders of the 2022 Convertible Notes may require the Company to repurchase for cash all or part of their 2022 Convertible Notes at a repurchase price equal to 100% of the principal amount of the 2022 Convertible Notes to be repurchased, plus accrued and unpaid interest through, but excluding, the required repurchase date.

The 2022 Convertible Notes are accounted for in accordance with ASC Subtopic 470-20 (“Debt with Conversion and Other Options”). In accounting for the 2022 Convertible Notes, the Company estimated at the time of issuance that the values of the debt and the embedded conversion feature of the 2022 Convertible Notes were approximately 98.5% and 1.5%, respectively. The OID of 1.5% or $3.4 million, attributable to the conversion feature of the 2022 Convertible Notes was recorded in “capital in excess of par value” in the Consolidated Statements of Assets and Liabilities. As a result, the Company records interest expense comprised of both stated interest expense as well as accretion of the OID resulting in an estimated effective interest rate of approximately 4.76%.

As of September 30, 2020 and December 31, 2019, the components of the carrying value of the 2022 Convertible Notes were as follows:

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense, fees and cash paid for interest expense for the 2022 Convertible Notes were as follows:

As of September 30, 2020, the Company was in compliance with the terms of the indentures governing the 2022 Convertible Notes.

As of September 30, 2020 and December 31, 2019, the Company has two available credit facilities, the Wells Facility and the Union Bank Facility (together, the “Credit Facilities”).

On June 29, 2015, the Company, through a special purpose wholly owned subsidiary, Hercules Funding II LLC (“Hercules Funding II”), entered into an Amended and Restated Loan and Security Agreement (the “Wells Facility”) with Wells Fargo Capital Finance, LLC, as a lender and as the arranger and the administrative agent, and the lenders party thereto from time to time.

On January 11, 2019, Hercules Funding II entered into the Seventh Amendment to the Wells Facility, (the “Wells Facility Seventh Amendment”). The Wells Facility Seventh Amendment, among other things, amends certain key provisions of the Wells Facility to reduce the current interest rate to LIBOR plus 3.00% with an interest rate floor of 3.00%. The Wells Facility Seventh Amendment also extends the maturity date to January 2023, unless terminated earlier in accordance with its terms. In addition, Wells Fargo Capital Finance, LLC has committed $75.0 million in credit capacity with an accordion feature, in which the Company can increase the credit line up to an aggregate of $125.0 million, funded by additional lenders and with the agreement of Wells Fargo and subject to other customary conditions. The Wells Facility has an advance rate of 55% against eligible debt investments, and it is secured by all of the assets of Hercules Funding II. The Wells Facility requires payment of a non-use fee of up to 0.375% depending on the average monthly outstanding balance under the facility relative to the maximum amount of commitments at such time.

The Wells Facility also includes various financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding II, including covenants relating to certain changes of control of the Company and Hercules Funding II. Among other things, these covenants also require the Company to maintain certain financial ratios, including a maximum debt to worth ratio, minimum interest coverage ratio, and a minimum tangible net worth ratio.

On July 2, 2019, Hercules Funding II entered into the Eighth Amendment to the Wells Facility (the “Wells Facility Eighth Amendment”). The Wells Facility Eighth Amendment amends certain provisions of the Wells Facility to, among other things, revise certain provisions thereof to further permit a third party special servicer to act as servicer after an event of default instead of the Company with respect to split-funded notes receivable owned by Hercules Funding II and an affiliate thereof (including Hercules Funding IV LLC).

The Wells Facility provides for customary events of default, including, without limitation, with respect to payment defaults, breach of representations and covenants, certain key person provisions, cross acceleration provisions to certain other debt, lien, and judgment limitations, and bankruptcy.

As of both September 30, 2020 and December 31, 2019, the Company had no borrowings outstanding under the Wells Facility.

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the Wells Facility were as follows:

As of September 30, 2020, the Company was in compliance with the terms of the Wells Facility.

On February 20, 2020, the Company, through a special purpose wholly owned subsidiary, Hercules Funding IV LLC (“Hercules Funding IV”), as borrower, entered into the credit facility (the “Union Bank Facility”) with MUFG Union Bank, as the arranger and administrative agent, and the lenders party to the Union Bank Facility from time to time. The Union Bank Facility replaced the Company’s credit facility (the “2019 Union Bank Facility”) entered into on February 20, 2019 with MUFG Union Bank, as the arranger and administrative agent, and the lenders party thereto. The 2019 Union Bank Facility replaced the Company’s credit facility (the “Prior Union Bank Facility”) entered into on May 5, 2016 with MUFG Union Bank, as the arranger and administrative agent, and the lenders party thereto. Any references to amounts related to the Union Bank Facility prior to February 20, 2020 were incurred and relate to the Prior Union Bank Facility or the 2019 Union Bank Facility, as applicable.

Under the Union Bank Facility, the lenders have made commitments of $400.0 million. The Union Bank Facility contains an accordion feature, in which the Company can increase the credit line up to an aggregate of $200.0 million, funded by existing or additional lenders and with the agreement of MUFG Union Bank and subject to other customary conditions. There can be no assurances that additional lenders will join the Union Bank Facility to increase available borrowings. Borrowings under the Union Bank Facility generally bear interest at a rate per annum equal to LIBOR plus 2.50%. The Union Bank Facility matures on February 22, 2023 plus a 12-month amortization period, unless sooner terminated in accordance with its terms. The Union Bank Facility is secured by all of the assets of Hercules Funding IV.

The Union Bank Facility requires payment of a non-use fee during the revolving credit availability period as follows: (i) 0.50% if less than or equal to 50% utilization; (ii) 0.375% if more than 50% utilization but less than or equal to 80% utilization; and (iii) 0.20% if more than 80% is utilized.

The Union Bank Facility also includes financial and other covenants applicable to the Company and the Company’s subsidiaries, in addition to those applicable to Hercules Funding IV, including covenants relating to certain changes of control of Hercules Funding IV. Among other things, these covenants also require the Company to maintain certain financial ratios, including a minimum interest coverage ratio with respect to Hercules Funding IV and a minimum tangible net worth in an amount that is in excess of $723.0 million.

The Union Bank Facility provides for customary events of default, including with respect to payment defaults, breach of representations and covenants, servicer defaults, certain key person provisions, cross default provisions to certain other debt, lien and judgment limitations, and bankruptcy.

As of September 30, 2020, the Company had $37.5 million of borrowings outstanding on the Union Bank Facility. The Company had borrowings outstanding of $103.9 million on the Union Bank Facility at December 31, 2019.

For the three and nine months ended September 30, 2020 and 2019, the components of interest expense and related fees and cash paid for interest expense for the previous and current Union Bank Facility were as follows:

As of September 30, 2020, the Company was in compliance with the terms of the Union Bank Facility.

The Company intends to operate so as to qualify to be subject to tax as a RIC under Subchapter M of the Code and, as such, will not be subject to U.S. federal income tax on the portion of taxable income (including gains) distributed as dividends for U.S. federal income tax purposes to stockholders. Taxable income includes the Company’s taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses, and generally excludes net unrealized appreciation or depreciation, as such gains or losses are not included in taxable income until they are realized.

To qualify and be subject to tax as a RIC, the Company is required to meet certain income and asset diversification tests in addition to distributing dividends of an amount generally at least equal to 90% of its investment company taxable income, as defined by the Code and determined without regard to any deduction for distributions paid, to its stockholders. The amount to be paid out as a distribution is determined by the Board of Directors each quarter and is based upon the annual earnings estimated by the management of the Company. To the extent that the Company’s earnings fall below the amount of dividend distributions declared, however, a portion of the total amount of the Company’s distributions for the fiscal year may be deemed a return of capital for tax purposes to the Company’s stockholders.

During the three and nine months ended September 30, 2020, the Company declared and paid distributions of $0.32 per share and $1.04 per share, respectively. The determination of the tax attributes of the Company’s distributions is made annually as of the end of the Company’s taxable year generally based upon its taxable income for the full taxable year and distributions paid for the full taxable year. As a result, a determination made on a quarterly basis may not be representative of the actual tax attributes of the Company’s distributions for a full taxable year. If the Company had determined the tax attributes of our distributions taxable year-to-date as of September 30, 2020, 100% would be from our current and accumulated earnings and profits. However, there can be no certainty to stockholders that this determination is representative of what the actual tax attributes of the Company’s fiscal year of 2020 distributions to stockholders will be.

As a RIC, the Company will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income unless the Company makes distributions treated as dividends for U.S. federal income tax purposes in a timely manner to its stockholders in respect of each calendar year of an amount at least equal to the sum of (1) 98% of our ordinary income (taking into account certain

deferrals and elections) for each calendar year, (2) 98.2% of our capital gain net income (adjusted for certain ordinary losses) for the 1-year period ending October 31 of each such calendar year and (3) any ordinary income and capital gain net income realized, but not distributed, in preceding calendar years, or the excise tax avoidance requirement. The Company will not be subject to this excise tax on any amount on which the Company incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains).

Depending on the level of taxable income earned in a taxable year, the Company may choose to carry over taxable income in excess of current taxable year distributions from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent the Company chooses to carry over taxable income into the next taxable year, distributions declared and paid by the Company in a taxable year may differ from the Company’s taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

The Company has taxable subsidiaries which hold certain portfolio investments in an effort to limit potential legal liability and/or comply with source-income type requirements contained in the RIC tax provisions of the Code. These taxable subsidiaries are consolidated for U.S. GAAP and the portfolio investments held by the taxable subsidiaries are included in the Company’s consolidated financial statements and are recorded at fair value. These taxable subsidiaries are not consolidated with the Company for income tax purposes and may generate income tax expense, or benefit, and tax assets and liabilities as a result of their ownership of certain portfolio investments. Any income generated by these taxable subsidiaries generally would be subject to tax at normal corporate tax rates based on its taxable income.

Taxable income for the nine months ended September 30, 2020 was approximately $112.8 million or $1.01 per share. Taxable net realized gains for the same period were $14.2 million or approximately $0.13 per share. Taxable income for the nine months ended September 30, 2019 was approximately $110.0 million or $1.11 per share. Taxable net realized gains for the same period were $15.6 million or approximately $0.16 per share.

For the nine months ended September 30, 2020, the Company paid approximately $2.5 million of income tax, including excise tax, and had $1.8 million of accrued but unpaid tax expense as of September 30, 2020. For the nine months ended September 30, 2019, the Company paid approximately $1.4 million of income tax, including excise tax, and had $835,000 accrued but unpaid tax expense as of September 30, 2019.

The Company intends to timely distribute to its stockholders substantially all of its annual taxable income for each year, except that it may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

On September 7, 2017, the Company entered into an At-The-Market, (“ATM”) equity distribution agreement (the “2017 Equity Distribution Agreement”), with JMP Securities LLC (“JMP”). The 2017 Equity Distribution Agreement provided that the Company may offer and sell up to 12.0 million shares of its common stock from time to time through JMP, as its sales agent.

On May 6, 2019, the Company terminated the 2017 Equity Distribution Agreement and entered into a new ATM equity distribution agreement (the “2019 Equity Distribution Agreement”). As a result, the remaining shares that were available under the 2017 Equity Distribution agreement are no longer available for issuance. The 2019 Equity Distribution Agreement provided that the Company may offer and sell up to 12.0 million shares of its common stock from time to time through JMP, as its sales agent.

On July 2, 2020, the Company terminated the 2019 Equity Distribution Agreement and entered into a new ATM equity distribution agreement with JMP (the “2020 Equity Distribution Agreement”). As a result, the remaining shares that were available under the 2019 Equity Distribution Agreement are no longer available for issuance. The 2020 Equity Distribution Agreement provides that the Company may offer and sell up to 16.5 million shares of its common stock from time to time through JMP, as its sales agent. Sales of the Company’s common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act of 1933, as amended (the “Securities Act”), including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

There were no shares of common stock sold under the 2019 Equity Distribution Agreement or the 2020 Equity Distribution Agreement during the three months ended September 30, 2020. During the nine months ended September 30, 2020, the Company sold approximately 6.0 million shares of common stock under the 2019 Equity Distribution Agreement. For the same period, the Company received total accumulated net proceeds of approximately $73.9 million, including offering expenses of $810,000, from these sales.

There were no shares of common stock sold under the 2019 Equity Distribution Agreement during the three months ended September 30, 2019. During the nine months ended September 30, 2019, the Company sold approximately 2.0 million shares of common stock, of which 679,000 shares and 1.3 million shares were issued under the 2017 Equity Distribution Agreement and the 2019 Equity Distribution Agreement, respectively. For the same period, the Company received total accumulated net proceeds of approximately $25.1 million, including $311,000 of offering expenses, from these sales, of which $8.5 million, including offering expenses of $146,000, was received under the 2017 Equity Distribution Agreement and $16.6 million, including offering expenses of $165,000, was received under the 2019 Equity Distribution Agreement.

The Company generally uses net proceeds from these offerings to make investments, to repurchase or pay down liabilities and for general corporate purposes. As of September 30, 2020, approximately 16.5 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement.

On June 17, 2019, the Company closed its underwritten public offering of 5.8 million shares of common stock, including an over-allotment option to purchase an additional 750,000 shares of common stock (“June 2019 Equity Offering”). The June 2019 Equity Offering generated net proceeds, before expenses, of $70.5 million, including the underwriting discount and commissions of $2.2 million.

The Company has issued stock options for common stock subject to future issuance, of which 456,484 and 449,116 were outstanding at September 30, 2020 and December 31, 2019, respectively.

The Company and its stockholders authorized and adopted the 2004 Equity Incentive Plan (the “2004 Plan”) for purposes of attracting and retaining the services of its executive officers and key employees. The Company and its stockholders have authorized and adopted the 2006 Non-Employee Director Plan (the “2006 Plan”) for purposes of attracting and retaining the services of its Board of Directors. On June 21, 2017, the 2006 Plan expired in accordance with its terms and no additional awards may be granted under the 2006 Plan.

On May 13, 2018, the Board of Directors further amended and restated the 2004 Plan and renamed it the Hercules Capital, Inc. Amended and Restated 2018 Equity Incentive Plan (the “2018 Equity Incentive Plan”). Under the 2004 Plan, prior to the amendment and restatement, the Company was authorized to issue 12.0 million shares of common stock. The 2018 Equity Incentive Plan, among other things, increased the number of shares available for issuance to eligible participants by an additional 6.7 million shares. Unless earlier terminated by the Board of Directors, the 2018 Equity Incentive Plan will terminate on May 12, 2028. On May 13, 2018, the Board of Directors adopted the Hercules Capital, Inc. 2018 Non-Employee Director Plan (the “Director Plan”). The Director Plan provides equity compensation in the form of restricted stock to the Company’s non-employee directors. Subject to certain adjustments, the maximum aggregate number of shares of stock that may be authorized for issuance as restricted stock awards granted under the Director Plan is 300,000 shares. Unless earlier terminated by the Board of Directors, the Director Plan will terminate on May 12, 2028. The 2018 Equity Incentive Plan and the Director Plan were each approved by stockholders on June 28, 2018. Except for the Retention PSUs (as described below), these employee awards generally vest 33% one year after the date of grant and ratably over the succeeding 24 months.

On May 29, 2018, the Company filed an exemptive application with the Securities and Exchange Commission (the “SEC”) and an amendment to the application on September 27, 2018, with respect to the 2018 Equity Incentive Plan and the Director Plan for exemptive relief from certain provisions of the 1940 Act. On January 30, 2019, the Company received approval from the SEC on its request for exemptive relief that permits it to issue restricted stock to non-employee directors under the Director Plan and restricted stock and restricted stock units to certain of its employees, officers, and directors (excluding non-employee directors) under the 2018 Equity Incentive Plan. The exemptive order also allows participants in the Director Plan and the 2018 Equity Incentive Plan to (i) elect to have the Company withhold shares of its common stock to pay for the exercise price and applicable taxes with respect to an option exercise (“net issuance exercise”) and/or (ii) permit the holders of restricted stock to elect to have the Company withhold shares of its stock to pay the applicable taxes due on restricted stock at the time of vesting. Each individual employee would be able to make a cash payment to satisfy applicable tax withholding at the time of option exercise or vesting on restricted stock.

The following table summarizes the common stock options activities for the nine months ended September 30, 2020 and 2019:

All options may be exercised for a period ending seven to ten years after the date of grant. At September 30, 2020, options for approximately 456,484 shares were outstanding at a weighted average exercise price of approximately $13.16 per share with weighted average of remaining contractual term of 4.24 years and $42,000 aggregate intrinsic value. At September 30, 2020, options for approximately 320,974 shares were exercisable at a weighted average exercise price of approximately $13.49 per share with weighted average of remaining contractual term of 3.44 years and $11,000 aggregate intrinsic value.

The Company determined that the fair value of options granted under the 2018 Equity Incentive Plan during the nine months ended September 30, 2020 and 2019 was approximately $9,000 and $40,000, respectively. During the nine months ended September 30, 2020 and 2019, approximately $22,000 and $35,000 of share-based cost due to stock option grants was expensed, respectively. As of September 30, 2020, there was approximately $32,000 of total unrecognized compensation costs related to stock options. These costs are expected to be recognized over a weighted average period of 1.61 years.

The Company follows ASC Topic 718 (“Compensation - Stock Compensation”) to account for stock options granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life. The fair value of options granted is based upon a Black Scholes OPM using the assumptions in the following table for each of the nine months ended September 30, 2020 and 2019 and is as follows:

During the nine months ended September 30, 2020 and 2019, the Company granted 693,248 shares and 134,247 shares, respectively, of restricted stock awards pursuant to the 2018 Equity Incentive Plan and the Director Plan. The Company determined that the fair values, based on grant date close price, of restricted stock awards granted under the 2018 Equity Incentive Plan and the Director Plan during the nine months ended September 30, 2020 and 2019 were approximately $9.7 million and $1.7 million, respectively. As of September 30, 2020, there were approximately $8.3 million of total unrecognized compensation costs related to restricted stock awards. These costs are expected to be recognized over a weighted average period of 2.19 years.

The following table summarizes the activities for the Company’s unvested restricted stock awards for the nine months ended September 30, 2020 and 2019:

During the nine months ended September 30, 2020, the Company did not grant restricted stock units pursuant to the 2018 Equity Incentive Plan. The Company granted approximately 1,029,836 shares of restricted stock units during the nine months ended September 30, 2019. The Company also granted approximately 67,363 shares and 124,708 shares, respectively, of distribution equivalent units pursuant to the 2018 Equity Incentive Plan during the nine months ended September 30, 2020 and 2019. The Company determined that the fair values, based on grant date close price, of restricted stock units granted under the 2018 Equity Incentive Plan during the nine months ended September 30, 2020 and 2019 were approximately $904,900 and $15.2 million, respectively. As of September 30, 2020, there were approximately $2.8 million of total unrecognized compensation costs related to restricted stock units. These costs are expected to be recognized over a weighted average period of 1.32 years.

The following table summarizes the activities for the Company’s unvested restricted stock units for the nine months ended September 30, 2020 and 2019:

During the nine months ended September 30, 2020, the Company expensed approximately $5.0 million of compensation expense related to restricted stock awards and restricted stock units. The Company had approximately $7.7 million in compensation expense related to restricted stock awards and restricted stock units during the nine months ended September 30, 2019.

On May 2, 2018, the Company granted long-term Retention Performance Stock Unit awards (the “Retention PSUs”) under the 2004 Plan and separate cash bonus awards with similar terms (the “Cash Awards”) to senior personnel. The awards are designed to provide incentives that increase along with the total shareholder return (“TSR”). On May 2, 2018, the target number of Retention PSUs granted to senior personnel was 1,299,757 in the aggregate and the target amount of the Cash Awards granted to senior personnel was $4.0 million in the aggregate. As of September 30, 2020, there were 487,409 Retention PSUs outstanding at target and the target amount of the Cash Awards was $3.0 million in the aggregate. During the nine months ended September 30, 2020, no Retention PSUs at target were forfeited. The Retention PSUs and Cash Awards do not vest until the fourth anniversary “cliff vest” of the grant date (or a change in control of the Company, if earlier) and the Retention PSUs must generally be held and not disposed of until the fifth anniversary of the grant date, except in the event of death, disability or a change in control (the “Performance Period”). Distribution equivalent units will accrue in respect only of the Retention PSUs in the form of additional Retention PSUs, but will not be paid unless the Retention PSUs to which such distribution equivalent units relate actually vest. The Cash Awards are not eligible to accrue distribution equivalent units.

The Company follows ASC Topic 718 to account for the Retention PSUs and Cash Awards granted. Under ASC Topic 718, compensation cost associated with Retention PSUs is measured at the grant date based on the fair value of the award and is recognized over the Performance Period. As the Cash Awards are settled in cash, the award is expensed as a liability, and will be re-measured at each reporting period until the Performance Period is complete. The compensation expense for these awards is based on the per unit grant date valuation using a Monte-Carlo simulation multiplied by the target payout level. The payout level is calculated based the Company’s TSR relative to specified BDCs during the performance period.

As of September 30, 2020, all outstanding Retention PSUs and Cash Awards were unvested and there were approximately $2.7 million of total unrecognized compensation costs related to the Retention PSUs. These costs are expected to be recognized over a weighted average remaining vesting period of 1.59 years. As of September 30, 2020, there was approximately $2.5 million of accumulated compensation expense related to the Cash Awards. The accumulated expense related to the Cash Awards is included within Accounts payable and accrued liabilities on the Consolidated Statements of Assets and Liabilities.

Shares used in the computation of the Company’s basic and diluted earnings per share are as follows:

	Three Months Ended September 30,						Nine Months Ended September 30,
(in thousands, except per share data)	2020			2019			2020			2019
Numerator
Net increase (decrease) in net assets resulting from operations	$	43,047		$	19,271		$	76,089		$	128,987
Less: Distributions declared-common and restricted shares		(36,557	)		(35,555	)		(116,782	)		(97,606	)
Undistributed earnings (loss)		6,490			(16,284	)		(40,693	)		31,381
Undistributed earnings (loss)-common shares		6,445			(16,284	)		(40,693	)		31,313
Add: Distributions declared-common shares		36,309			35,490			115,936			97,388
Numerator for basic and diluted change in net assets per common share	$	42,754		$	19,206		$	75,243		$	128,701

Denominator
Basic weighted average common shares outstanding		113,489			104,314			111,342			99,615
Common shares issuable		255			341			248			428
Weighted average common shares outstanding assuming dilution		113,744			104,655			111,590			100,043

Change in net assets per common share
Basic	$	0.38		$	0.18		$	0.68		$	1.29
Diluted	$	0.38		$	0.18		$	0.67		$	1.29

In the table above, unvested share-based payment awards that have non-forfeitable rights to distributions or distribution equivalents are treated as participating securities for calculating earnings per share. Unvested common stock options and restricted stock units are also considered for the purpose of calculating diluted earnings per share.

For the three and nine months ended September 30, 2020 and 2019, the effect of the 2022 Convertible Notes under the treasury stock method was anti-dilutive and, accordingly, was excluded from the calculation of diluted earnings per share.

The calculation of change in net assets resulting from operations per common share—assuming dilution, excludes all anti-dilutive shares. For the three months ended September 30, 2020, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, consisted of 6.7 million shares of 2022 Convertible Notes, 90,689 shares of unvested common stock options, no shares of unvested restricted stock units, 17,883 shares of unvested restricted stock awards, and no shares of unvested Retention PSUs. For the nine months ended September 30, 2020, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the period, consisted of 6.1 million shares of 2022 Convertible Notes, 80,342 shares of unvested common stock options, no shares of unvested restricted stock units, 63,737 shares of unvested restricted stock awards, and no shares of unvested Retention PSUs. For the three and nine months ended September 30, 2019, the number of anti-dilutive shares, as calculated based on the weighted average closing price of the Company’s common stock for the periods, consisted of 3.6 million and 3.8 million shares, respectively, related to 2022 Convertible Notes, 25,396 and 30,110 shares, respectively, of unvested common stock options, no shares of unvested restricted stock units, and no shares of unvested Retention PSUs.

At both September 30, 2020 and December 31, 2019, the Company was authorized to issue 200.0 million shares of common stock with a par value of $0.001. Each share of common stock entitles the holder to one vote.

Following is a schedule of financial highlights for the nine months ended September 30, 2020 and 2019:

The Company’s commitments and contingencies consist primarily of unused commitments to extend credit in the form of loans to the Company’s portfolio companies. A portion of these unfunded contractual commitments as of September 30, 2020 are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, the Company’s credit agreements with its portfolio companies generally contain customary lending provisions which allow the Company relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the Company. Since a portion of these commitments may expire without being drawn, unfunded contractual commitments do not necessarily represent future cash requirements. As such, the Company’s disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones.

At September 30, 2020, the Company had approximately $242.5 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones.

The Company also had approximately $97.9 million of non-binding term sheets outstanding at September 30, 2020. Non-binding outstanding term sheets are subject to completion of the Company’s due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of the Company’s unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

As of September 30, 2020, the Company’s unfunded contractual commitments available at the request of the portfolio company, including undrawn revolving facilities, and unencumbered by milestones were as follows:

Certain premises are leased or licensed under agreements which expire at various dates through June 2027. Total rent expense, including short-term leases, amounted to approximately $800,000 and $2.3 million during the three and nine months ended September 30, 2020, respectively. Total rent expense amounted to approximately $764,000 and $2.0 million during the three and nine months ended September 30, 2019, respectively. The Company recognizes an operating lease liability and a ROU asset for all leases, with the exception of short-term leases. The lease payments on short-term leases are recognized as rent expense on a straight-line basis. The discount rate applied to measure each ROU asset and lease liability is based on the Company’s weighted average cost of debt. The Company considers the general economic environment and its credit rating and factors in various financing and asset specific adjustments to ensure the discount rate applied is appropriate to the intended use of the underlying lease. While some of the leases contained options to extend and terminate, it is not reasonably certain that either option will be utilized and therefore, only the payments in the initial term of the leases were included in the lease liability and ROU asset.

The following table sets forth information related to the measurement of the Company’s operating lease liabilities and supplemental cash flow information related to operating leases as of September 30, 2020:

The following table shows future minimum lease payments under the Company’s operating leases and a reconciliation to the operating lease liability as of September 30, 2020:

The Company may, from time to time, be involved in litigation arising out of its operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on the Company in connection with the activities of its portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, the Company does not expect any current matters will materially affect the Company’s financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on the Company’s financial condition or results of operations in any future reporting period.

In August 2018, the FASB issued ASU 2018-13, “Fair Value Measurement (Topic 820): Disclosure Framework – Changes to Disclosure Requirements for Fair Value Measurement”, which is intended to improve the effectiveness of fair value measurement disclosures. The amendment, among other things, affects certain disclosure requirements related to transfers between level 1 and level 2 of the fair value hierarchy, and level 3 fair value measurements as they relate to valuation process, unrealized gains and losses, measurement uncertainty, and significant unobservable inputs. The new guidance is effective for interim and annual periods beginning after December 15, 2019. The Company partially adopted the standard effective July 1, 2019 and fully adopted this standard effective January 1, 2020, which did not have a material impact, on its consolidated financial statements and related disclosures for the periods presented.

In March 2020, the FASB issued ASU 2020-04, "Reference Rate Reform (Topic 848) - Facilitation of the Effects of Reference Rate Reform on Financial Reporting”. This guidance provides optional expedients and exceptions for applying U.S. GAAP to certain contracts, hedging relationships and other transactions, subject to meeting certain criteria, that reference LIBOR or another reference rate expected to be discontinued due to reference rate reform. The Company has agreements that have LIBOR as a reference rate with certain portfolio companies and also with certain lenders. These agreements include language for choosing an alternative successor rate if LIBOR reference is no longer considered to be appropriate. The change from LIBOR to a successor rate will result in an amendment to such agreements. The Company has adopted this amendment as of March 12, 2020 and there was no material impact on the Company’s consolidated financial statements and disclosures for the periods presented.

In August 2020, the FASB issued ASU 2020-6, “Debt - Debt with Conversion and Other Options (Subtopic 470-20) and Derivatives and Hedging - Contracts in Entity’s Own Equity (Subtopic 815-40)”, which is intended to address issues identified as a result of the complexity associated with applying U.S. GAAP for certain financial instruments with characteristics of liabilities and equity. The amendment, among other things, reduces the number of accounting models for convertible debt instruments and convertible preferred stock and enhances information transparency by making targeted improvements to the disclosures for convertible instruments and earnings-per-share. The new guidance is effective for interim and annual periods beginning after December 15, 2021. The Company does not intend to early adopt the standard and is in the process of assessing the impact, if any, on its consolidated financial statements and related disclosures.

In May 2020, the SEC revised its measure of “significant subsidiary” set forth in Rule 1-02(w)(2) for investment companies. The new definition includes an alternative income measure to determine a “significant subsidiary”. The final rule will be effective on January 1, 2021, but voluntary compliance is permitted in advance of the effective date. The Company has elected to implement this new rule effective June 30, 2020 which is expected to require the Company to provide separate audited financial statements and summarized financial information for fewer of its controlled portfolio companies going forward.

In August 2020, the SEC issued Final Rule Release Nos. 33-10825 and 34-89670 (collectively, the “Modernization of Regulation S-K Items 101, 103, and 105”). These rules amend certain SEC disclosure requirements to improve disclosures for investors, and to simplify compliance obligations for registrants. The final rules are effective on November 9, 2020. The Company has evaluated the impact of the amendments and determined that the adoption of these rules will not have any material impact on its consolidated financial statements and related disclosures.

Subsequent to September 30, 2020 and as of October 26, 2020, the Company sold 306,401 shares of its common stock under the 2020 Equity Distribution Agreement. As of October 26, 2020, 16.2 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement.

On October 21, 2020, the Board of Directors declared a cash distribution of $0.32 per share to be paid on November 16, 2020 to stockholders of record as of November 9, 2020. In addition to the cash distribution, on October 21, 2020, the Board of Directors declared a supplemental cash distribution of $0.02 per share to be paid on November 16, 2020 to stockholders of record as of November 9, 2020.

On October 27, 2020, HT IV was licensed to operate as a SBIC under the SBA. This additional license has a 10-year term. The Company will gain access to $175.0 million of capital through the SBA debenture program, in addition to its regulatory capital contribution of $87.5 million to HT IV which will be used for investment purposes, subject to the issuance of a capital commitment by the SBA and customary procedures.

The Company continues to closely monitor the COVID-19 pandemic and its broader impact on both the U.S. and the global economy. As of October 29, 2020, there is no indication of a reportable subsequent event impacting the Company’s financial statements for the three and nine months ended September 30, 2020. The Company continues to observe and respond, if necessary, to the evolving COVID-19 environment and its potential impact on areas across its business.

The matters discussed in this report, as well as in future oral and written statements by management of Hercules Capital, Inc., that are forward-looking statements are based on current management expectations that involve substantial risks and uncertainties which could cause actual results to differ materially from the results expressed in, or implied by, these forward-looking statements. Forward-looking statements relate to future events or our future financial performance. We generally identify forward-looking statements by terminology such as “may,” “will,” “should,” “expects,” “plans,” “anticipates,” “could,” “intends,” “target,” “projects,” “contemplates,” “believes,” “estimates,” “predicts,” “potential” or “continue” or the negative of these terms or other similar expressions. Important assumptions include our ability to originate new investments, achieve certain margins and levels of profitability, the availability of additional capital, and the ability to maintain certain debt to asset ratios. In light of these and other uncertainties, the inclusion of a projection or forward-looking statement in this report should not be regarded as a representation by us that our plans or objectives will be achieved. The forward-looking statements contained in this report include statements as to:

You should not place undue reliance on these forward-looking statements. The forward-looking statements made in this report relate only to events as of the date on which the statements are made. We undertake no obligation to update any forward-looking statement to reflect events or circumstances occurring after the date of this report.

The following discussion should be read in conjunction with our consolidated financial statements and related notes and other financial information appearing elsewhere in this report. In addition to historical information, the following discussion and other parts of this report contain forward-looking information that involves risks and uncertainties. Our actual results could differ materially from those anticipated by such forward-looking information due to the factors discussed under Item 1A— “Risk Factors” of Part II of this quarterly report on Form 10-Q, Item 1A— “Risk Factors” of our annual report on Form 10-K filed with the SEC on February 20, 2020 and under “Forward-Looking Statements” of this Item 2.

We are continuing to closely monitor the impact of the outbreak of COVID-19 on all aspects of our business, including how it impacts our portfolio companies, employees, due diligence and underwriting processes, and financial markets. While COVID-19 had a negative impact on our net assets resulting from operations for the nine months ended September 30, 2020, other key financial components such as total investment income and net investment income increased as compared to previous periods. Given the fluidity of the situation, we cannot estimate the long-term impact of COVID-19 on our business, future results of operations, financial position or cash flows at this time. The extent to which our operations may be impacted by the COVID-19 pandemic will depend largely on future developments, which are highly uncertain and cannot be accurately predicted, including new information which may emerge concerning the severity of the outbreak, the uncertainty surrounding its resurgence and actions by government authorities to contain the outbreak or treat its impact. Many public health experts have predicted that the COVID-19 pandemic will worsen in the fall and winter months as people in the U.S. spend more time indoors where the virus can spread more easily. Furthermore, the impacts of a potential worsening of global economic conditions and the continued disruptions to and volatility in the financial markets remain unknown.

We are a specialty finance company focused on providing senior secured loans to high-growth, innovative venture capital-backed companies in a variety of technology, life sciences, and sustainable and renewable technology industries. We source our investments through our principal office located in Palo Alto, CA, as well as through our additional offices in Boston, MA, New York, NY, Bethesda, MD, Hartford, CT, and San Diego, CA.

Our goal is to be the leading structured debt financing provider for venture capital-backed companies in technology-related industries requiring sophisticated and customized financing solutions. Our strategy is to evaluate and invest in a broad range of technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare, and sustainable and renewable technology and to offer a full suite of growth capital products. We invest primarily in structured debt with warrants and, to a lesser extent, in senior debt and equity investments. We invest primarily in private companies but also have investments in public companies.

We use the term “structured debt with warrants” to refer to any debt investment, such as a senior or subordinated secured loan, that is coupled with an equity component, including warrants, options or other rights to purchase or convert into common or preferred stock. Our structured debt with warrants investments typically are secured by some or all of the assets of the portfolio company. We also provide “unitranche” loans, which are loans that combine both senior and mezzanine debt, generally in a first lien position.

Our investment objective is to maximize our portfolio total return by generating current income from our debt investments and capital appreciation from our warrant and equity-related investments. Our primary business objectives are to increase our net income, net operating income, and net asset value (“NAV”) by investing in structured debt with warrants and equity of venture capital-backed companies in technology-related industries with attractive current yields and the potential for equity appreciation and realized gains. Our equity ownership in our portfolio companies may exceed 25% of the voting securities of such companies, which represents a controlling interest under the 1940 Act. In some cases, we receive the right to make additional equity investments in our portfolio companies in connection with future equity financing rounds. Capital that we provide directly to venture capital-backed companies in technology-related industries is generally used for growth and general working capital purposes as well as in select cases for acquisitions or recapitalizations.

We also make investments in qualifying small businesses through HT III, which is our wholly owned SBIC. HT III holds approximately $190.8 million in tangible assets which accounted for approximately 7.6% of our total assets at September 30, 2020.

We have qualified as and have elected to be treated for tax purposes as a RIC under Subchapter M of the Code. Pursuant to this election, we generally will not be subject to corporate-level taxes on any income and gains that we distribute as dividends for federal income tax purposes to our stockholders. However, our qualification and election to be treated as a RIC requires that we comply with provisions contained in Subchapter M of the Code. For example, as a RIC we must earn 90% or more of our gross income during each taxable year from qualified sources, typically referred to as “good income,” as well as satisfy certain quarterly asset diversification and annual income distribution requirements.

We are an internally managed, non-diversified, closed-end investment company that has elected to be regulated as a BDC under the 1940 Act. As a BDC, we are required to comply with certain regulatory requirements. For instance, we generally have to invest at least 70% of our total assets in “qualifying assets,” which includes securities of private U.S. companies, cash, cash equivalents and high-quality debt investments that mature in one year or less.

Our portfolio is comprised of, and we anticipate that our portfolio will continue to be comprised of, investments primarily in technology related companies at various stages of their development. Consistent with requirements under the 1940 Act, we invest primarily in United-States based companies and to a lesser extent in foreign companies.

We regularly engage in discussions with third parties with respect to various potential transactions. We may acquire an investment or a portfolio of investments or an entire company or sell a portion of our portfolio on an opportunistic basis. We, our subsidiaries or our affiliates may also agree to manage certain other funds that invest in debt, equity or provide other financing or services to companies in a variety of industries for which we may earn management or other fees for our services. We may also invest in the equity of these funds, along with other third parties, from which we would seek to earn a return and/or future incentive allocations. Some of these transactions could be material to our business. Consummation of any such transaction will be subject to completion of due diligence, finalization of key business and financial terms (including price) and negotiation of final definitive documentation as well as a number of other factors and conditions including, without limitation, the approval of our board of directors and required regulatory or third party consents and, in certain cases, the approval of our stockholders. Accordingly, there can be no assurance that any such transaction would be consummated. Any of these transactions or funds may require significant management resources either during the transaction phase or on an ongoing basis depending on the terms of the transaction.

The total fair value of our investment portfolio was approximately $2.4 billion and $2.3 billion at September 30, 2020 and December 31, 2019, respectively. The fair value of our debt investment portfolio at September 30, 2020 was approximately $2.3 billion, compared to a fair value of approximately $2.1 billion at December 31, 2019. The fair value of the equity portfolio at September 30, 2020 was approximately $133.8 million, compared to a fair value of approximately $145.0 million at December 31, 2019. The fair value of the warrant portfolio at September 30, 2020 was approximately $22.5 million, compared to a fair value of approximately $20.9 million at December 31, 2019.

Our investments in portfolio companies take a variety of forms, including unfunded contractual commitments and funded investments. From time to time, unfunded contractual commitments depend upon a portfolio company reaching certain milestones before the debt commitment is available to the portfolio company, which is expected to affect our funding levels. These commitments are subject to the same underwriting and ongoing portfolio maintenance as the on-balance sheet financial instruments that we hold. Debt commitments generally fund over the two succeeding quarters from close. Not all debt commitments represent future cash requirements. Similarly, unfunded contractual commitments may expire without being drawn and thus do not represent future cash requirements.

Prior to entering into a contractual commitment, we generally issue a non-binding term sheet to a prospective portfolio company. Non-binding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. These non-binding term sheets generally convert to contractual commitments in approximately 90 days from signing. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

Our portfolio activity for the nine months ended September 30, 2020 and the year ended December 31, 2019 was comprised of the following:

We receive principal payments on our debt investment portfolio based on scheduled amortization of the outstanding balances. In addition, we receive principal repayments for some of our loans prior to their scheduled maturity date. The frequency or volume of these early principal repayments may fluctuate significantly from period to period. During the nine months ended September 30, 2020, we received approximately $480.7 million in aggregate principal repayments. Of the approximately $480.7 million of aggregate principal repayments, approximately $54.0 million were scheduled principal payments and approximately $426.7 million were early principal repayments related to 27 portfolio companies. Of the approximately $426.7 million early principal repayments, approximately $76.1 million were early repayments due to merger and acquisition transactions for four portfolio companies.

Total portfolio investment activity (inclusive of unearned income and excluding activity related to taxes payable and escrow receivables) as of and for the nine months ended September 30, 2020 and the year ended December 31, 2019 was as follows:

As of September 30, 2020, we held debt, warrants, or equity positions in four companies that have filed registration statements on Form S-1 with the SEC in contemplation of potential initial public offerings. Three of these companies filed confidentially under the Jumpstart Our Business Startups Act. There can be no assurance that companies that have yet to complete their initial public offerings will do so in a timely manner or at all.

We generate revenue in the form of interest income, primarily from our investments in debt securities, and commitment and facility fees. Interest income is recognized in accordance with the contractual terms of the loan agreement to the extent that such amounts are expected to be collected. Fees generated in connection with our debt investments are recognized over the life of the loan or, in some cases, recognized as earned. In addition, we generate revenue in the form of capital gains, if any, on warrants or other equity-related securities that we acquire from our portfolio companies. Our investments generally range from $15.0 million to $40.0 million, although we may make investments in amounts above or below that range. As of September 30, 2020, our debt investments generally have a term of between two and five years and typically bear interest at a rate ranging from approximately 6.9% to approximately 11.5%. In addition to the cash yields received on our debt investments, in some instances, our debt investments may also include any of the following: exit fees, balloon payment fees, commitment fees, success fees, PIK provisions or prepayment fees which may be required to be included in income prior to receipt.

Interest on debt securities is generally payable monthly, with amortization of principal typically occurring over the term of the investment. In addition, our loans may include an interest-only period ranging from three to eighteen months or longer. In limited instances in which we choose to defer amortization of the loan for a period of time from the date of the initial investment, the principal amount of the debt securities and any accrued but unpaid interest become due at the maturity date.

Loan origination and commitment fees received in full at the inception of a loan are deferred and amortized into fee income as an enhancement to the related loan’s yield over the contractual life of the loan. We recognize nonrecurring fees amortized over the remaining term of the loan commencing in the quarter relating to specific loan modifications. We had approximately $41.5 million of unamortized fees at September 30, 2020, of which approximately $34.3 million was included as an offset to the cost basis of our current debt investments and approximately $7.2 million was deferred contingent upon the occurrence of a funding or milestone. At December 31, 2019, we had approximately $42.0 million of unamortized fees, of which approximately $34.6 million was included as an offset to the cost basis of our current debt investments and approximately $7.4 million was deferred contingent upon the occurrence of a funding or milestone.

Loan exit fees to be paid at the termination of the loan are accreted into interest income over the contractual life of the loan. At September 30, 2020, we had approximately $42.8 million in exit fees receivable, of which approximately $38.3 million was included as a component of the cost basis of our current debt investments and approximately $4.5 million was a deferred receivable related to expired commitments. At December 31, 2019, we had approximately $33.5 million in exit fees receivable, of which approximately $31.9 million was included as a component of the cost basis of our current debt investments and approximately $1.6 million was a deferred receivable related to expired commitments.

We have debt investments in our portfolio that contain a PIK provision. The PIK interest, computed at the contractual rate specified in each loan agreement, is recorded as interest income and added to the principal balance of the loan on specified capitalization dates. To maintain our ability to be subject to tax as a RIC, this non-cash source of income must be distributed to stockholders with other sources of income in the form of dividend distributions even though we have not yet collected any cash from the borrower. Amounts necessary to pay these distributions may come from available cash or the liquidation of certain investments. We recorded approximately $2.3 million and $2.2 million in PIK income during the three months ended September 30, 2020 and 2019, respectively. We recorded approximately $6.5 million and $6.6 million in PIK income during the nine months ended September 30, 2020 and 2019, respectively.

The core yield on our debt investments, which excludes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications and other one-time events and includes income from expired commitments, was 11.3% and 12.4% during the three months ended September 30, 2020 and 2019, respectively. The effective yield on our debt investments, which includes the effects of fee and income accelerations attributed to early payoffs, restructuring, loan modifications and other one-time events, was 12.6% and 13.4% for the three months ended September 30, 2020 and 2019, respectively. The effective yield is derived by dividing total investment income by the weighted average earning investment portfolio assets outstanding during the quarter, excluding non-interest earning assets such as warrants and equity investments. Both the core yield and effective yield may be higher than what our common stockholders may realize as the core yield and effective yield do not reflect our expenses and any sales load paid by our common stockholders. The total yield on our investment portfolio was 11.5% and 12.1% during the three months ended September 30, 2020 and 2019, respectively. The total yield is derived by dividing total investment income by the weighted average investment portfolio assets outstanding during the quarter, including non-interest earning assets such as warrants and equity investments at amortized cost.

The total return for our investors was approximately (10.2%) and 29.9% during the nine months ended September 30, 2020 and 2019, respectively. The total return equals the change in the ending market value over the beginning of the period price per share plus distributions paid per share during the period, divided by the beginning price assuming the distribution is reinvested on the date of the distribution. The total return does not reflect any sales load that must be paid by investors. See “Note 9 – Financial Highlights” included in the notes to our consolidated financial statements appearing elsewhere in this report.

Our portfolio companies are primarily privately held companies and public companies which are active in sectors characterized by high margins, high growth rates, consolidation and product and market extension opportunities. As of September 30, 2020, approximately 91.9% of the fair value of our portfolio was composed of investments in five industries: 35.6% was composed of investments in the "Drug Discovery & Development" industry, 31.2% was composed of investments in the "Software" industry, 20.4% was composed of investments in the "Internet Consumer & Business Services" industry, 2.5% was composed of investments in the "Sustainable and Renewable Technology" industry, and 2.2% was composed of investments in the "Information Services" industry.

Industry and sector concentrations vary as new loans are recorded and loans are paid off. Loan revenue, consisting of interest, fees, and recognition of gains on equity and warrants or other equity-related interests, can fluctuate materially when a loan is paid off or a warrant or equity interest is sold. Revenue recognition in any given year can be highly concentrated in several portfolio companies.

For the nine months ended September 30, 2020 and the year ended December 31, 2019, our ten largest portfolio companies represented approximately 27.1% and 27.8% of the total fair value of our investments in portfolio companies, respectively. At September 30, 2020 and December 31, 2019, we had seven and six investments, respectively, that represented 5% or more of our net assets. At September 30, 2020, we had five equity investments representing approximately 62.6% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. At December 31, 2019, we had six equity investments which represented approximately 63.3% of the total fair value of our equity investments, and each represented 5% or more of the total fair value of our equity investments. No single portfolio investment represents more than 10% of the fair value of our total investments as of September 30, 2020 and December 31, 2019.

As of September 30, 2020, approximately 97.9% of the debt investment portfolio was priced at floating interest rates or floating interest rates with a Prime- or LIBOR-based interest rate floor. Changes in interest rates, including Prime rate and LIBOR, may affect the interest income and the value of our investment portfolio for portfolio investments with floating rates. We believe we are well positioned to benefit should market interest rates rise in the future.

Our investments in senior secured debt with warrants have detachable equity enhancement features, typically in the form of warrants or other equity-related securities designed to provide us with an opportunity for capital appreciation. These features are treated as OID and are accreted into interest income over the term of the loan as a yield enhancement. Our warrant coverage generally ranges from 3% to 20% of the principal amount invested in a portfolio company, with a strike price generally equal to the most recent equity financing round. As of September 30, 2020, we held warrants in 108 portfolio companies, with a fair value of approximately $22.5 million. The fair value of our warrant portfolio increased by approximately $1.6 million, as compared to a fair value of $20.9 million at December 31, 2019 primarily related to the increase in fair value of portfolio companies.

Our existing warrant holdings would require us to invest approximately $70.2 million to exercise such warrants as of September 30, 2020. Warrants may appreciate or depreciate in value depending largely upon the underlying portfolio company’s performance and overall market conditions. Accordingly, we may experience losses from our warrant portfolio.

We use an investment grading system, which grades each debt investment on a scale of 1 to 5 to characterize and monitor our expected level of risk on the debt investments in our portfolio with 1 being the highest quality. The following table shows the distribution of our outstanding debt investments on the 1 to 5 investment grading scale at fair value as of September 30, 2020 and December 31, 2019, respectively:

As of September 30, 2020 and December 31, 2019, our debt investments had a weighted average investment grading of 2.22 and 2.15 on a cost basis, respectively. Our policy is to lower the grading on our portfolio companies as they approach the point in time when they will require additional equity capital. Additionally, we may downgrade our portfolio companies if they are not meeting our financing criteria or are underperforming relative to their respective business plans. Various companies in our portfolio will require additional funding in the near term or have not met their business plans and therefore have been downgraded until their funding is complete or their operations improve.

As the COVID-19 situation continues to evolve, we are maintaining close communications with our portfolio companies to proactively assess and manage potential risks across our debt investment portfolio. We have also increased oversight and analysis of credits in vulnerable industries in an attempt to improve loan performance and reduce credit risk.

Total investment income for the three months ended September 30, 2020 was approximately $70.3 million as compared to approximately $69.2 million for the three months ended September 30, 2019. Total investment income for the nine months ended September 30, 2020 was approximately $211.9 million as compared to approximately $197.3 million for the nine months ended September 30, 2019.

For the three and nine months ended September 30, 2020 and 2019, the components of interest income were as follows:

Interest income for the three months ended September 30, 2020 totaled approximately $65.4 million as compared to approximately $64.2 million for the three months ended September 30, 2019. Interest income for the nine months ended September 30, 2020 totaled approximately $195.1 million as compared to approximately $181.4 million for the nine months ended September 30, 2019. The increase in interest income for the three and nine months ended September 30, 2020 as compared to the same period ended September 30, 2019 is primarily attributable to an increase in recurring interest income caused by an increase in the weighted average principal outstanding of loans, and an increase in the acceleration of interest income due to early loan repayments.

Of the $65.4 million in interest income for the three months ended September 30, 2020, approximately $61.0 million represents recurring income from the contractual servicing of our loan portfolio and approximately $4.4 million represents income related to the acceleration of income due to early loan repayments and other one-time events during the period. Income from recurring interest and the acceleration of interest income due to early loan repayments represented approximately $61.4 million and $2.8 million, respectively, of the $64.2 million interest income for the three months ended September 30, 2019.

Of the $195.1 million in interest income for the nine months ended September 30, 2020, approximately $183.1 million represents recurring income from the contractual servicing of our loan portfolio and approximately $12.0 million represents income related to the acceleration of income due to early loan repayments and other one-time events during the period. Income from recurring interest and the acceleration of interest income due to early loan repayments represented $175.3 million and $6.1 million, respectively, of the $181.4 million interest income for the nine months ended September 30, 2019.

The following table shows the PIK-related activity for the nine months ended September 30, 2020 and 2019, at cost:

The slight decrease in PIK interest income during the nine months ended September 30, 2020 as compared to the nine months ended September 30, 2019 is due to a decrease in the weighted average principal outstanding for loans on accrual which bear PIK interest.

Fee income from commitment, facility and loan related fees for each of the three months ended September 30, 2020 and 2019 totaled approximately $5.0 million. Fee income from commitment, facility and loan related fees for the nine months ended September 30, 2020 totaled approximately $16.8 million as compared to approximately $15.9 million for the nine months ended September 30, 2019. The increase in fee income for the nine months ended September 30, 2020 is primarily due to an increase in the facilities fees and one-time fees due to early repayments.

Of the $5.0 million in fee income for the three months ended September 30, 2020, approximately $2.1 million represents income from recurring fee amortization and approximately $2.9 million represents income related to the acceleration of unamortized fees due to early repayments, including one-time fees of $2.0 million for the period. Income from recurring fee amortization and the acceleration of unamortized fees due to early loan repayments represented $2.3 million and $2.7 million, respectively, of the $5.0 million in income for the three months ended September 30, 2019.

Of the $16.8 million in fee income for the nine months ended September 30, 2020, approximately $7.8 million represents income from recurring fee amortization and approximately $9.0 million represents income related to the acceleration of unamortized fees due to early repayments, including one-time fees of $6.1 million for the period. Income from recurring fee amortization and the acceleration of unamortized fees due to early loan repayments represented $7.0 million and $8.9 million, respectively, of the $15.9 million in income for the nine months ended September 30, 2019.

In certain investment transactions, we may earn income from advisory services; however, we had no income from advisory services in the three and nine months ended September 30, 2020 or 2019.

Our operating expenses are comprised of interest and fees on our borrowings, general and administrative expenses and employee compensation and benefits. Our operating expenses totaled approximately $31.6 million and $30.4 million during the three months ended September 30, 2020 and 2019, respectively. Our operating expenses totaled approximately $96.9 million and $94.1 million during the nine months ended September 30, 2020 and 2019, respectively.

Interest and fees on our borrowings totaled approximately $16.6 million and $15.0 million for the three months ended September 30, 2020 and 2019, respectively, and approximately $49.7 million and $45.7 million during the nine months ended September 30, 2020 and 2019, respectively. Interest and fee expense during the three and nine months ended September 30, 2020, as compared to the same periods ended September 30, 2019, increased due to the issuance of our July 2024 Notes in July 2019, the issuance of our February 2025 Notes in February 2020 and the issuance of our June 2025 Notes in June 2020.

We had a weighted average cost of debt, comprised of interest and fees, of approximately 5.1% for each of the three months ended September 30, 2020 and 2019, and a weighted average cost of debt of approximately 5.1% and 5.4% for the nine months ended September 30, 2020 and 2019, respectively. The decrease in the weighted average cost of debt for the nine months ended September 30, 2020, as compared to the nine months ended September 30, 2019, is primarily driven by a reduction in the weighted average principal outstanding on our higher yielding debt instruments compared to the prior period.

General and administrative expenses include legal fees, consulting fees, accounting fees, printer fees, insurance premiums, taxes, rent, expenses associated with the workout of underperforming investments and various other expenses. Our general and administrative expenses decreased to $5.3 million from $6.4 million for the three months ended September 30, 2020 and 2019, respectively. Our general and administrative expenses increased to $17.2 million from $16.3 million for the nine months ended September 30, 2020 and 2019, respectively. The decrease in general and administrative expenses for the three months ended September 30, 2020 is mainly due to a decrease in legal expenses. The increase in general and administrative expenses for the nine months ended September 30, 2020 is mainly due to an increase in excise taxes.

Employee compensation and benefits totaled $7.2 million for the three months ended September 30, 2020 as compared to $7.6 million for the three months ended September 30, 2019, and $22.6 million for the nine months ended September 30, 2020 as compared to $23.4 million for the nine months ended September 30, 2019. The decrease between both of the three and nine months ended September 30, 2020 and 2019 was primarily due to decreased variable compensation and payroll related expenses.

Employee stock-based compensation totaled $2.5 million for the three months ended September 30, 2020 as compared to $1.4 million for the three months ended September 30, 2019, and $7.5 million for the nine months ended September 30, 2020 as compared to $8.7 million for the nine months ended September 30, 2019. The increase in employee stock-based compensation for the three months ended September 30, 2020 was primarily due to the elimination of stock-based compensation in the three months ended September 30, 2019, pursuant to a settlement with our former Chairman and Chief Executive Officer. The decrease between the nine months ended September 30, 2020 and 2019 was primarily due to the above settlement, and elimination of associated stock-based compensation expense.

Net Investment Realized Gains and Losses and Net Unrealized Appreciation and Depreciation

Realized gains or losses are measured by the difference between the net proceeds from the repayment or sale and the cost basis of an investment without regard to unrealized appreciation or depreciation previously recognized, and includes investments written off during the period, net of recoveries. Net change in unrealized appreciation or depreciation primarily reflects the change in portfolio investment values during the reporting period, including the reversal of previously recorded unrealized appreciation or depreciation when gains or losses are realized.

A summary of realized gains and losses for the three and nine months ended September 30, 2020 and 2019 is as follows:

During the three and nine months ended September 30, 2020, we recognized net realized losses of $48.5 million and $41.4 million, respectively, on the portfolio. During the three months ended September 30, 2020, we recorded gross realized gains of $1.5 million primarily from the sale of our public equity holdings. These gains were offset by gross realized losses of $50.0 million primarily from the write-off of our debt investments in Patron Technology and Motif BioSciences, Inc. during the period.

During the nine months ended September 30, 2020, we recorded gross realized gains of $16.2 million primarily from the sale of public equity positions and sale of our holdings due to merger and acquisition transactions. These gains were offset by gross realized losses of $57.6 million primarily from write-off of our debt investments in Patron Technology and Motif BioSciences, Inc., as well as the liquidation or write-off of our equity or warrant positions during the period.

During the three and nine months ended September 30, 2019, we recognized net realized gains of $4.8 million and $13.6 million, respectively, on the portfolio. During the three months ended September 30, 2019, we recorded gross realized gains of $9.0 million primarily from the sale of our public equity holdings. These gains were offset by gross realized losses of $4.2 million primarily from the liquidation or write-off of our debt, equity, and warrant positions during the period.

During the nine months ended September 30, 2019, we recorded gross realized gains of $23.9 million primarily from the sale of public equity positions and sale of our holdings due to merger and acquisition transactions. These gains were offset by gross realized losses of $10.3 million primarily from the liquidation or write-off of our debt, equity, or warrant positions during the period.

The net unrealized appreciation and depreciation of our investments is based on the fair value of each investment determined in good faith by our Board of Directors. The following table summarizes the change in net unrealized appreciation or depreciation of investments for the three and nine months ended September 30, 2020 and 2019:

During the three months ended September 30, 2020, we recorded $52.8 million of net unrealized appreciation, all of which was net unrealized appreciation from our debt, equity and warrant investments. We recorded $43.3 million of net unrealized appreciation on our debt investments which was primarily related to $7.4 million of net unrealized appreciation on the debt portfolio and $35.9 million of unrealized appreciation due to the reversal of unrealized depreciation upon write-off or pay-off of our debt investments during the period.

We recorded $6.5 million of net unrealized appreciation on our equity investments and $3.0 million of net unrealized appreciation on our warrant investments during the three months ended September 30, 2020. This net unrealized appreciation of $9.5 million was primarily attributable to $7.6 million of unrealized appreciation on the equity and warrant portfolio and $1.9 million of unrealized appreciation due to the reversal of unrealized depreciation upon acquisition or liquidation of our equity and warrant investments.

During the nine months ended September 30, 2020, we recorded $2.5 million of net unrealized appreciation, all of which was net unrealized appreciation from our debt, equity and warrant investments. We recorded $2.3 million of net unrealized appreciation on our debt investments which was primarily related to $34.9 million of unrealized depreciation on the debt portfolio offset by $37.2 million of unrealized appreciation due to the reversal of unrealized depreciation upon write-off or pay-off of our debt investments.

We recorded $7.6 million of net unrealized depreciation on our equity investments and $7.8 million of net unrealized appreciation on our warrant investments during the nine months ended September 30, 2020. This net unrealized appreciation of $0.2 million was primarily attributable to $1.1 million of unrealized appreciation on the equity and warrant portfolio and the $922,000 of unrealized depreciation due to the reversal of unrealized appreciation upon acquisition or liquidation of our equity and warrant investments.

During the three months ended September 30, 2019, we recorded $24.4 million of net unrealized depreciation, of which $25.5 million was net unrealized depreciation from our debt, equity and warrant investments. We recorded $5.8 million of net unrealized depreciation on our debt investments which was primarily related to $9.9 million of net unrealized depreciation on the debt portfolio partially offset by $4.1 million of unrealized appreciation due to the reversal of unrealized depreciation upon pay-off or write-off of our portfolio companies.

We recorded $13.9 million of net unrealized depreciation on our equity investments and $5.8 million of net unrealized depreciation on our warrant investments during the three months ended September 30, 2019. This net unrealized depreciation of $19.7 million was primarily attributable to $11.5 million of unrealized depreciation on the equity and warrant portfolio and $8.4 million of unrealized depreciation due to the reversal of unrealized appreciation upon acquisition or liquidation of our equity and warrant investments.

During the nine months ended September 30, 2019, we recorded $12.2 million of net unrealized appreciation, of which $11.0 million was net unrealized appreciation from our debt, equity and warrant investments. We recorded $1.9 million of net unrealized depreciation on our debt investments which was primarily related to $8.3 million of unrealized depreciation on the debt portfolio and partially offset by $6.4 million of unrealized appreciation primarily due to the reversal of unrealized depreciation upon pay-off or write-off of our portfolio companies.

We recorded $19.1 million of net unrealized appreciation on our equity investments and $6.2 million of net unrealized depreciation on our warrant investments during the nine months ended September 30, 2019. This net unrealized appreciation of $12.9 million was primarily attributable to $29.6 million of unrealized appreciation on the equity and warrant portfolio partially offset by the $16.7 million of unrealized depreciation due to the reversal of unrealized appreciation upon acquisition or liquidation of our equity and warrant investments.

We account for income taxes in accordance with the provisions of ASC Topic 740 (“Income Taxes”), under which income taxes are provided for amounts currently payable and for amounts deferred based upon the estimated future tax effects of differences between the financial statements and tax basis of assets and liabilities given the provisions of the enacted tax law. Valuation allowances may be used to reduce deferred tax assets to the amount likely to be realized. We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

Because federal income tax regulations differ from accounting principles generally accepted in the United States, distributions in accordance with tax regulations may differ from net investment income and realized gains recognized for financial reporting purposes. Differences may be permanent or temporary. Permanent differences are reclassified among capital accounts in the financial statements to reflect their appropriate tax character. Permanent differences may also result from the classification of certain items, such as the treatment of short-term gains as ordinary income for tax purposes. Temporary differences arise when certain items of income, expense, gain or loss are recognized at some time in the future.

For the three months ended September 30, 2020, we had a net increase in net assets resulting from operations of approximately $43.0 million and for the three months ended September 30, 2019, we had a net increase in net assets resulting from operations of approximately $19.3 million. For the nine months ended September 30, 2020, we had a net increase in net assets resulting from operations of approximately $76.1 million and for the nine months ended September 30, 2019, we had a net increase in net assets resulting from operations of approximately $129.0 million.

Both the basic and fully diluted net change in net assets per common share were $0.38 per share for the three months ended September 30, 2020. The basic and fully diluted net change in net assets per common share for the nine months ended September 30, 2020 were $0.68 per share and $0.67 per share, respectively. Both the basic and fully diluted net change in net assets per common share were $0.18 per share and $1.29 per share for the three and nine months ended September 30, 2019, respectively.

For the purpose of calculating diluted earnings per share for the three and nine months ended September 30, 2020 and 2019, the dilutive effect of the 2022 Convertible Notes, outstanding options, restricted stock units and awards and Retention PSUs under the treasury stock method was considered. The effect of the 2022 Convertible Notes was excluded from these calculations for the three and nine months ended September 30, 2020 and 2019, as our share price was less than the conversion price in effect which results in anti-dilution.

Our liquidity and capital resources are derived from our SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes, Credit Facilities and cash flows from operations, including investment sales and repayments, and income earned. Our primary use of funds from operations includes investments in portfolio companies and payments of fees and other operating expenses we incur. We have used, and expect to continue to use, our borrowings and the proceeds from the turnover of our portfolio and from public and private offerings of securities to finance our investment objectives. We may also raise additional equity or debt capital through registered offerings off a shelf registration, ATM, and private offerings of securities, by securitizing a portion of our investments, or by borrowing from the SBA through our SBIC subsidiaries. This “Financial Condition, Liquidity and Capital Resources” section should be read in conjunction with the “COVID-19 Developments” section above.

On July 13, 2018, we completed repayment of the remaining outstanding HT II debentures and subsequently surrendered the SBA license with respect to HT II.

On March 1, 2020, and September 1, 2020, we paid down $38.7 million and $11.3 million of SBA debentures, respectively.

On October 23, 2017, we issued $150.0 million in aggregate principal amount of the 2022 Notes pursuant to the 2022 Notes Indenture. The sale of the 2022 Notes generated net proceeds of approximately $147.4 million, including a public offering discount of $826,500. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions of approximately $975,000, were approximately $1.8 million.

On July 16, 2019, we issued $105.0 million in aggregate principal amount of July 2024 Notes. The sale of the July 2024 Notes generated net proceeds of approximately $103.5 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $1.5 million.

On February 5, 2020, we issued $50.0 million in aggregate principal amount of February 2025 Notes pursuant to the 2025 Note Purchase Agreement. The sale of the February 2025 Notes generated net proceeds of approximately $49.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $581,000.

On June 3, 2020, we issued $70.0 million in aggregate principal amount of June 2025 Notes pursuant to the 2025 Note Purchase Agreement. The sale of the June 2025 Notes generated net proceeds of approximately $69.2 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $819,000.

On April 26, 2018, we issued $75.0 million in aggregate principal amount of the 2025 Notes pursuant to the 2025 Notes Indenture. The sale of the 2025 Notes generated net proceeds of approximately $72.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $2.6 million.

On September 20, 2018, we issued $40.0 million in aggregate principal amount of the 2033 Notes pursuant to the 2033 Notes Indenture. The sale of the 2033 Notes generated net proceeds of approximately $38.4 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $1.6 million.

On November 1, 2018, we issued $200.0 million in aggregate principal amount of the 2027 Asset-Backed Notes. The sale of the 2027 Asset-Backed Notes generated net proceeds of approximately $197.0 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $3.0 million.

On January 22, 2019, we issued $250.0 million in aggregate principal amount of the 2028 Asset-Backed Notes. The sale of the 2028 Asset-Backed Notes generated net proceeds of approximately $247.1 million. Aggregate estimated offering expenses in connection with the transaction, including the underwriter’s discount and commissions, were approximately $2.9 million.

On December 7, 2018, our Board of Directors approved a full redemption, in two equal transactions, of $83.5 million of the outstanding aggregate principal amount of the 2024 Notes. The 2024 Notes were fully redeemed on January 14, 2019 and February 4, 2019.

On January 25, 2017, we issued $230.0 million in aggregate principal amount of 2022 Convertible Notes, which amount includes the additional $30.0 million aggregate principal amount issued pursuant to the initial purchaser’s exercise in full of its overallotment option. The sale generated net proceeds of approximately $225.5 million, including $4.5 million of debt issuance costs. Aggregate issuances costs include the initial purchaser’s discount of approximately $5.2 million, offset by the reimbursement of $1.2 million by the initial purchaser.

On January 11, 2019, Hercules Funding II entered into the Wells Facility Seventh Amendment. The Wells Facility Seventh Amendment, among other things, amends certain key provisions of the Wells Facility to reduce the current interest rate to LIBOR plus 3.00% with an interest rate floor of 3.00% and extends the maturity date to January 2023. In addition, the Wells Fargo Capital Finance, LLC has committed $75.0 million in credit capacity under a $125.0 million accordion credit facility, subject to borrowing base, leverage and other restrictions.

On February 20, 2019, we, through a special purpose wholly owned subsidiary, Hercules Funding IV, as borrower, entered into the 2019 Union Bank Facility. The 2019 Union Bank Facility replaced the Prior Union Bank Facility. Any references to amounts related to the 2019 Union Bank Facility prior to February 20, 2019 were incurred and relate to the Prior Union Bank Facility. Under the 2019 Union Bank Facility, the lenders have made commitments of $200.0 million.

On June 28, 2019, Hercules Funding IV entered into the Union Bank Facility Amendment to the 2019 Union Bank Facility. The Union Bank Facility Amendment amends certain provisions of the 2019 Union Bank Facility to, among other things, (i) delete the financial covenant with respect to maintaining minimum portfolio funding liquidity, (ii) add a covenant prohibiting Hercules Funding IV from acquiring or owning unfunded commitments to makers of certain notes receivable, and (iii) revise certain provisions thereof to further permit a third party special servicer to act as servicer after an event of default instead of us with respect to split-funded notes receivable owned by Hercules Funding IV and an affiliate thereof (including Hercules Funding II).

On February 20, 2020, we, through a special purpose wholly owned subsidiary, Hercules Funding IV, as borrower, entered into the Union Bank Facility. The Union Bank Facility replaced the 2019 Union Bank Facility. Any references to amounts related to the Union Bank Facility from February 20, 2019 to February 20, 2020 were incurred and relate to the 2019 Union Bank Facility. Under the Union Bank Facility, the lenders have made commitments of $400.0 million.

On May 6, 2019, we entered into the 2019 Equity Distribution Agreement. The 2019 Equity Distribution Agreement provided that we may offer and sell up to 12.0 million shares of our common stock from time to time through JMP, as our sales agent.

On July 2, 2020, we terminated the 2019 Equity Distribution Agreement and entered into a new ATM equity distribution agreement with JMP (the “2020 Equity Distribution Agreement”). As a result, the remaining shares that were available under the 2019 Equity Distribution Agreement are no longer available for issuance.

The 2020 Equity Distribution Agreement provides that we may offer and sell up to 16.5 million shares of our common stock from time to time through JMP, as our sales agent. Sales of our common stock, if any, may be made in negotiated transactions or transactions that are deemed to be “at the market,” as defined in Rule 415 under the Securities Act, including sales made directly on the NYSE or similar securities exchange or sales made to or through a market maker other than on an exchange, at prices related to the prevailing market prices or at negotiated prices.

There were no shares of common stock sold under the 2019 Equity Distribution Agreement or the 2020 Equity Distribution Agreement during the three months ended September 30, 2020. During the nine months ended September 30, 2020, we sold 6.0 million shares of common stock under the 2019 Equity Distribution Agreement. As of September 30, 2020, approximately 16.5 million shares remain available for issuance and sale under the Equity 2020 Distribution Agreement.

On June 17, 2019, we closed the June 2019 Equity Offering. The offering generated net proceeds, before expenses, of $70.5 million, including the underwriting discount and commissions of $2.2 million.

We may from time to time seek to retire or repurchase our common stock through cash purchases, as well as retire, cancel or purchase our outstanding debt through cash purchases and/or exchanges, in open market purchases, privately negotiated transactions or otherwise. Such repurchases or exchanges, if any, will depend on prevailing market conditions, our liquidity requirements, contractual and regulatory restrictions and other factors. The amounts involved may be material.

On December 17, 2018, our Board of Directors authorized a stock repurchase plan permitting us to repurchase up to $25.0 million of our common stock until June 18, 2019, after which the plan expired. We had no common stock repurchases during 2019.

At September 30, 2020, we had $99.0 million of SBA debentures, $150.0 million of 2022 Notes, $105.0 million of July 2024 Notes, $50.0 million of February 2025 Notes, $70.0 million of June 2025 Notes, $75.0 million of 2025 Notes, $40.0 million of 2033 Notes, $200.0 million of 2027 Asset-Backed Notes, $250.0 million of 2028 Asset-Backed Notes, and $230.0 million of 2022 Convertible Notes payable, along with $37.5 million outstanding on the Union Facility and no outstanding borrowings on the Wells Facility.

At September 30, 2020, we had $465.1 million in available liquidity, including $27.6 million in cash and cash equivalents. We had available borrowing capacity of $75.0 million under the Wells Facility and $362.5 million under the Union Bank Facility, both subject to existing terms, borrowing base, advance rates and regulatory requirements. We primarily invest cash on hand in interest bearing deposit accounts.

At September 30, 2020, we had $74.5 million of capital outstanding in restricted accounts related to our SBIC. With our net investment of $74.5 million in HT III, we have the approved capacity to issue a total of $99.0 million of SBA guaranteed debentures. At September 30, 2020, we have issued $99.0 million in SBA guaranteed debentures in our SBIC subsidiaries. As we are past our investment period for HT III, we will no longer make any future commitments to new portfolio companies. We will only satisfy contractually agreed upon follow-on fundings to existing portfolio companies and may seek to pay-off a portion or all of the outstanding debentures early as per the available liquidity in HT III.

At September 30, 2020, we had approximately $20.5 million of restricted cash, which consists of collections of interest and principal payments on assets that are securitized. In accordance with the terms of the related securitized 2027 Asset-Backed Notes and 2028 Asset-Backed Notes, based on current characteristics of the securitized debt investment portfolios, the restricted funds may be used to pay monthly interest and principal on the securitized debt with any excess distributed to us or available for our general operations.

During the nine months ended September 30, 2020, we principally funded our operations from (i) cash receipts from interest, dividend and fee income from our investment portfolio and (ii) cash proceeds from the realization of portfolio investments through the repayments of debt investments and the sale of debt and equity investments, (iii) debt offerings along with borrowings on our credit facilities, and (iv) equity offerings.

During the nine months ended September 30, 2020, our operating activities used $24.0 million of cash and cash equivalents, compared to $226.8 million used during the nine months ended September 30, 2019. This $202.8 million decrease in cash used in operating activities is primarily related to a decrease of $153.4 million in purchase of investments and a $56.2 million increase in principal and fee payments received on investments.

During the nine months ended September 30, 2020, our investing activities used approximately $115,000 of cash, compared to $484,000 used during the nine months ended September 30, 2019. The $369,000 decrease in cash used in investing activities was due to a decrease in purchases of capital equipment.

During the nine months ended September 30, 2020, our financing activities used $42.8 million of cash, compared to $217.3 million provided by financing activities during the nine months ended September 30, 2019. The $260.1 million decrease in cash provided by financing activities was primarily due to a $221.8 million decrease in borrowings from new note issuances and credit facilities for the nine months ended September 30, 2020 compared to the nine months ended September 30, 2019.

As of September 30, 2020, our net assets totaled $1.2 billion, with a NAV per share of $10.26. We intend to continue to operate in order to generate cash flows from operations, including income earned from investments in our portfolio companies. Our primary use of funds will be investments in portfolio companies and cash distributions to holders of our common stock.

As described above, our diverse and well-structured balance sheet is designed to provide a long-term focused and sustainable investment platform. Currently, we believe we have ample liquidity to support our near-term capital requirements. As the impact of the COVID-19 continues to unfold, we will continue to evaluate our overall liquidity position and take proactive steps to maintain the appropriate liquidity position based upon the current circumstances.

The SBCAA, which was signed into law in March 2018, decreased the minimum asset coverage ratio in Section 61(a) of the 1940 Act for BDCs from 200% to 150% (subject to either stockholder approval or approval of both a majority of the board of directors and a majority of directors who are not interested persons). On September 4, 2018 and December 6, 2018, our Board of Directors, including a “required majority” (as such term is defined in Section 57(o) of the 1940 Act) and our stockholders, respectively, approved the application to us of the 150% minimum asset coverage ratio set forth in Section 61(a)(2) of the 1940 Act. As a result, effective December 7, 2018, the asset coverage ratio under the 1940 Act applicable to us decreased from 200% to 150%, permitting us to incur additional leverage. As of September 30, 2020, our asset coverage ratio under our regulatory requirements as a BDC was 197.0% excluding our SBA debentures as a result of our exemptive order from the SEC that allows us to exclude all SBA leverage from our asset coverage ratio. As a result of the SEC exemptive order, our ratio of total assets on a consolidated basis to outstanding indebtedness may be less than 150%, which while providing increased investment flexibility, also may increase our exposure to risks associated with leverage. Total asset coverage when including our SBA debentures was 189.7% at September 30, 2020.

Refer to “Note 4 – Borrowings” included in the notes to our consolidated financial statements appearing elsewhere in this report for a discussion of our borrowings.

In the normal course of business, we are party to financial instruments with off-balance sheet risk. These consist primarily of unfunded contractual commitments to extend credit, in the form of loans, to our portfolio companies. Unfunded contractual commitments to provide funds to portfolio companies are not reflected on our balance sheet. Our unfunded contractual commitments may be significant from time to time. A portion of these unfunded contractual commitments are dependent upon the portfolio company reaching certain milestones before the debt commitment becomes available. Furthermore, our credit agreements with our portfolio companies generally contain customary lending provisions which allow us relief from funding obligations for previously made commitments in instances where the underlying company experiences materially adverse events that affect the financial condition or business outlook for the company. These commitments will be subject to the same underwriting and ongoing portfolio maintenance as are the on-balance sheet financial instruments that we hold. Since these commitments may expire without being drawn upon, the total commitment amount does not necessarily represent future cash requirements. As such, our disclosure of unfunded contractual commitments includes only those which are available at the request of the portfolio company and unencumbered by milestones.

At September 30, 2020, we had approximately $242.5 million of unfunded commitments, including undrawn revolving facilities, which were available at the request of the portfolio company and unencumbered by milestones. We intend to use cash flow from normal and early principal repayments, and proceeds from borrowings and notes to fund these commitments.

We also had approximately $97.9 million of non-binding term sheets outstanding to two new company and one existing company, which generally convert to contractual commitments within approximately 90 days of signing. Non-binding outstanding term sheets are subject to completion of our due diligence and final investment committee approval process, as well as the negotiation of definitive documentation with the prospective portfolio companies. Not all non-binding term sheets are expected to close and do not necessarily represent future cash requirements.

The fair value of our unfunded commitments is considered to be immaterial as the yield determined at the time of underwriting is expected to be materially consistent with the yield upon funding, given that interest rates are generally pegged to market indices and given the existence of milestones, conditions and/or obligations imbedded in the borrowing agreements.

We have entered into indemnification agreements with our directors and executive officers. The indemnification agreements are intended to provide our directors and executive officers the maximum indemnification permitted under Maryland law and the 1940 Act. Each indemnification agreement provides that we shall indemnify the director or executive officer who is a party to the agreement, or an “Indemnitee,” including the advancement of legal expenses, if, by reason of his or her corporate status, the Indemnitee is, or is threatened to be, made a party to or a witness in any threatened, pending, or completed proceeding, to the maximum extent permitted by Maryland law and the 1940 Act.

We and our executives and directors are covered by Directors and Officers Insurance, with the directors and officers being indemnified by us to the maximum extent permitted by Maryland law subject to the restrictions in the 1940 Act.

Our Board of Directors maintains a variable distribution policy with the objective of distributing four quarterly distributions in an amount that approximates 90% - 100% of our taxable quarterly income or potential annual income for a particular taxable year. In addition, our Board of Directors may choose to pay additional special distributions, so that we may distribute approximately all of our annual taxable income in the taxable year in which it was earned, or may elect to maintain the option to spill over our excess taxable income into the following taxable year as part of any future distribution payments.

Distributions from our taxable income (including gains) to a stockholder generally will be treated as a dividend for U.S. federal income tax purposes to the extent of such stockholder’s allocable share of our current or accumulated earnings and profits. Distributions in excess of our current and accumulated earnings and profits would generally be treated first as a return of capital to the extent of a stockholder’s tax basis in our shares, and any remaining distributions would be treated as a capital gain. The determination of the tax attributes of our distributions is made annually as of the end of our taxable year based upon our taxable income for the full taxable year and distributions paid for the full taxable year. As a result, any determination of the tax attributes of our distributions made on a quarterly basis may not be representative of the actual tax attributes of our distributions for a full taxable year. Of the distributions declared during the year ended December 31, 2019, 100% were distributions derived from our current and accumulated earnings and profits. There can be no certainty to stockholders that this determination is representative of what the tax attributes of our 2020 distributions to stockholders will actually be.

We maintain an “opt out” dividend reinvestment plan that provides for reinvestment of our distribution on behalf of our stockholders, unless a stockholder elects to receive cash. As a result, if our Board of Directors authorizes, and we declare, a cash distribution, then our stockholders who have not “opted out” of our dividend reinvestment plan will have their cash distribution automatically reinvested in additional shares of our common stock, rather than receiving the cash distributions.

Shortly after the close of each calendar year information identifying the source of the distribution (i.e., paid from ordinary income, paid from net capital gains on the sale of securities, and/or a return of paid-in-capital surplus which is a nontaxable distribution, if any) will be provided to our stockholders subject to information reporting. To the extent our taxable earnings fall below the total amount of our distributions for any taxable year, a portion of those distributions may be deemed a tax return of capital to our stockholders.

We expect to qualify to be subject to tax as a RIC under Subchapter M of the Code. In order to be subject to tax as a RIC, we are required to satisfy certain annual gross income and quarterly asset composition tests, as well as make distributions to our stockholders each taxable year treated as dividends for federal income tax purposes of an amount at least equal to 90% of the sum of our investment company taxable income, determined without regard to any deduction for dividends paid, plus our net tax-exempt income, if any. Upon being eligible to be subject to tax as a RIC, we would be entitled to deduct such distributions we pay to our stockholders in determining the overall components of our “taxable income.” Components of our taxable income include our taxable interest, dividend and fee income, reduced by certain deductions, as well as taxable net realized securities gains. Taxable income generally differs from net income for financial reporting purposes due to temporary and permanent differences in the recognition of income and expenses and generally excludes net unrealized appreciation or depreciation as such gains or losses are not included in taxable income until they are realized. In connection with maintaining our ability to be subject to tax as a RIC, among other things, we have made and intend to continue to make the requisite distributions to our stockholders each taxable year, which generally should relieve us from corporate-level U.S. federal income taxes.

As a RIC, we will be subject to a 4% nondeductible U.S. federal excise tax on certain undistributed income and gains unless we make distributions treated as dividends for U.S. federal income tax purposes in a timely manner to our stockholders in respect of each calendar year of an amount at least equal to the excise tax avoidance requirement. We will not be subject to this excise tax on any amount on which we incurred U.S. federal corporate income tax (such as the tax imposed on a RIC’s retained net capital gains).

Depending on the level of taxable income earned in a taxable year, we may choose to carry over taxable income in excess of current taxable year distributions treated as dividends for U.S. federal income tax purposes from such taxable income into the next taxable year and incur a 4% excise tax on such taxable income, as required. The maximum amount of excess taxable income that may be carried over for distribution in the next taxable year under the Code is the total amount of distributions treated as dividends for U.S. federal income tax purposes paid in the following taxable year, subject to certain declaration and payment guidelines. To the extent we choose to carry over taxable income into the next taxable year, distributions declared and paid by us in a taxable year may differ from our taxable income for that taxable year as such distributions may include the distribution of current taxable year taxable income, the distribution of prior taxable year taxable income carried over into and distributed in the current taxable year, or returns of capital.

We can offer no assurance that we will achieve results that will permit the payment of any cash distributions and, if we issue senior securities, we will be prohibited from making distributions if doing so causes us to fail to maintain the asset coverage ratios stipulated by the 1940 Act or if distributions are limited by the terms of any of our borrowings. Our ability to make distributions will be limited by the asset coverage requirements under the 1940 Act.

We intend to timely distribute to our stockholders substantially all of our annual taxable income for each year, except that we may retain certain net capital gains for reinvestment and, depending upon the level of taxable income earned in a year, we may choose to carry forward taxable income for distribution in the following year and pay any applicable U.S. federal excise tax.

The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, and disclosure of contingent assets and liabilities at the date of the consolidated financial statements, and revenues and expenses during the period reported. On an ongoing basis, our management evaluates its estimates and assumptions, which are based on historical experience and on various other assumptions that we believe to be reasonable under the circumstances. Actual results could differ from those estimates. Changes in our estimates and assumptions could materially impact our results of operations and financial condition.

The most significant estimate inherent in the preparation of our consolidated financial statements is the valuation of investments and the related amounts of unrealized appreciation and depreciation of investments recorded.

At September 30, 2020, approximately 96.7% of our total assets represented investments in portfolio companies whose fair value is determined in good faith by the Board of Directors. Value, as defined in Section 2(a)(41) of the 1940 Act, is (i) the market price for those securities for which a market quotation is readily available and (ii) for all other securities and assets, fair value is as determined in good faith by the Board of Directors. Our investments are carried at fair value in accordance with the 1940 Act and ASC Topic 946 and measured in accordance with ASC Topic 820. Our debt securities are primarily invested in venture capital-backed companies in technology-related industries including technology, drug discovery and development, biotechnology, life sciences, healthcare and sustainable and renewable technology at all stages of development. Given the nature of lending to these types of businesses, substantially all of our investments in these portfolio companies are considered Level 3 assets under ASC Topic 820 because there is no known or accessible market or market indexes for these investment securities to be traded or exchanged. As such, we value substantially all of our investments at fair value as determined in good faith pursuant to a consistent valuation policy by our Board of Directors in accordance with the provisions of ASC Topic 820 and the 1940 Act. Due to the inherent uncertainty in determining the fair value of investments that do not have a readily available market value, the fair value of our investments determined in good faith by our Board of Directors may differ significantly from the value that would have been used had a readily available market existed for such investments, and the differences could be material.

We intend to continue to engage one or more independent valuation firm(s) to provide us with valuation assistance regarding our determination of the fair value of selected portfolio investments each quarter unless directed by the Board of Directors to cancel such valuation services. Specifically, on a quarterly basis, we will identify portfolio investments with respect to which an independent valuation firm will assist in valuing. We select these portfolio investments based on a number of factors, including, but not limited to, the potential for material fluctuations in valuation results, credit quality and the time lapse since the last valuation of the portfolio investment by an independent valuation firm. The scope of the services rendered by an independent valuation firm is at the discretion of the Board of Directors. Our Board of Directors is ultimately, and solely, responsible for determining the fair value of our investments in good faith.

Refer to “Note 2 – Summary of Significant Accounting Policies” included in the notes to our consolidated financial statements appearing elsewhere in this report for a discussion of our valuation policies for the three and nine months ended September 30, 2020.

See “— Changes in Portfolio” for a discussion of our income recognition policies and results during the three and nine months ended September 30, 2020. See “— Results of Operations” for a comparison of investment income for the three and nine months ended September 30, 2020 and 2019.

We have issued and may, from time to time, issue stock options and restricted stock to employees under the 2018 Equity Incentive Plan and the Director Plan. We follow the guidelines set forth under ASC Topic 718 to account for stock options granted. Under ASC Topic 718, compensation expense associated with stock-based compensation is measured at the grant date based on the fair value of the award and is recognized over the vesting period. Determining the appropriate fair value model and calculating the fair value of stock-based awards at the grant date requires judgment, including estimating stock price volatility, forfeiture rate and expected option life.

Subsequent to September 30, 2020 and as of October 26, 2020, we sold 306,401 shares of common stock under the 2020 Equity Distribution Agreement. As of October 26, 2020, 16.2 million shares remain available for issuance and sale under the 2020 Equity Distribution Agreement.

On October 27, 2020, HT IV was licensed to operate as a SBIC under the SBA. This additional license has a 10-year term. We will gain access to $175.0 million of capital through the SBA debenture program, in addition to our regulatory capital contribution of $87.5 million to HT IV which will be used for investment purposes, subject to the issuance of a capital commitment by the SBA and customary procedures.

We continue to closely monitor the COVID-19 pandemic and its broader impact on both the U.S. and the global economy. As of October 29, 2020, there is no indication of a reportable subsequent event impacting our financial statements for the three and nine months ended September 30, 2020. We continue to observe and respond, if necessary, to the evolving COVID-19 environment and its potential impact on areas across our business. For more information, see “COVID-19 Developments”.

We are subject to financial market risks, including changes in interest rates. Interest rate risk is defined as the sensitivity of our current and future earnings to interest rate volatility, variability of spread relationships, the difference in re-pricing intervals between our assets and liabilities and the effect that interest rates may have on our cash flows. Changes in interest rates may affect both our cost of funding and our interest income from portfolio investments, cash and cash equivalents and idle fund investments. Our investment income will be affected by changes in various interest rates, including LIBOR and Prime rates, to the extent our debt investments include variable interest rates. As of September 30, 2020, approximately 97.9% of the loans in our portfolio had variable rates based on floating LIBOR or Prime rates with a floor. Our borrowings under the Credit Facilities bear interest at a floating rate and the borrowings under our SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, and 2022 Convertible Notes bear interest at a fixed rate. Changes in interest rates can also affect, among other things, our ability to acquire and originate loans and securities and the value of our investment portfolio.

Based on our Consolidated Statements of Assets and Liabilities as of September 30, 2020, the following table shows the approximate annualized increase (decrease) in components of net assets resulting from operations of hypothetical base rate changes in interest rates, assuming no changes in our investments and borrowings:

We do not currently engage in any hedging activities. However, we may, in the future, hedge against interest rate fluctuations (and foreign currency) by using standard hedging instruments such as futures, options, and forward contracts. While hedging activities may insulate us against changes in interest rates (and foreign currency), they may also limit our ability to participate in the benefits of lower interest rates with respect to our borrowed funds and higher interest rates with respect to our portfolio of investments. During the nine months ended September 30, 2020, we did not engage in interest rate or foreign currency hedging activities.

Although we believe that the foregoing analysis is indicative of our sensitivity to interest rate changes, it does not adjust for potential changes in the credit market, credit quality, size and composition of the assets in our portfolio. It also does not adjust for other business developments, including borrowings under our SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes and Credit Facilities that could affect the net increase in net assets resulting from operations, or net income. It also does not assume any repayments from borrowers. Accordingly, no assurances can be given that actual results would not differ materially from the statement above.

Because we currently borrow, and plan to borrow in the future, money to make investments, our net investment income is dependent upon the difference between the rate at which we borrow funds and the rate at which we invest the funds borrowed. Accordingly, there can be no assurance that a significant change in market interest rates will not have a material adverse effect on our net investment income. In periods of rising interest rates, our cost of funds would increase, which could reduce our net investment income if there is not a corresponding increase in interest income generated by variable rate assets in our investment portfolio.

For additional information regarding the interest rate associated with each of our SBA debentures, 2022 Notes, July 2024 Notes, February 2025 Notes, June 2025 Notes, 2025 Notes, 2033 Notes, 2027 Asset-Backed Notes, 2028 Asset-Backed Notes, 2022 Convertible Notes, and Credit Facilities, refer to Item 2 - “Management’s Discussion and Analysis of Financial Condition and Results of Operations - Financial Condition”, and Item 2 - “Financial Condition, Liquidity and Capital Resources” in this quarterly report on Form 10-Q and “Note 4 – Borrowings” included in the notes to our consolidated financial statements appearing elsewhere in this report.

Our chief executive and chief financial officers, under the supervision and with the participation of our management, conducted an evaluation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Securities Exchange Act of 1934, as amended. As of the end of the period covered by this quarterly report on Form 10-Q, our chief executive and chief financial officers have concluded that our disclosure controls and procedures were effective to ensure that information required to be disclosed by us in reports that we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in SEC rules and forms, and that information required to be disclosed by us in the reports that we file or submit under the Exchange Act is accumulated and communicated to our management, including our chief executive and chief financial officers, as appropriate to allow timely decisions regarding required disclosure.

There have been no changes in our internal control over financing reporting, as defined in Rules 13a-15(f) and 15d-15(f) under the Exchange Act that occurred during our most recently completed fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

We may, from time to time, be involved in litigation arising out of our operations in the normal course of business or otherwise. Furthermore, third parties may try to seek to impose liability on us in connection with the activities of our portfolio companies. While the outcome of any current legal proceedings cannot at this time be predicted with certainty, we do not expect any current matters will materially affect our financial condition or results of operations; however, there can be no assurance whether any pending legal proceedings will have a material adverse effect on our financial condition or results of operations in any future reporting period.

In addition to the risks discussed below, important risk factors that could cause results or events to differ from current expectations are described in Part I, Item 1A “Risk Factors” of the Company’s Annual Report on Form 10-K for the year ended December 31, 2019 filed with the SEC on February 20, 2020 (the “Annual Report”).

The effects of the outbreak of COVID-19 have negatively affected the global economy and the United States economy, and may disrupt our operations, which could have an adverse effect on our business, financial condition and results of operations.

The ongoing COVID-19 global and national health emergency has caused, and may continue to cause, significant disruption in the United States and global economies and financial markets. The spread of COVID-19 has caused quarantines, cancellation of events and travel, business and school shutdowns, reduction in business activity and financial transactions, labor shortages, supply chain interruptions and overall economic and financial market instability. The COVID-19 outbreak may disrupt our operations through its impact on our employees, our portfolio companies and their businesses, and certain industries in which our portfolio companies operate. Disruptions to our portfolio companies may impair their ability to fulfill their obligations to us and could result in increased risk of delinquencies, defaults, declining collateral values associated with our existing loans, and impairments or losses on our loans. Further, the spread of the COVID-19 outbreak has caused severe disruptions in the United States economy and may materially disrupt financial activity generally and in the areas in which we operate. This would likely result in a decline in demand for our loans which would negatively impact our liquidity position and our growth strategy. Any one or more of these developments could have a material adverse effect on our business, operations, consolidated financial condition, and consolidated results of operations. We are taking precautions to protect the safety and well-being of our employees. However, no assurance can be given that the steps being taken will be deemed to be adequate or appropriate, nor can we predict the level of disruption which will occur to our employees’ ability to service the portfolio.

The extent of the impact of the COVID-19 pandemic on our operational and financial performance, including our ability to execute our business strategies and initiatives in the expected time frame, will depend on future developments, including the duration and spread of the pandemic and related restrictions on travel and transportation, all of which are uncertain and cannot be predicted. Many public health experts have predicted that the COVID-19 pandemic will worsen in the fall and winter months as people in the U.S. spend more time indoors where the virus can spread more easily. An extended period of global supply chain and economic disruption could materially affect our business, results of operations, access to sources of liquidity and financial condition.

Our common stock price may be volatile or trade below its NAV per share, which may cause a decline in your investment or limit our ability to raise additional equity capital.

The stock markets have recently experienced extreme price and volume fluctuations that have affected and continue to affect the market prices of equity securities of many companies. These fluctuations often have been unrelated or disproportionate to the operating performance of those companies. These broad market and industry fluctuations, as well as general economic, political and market conditions such as recessions, interest rate changes or international currency fluctuations, may negatively impact the market price of shares of our common stock, regardless of our operating performance, and cause the value of your investment to decline.

If our common stock is trading below its NAV per share, we will generally not be able to issue additional shares of our common stock at its market price without first obtaining the approval for such issuance from our stockholders and our independent directors. We have received the approval from our stockholders to issue shares of our common stock at a price below its then current NAV per share, subject to certain limitations and with the approval of our independent directors. If our common stock trades below NAV, the higher cost of equity capital may result in it being unattractive to raise new equity, which may limit our ability to grow. The risk of trading below NAV is separate and distinct from the risk that our NAV per share may decline. We cannot predict whether shares of our common stock will trade above, at or below our NAV.

Additionally, in the past, companies that have experienced volatility in the market price of their stock have been subject to securities class action litigation or other derivative shareholder lawsuits. We may be the target of this type of litigation in the future. Securities litigation against us could result in substantial costs and divert our management’s attention from other business concerns, which could seriously harm our business regardless of the outcome.

If we sell common stock at a discount to our NAV per share, stockholders who do not participate in such sale will experience immediate dilution in an amount that may be material.

We have received the approval from our stockholders to issue shares of our common stock at a price below its then current NAV per share, subject to certain limitations and with the approval of our independent directors. The issuance or sale by us of shares of our common stock at a price per share, after offering expenses and commission, that is a discount to NAV poses a risk of dilution to our stockholders. In particular, stockholders who do not purchase additional shares at or below the discounted price in proportion to their current ownership will experience an immediate decrease in NAV per share (as well as in the aggregate NAV of their shares if they do not participate at all). These stockholders will also experience a disproportionately greater decrease in their participation in our earnings and assets and their voting power than the increase we experience in our assets, potential earning power and voting interests from such issuance or sale. In addition, such sales may adversely affect the price at which our common stock trades.

Our financial results could be negatively affected if a significant portfolio investment fails to perform as expected.

Our total investment in companies may be significant individually or in the aggregate. As a result, if a significant investment in one or more companies fails to perform as expected, our financial results could be more negatively affected and the magnitude of the loss could be more significant than if we had made smaller investments in more companies. The following table shows the fair value of the totals of investments held in portfolio companies at September 30, 2020 that represent greater than 5% of our net assets:

Our financial results could be materially adversely affected if these portfolio companies or any of our other significant portfolio companies encounter financial difficulty and fail to repay their obligations or to perform as expected.

During the nine months ended September 30, 2020, we issued 198,393 shares of common stock to stockholders in connection with the dividend reinvestment plan. These issuances were not subject to the registration requirements of the Securities Act. The aggregate value of the shares of our common stock issued under our dividend reinvestment plan was approximately $2.4 million.

Portfolio Company	Investment ⁽¹⁾	Amount of Interest Credited to Income⁽²⁾		Realized Gain (Loss)		As of December 31, 2019 Fair Value		Gross Additions ⁽³⁾		Gross Reductions⁽⁴⁾			Net Change in Unrealized Appreciation/ (Depreciation)			As of September 30, 2020 Fair Value
Control Investments
Majority Owned Control Investments
Gibraltar Business Capital, LLC ⁽⁷⁾	Unsecured Debt	$	1,683	$	—	$	14,780	$	43	$	—		$	124		$	14,947
	Preferred Stock		—		—		33,000		—		—			(3,293	)		29,707
	Common Stock		—		—		2,380		—		—			(237	)		2,143
Total Majority Owned Control Investments		$	1,683	$	—	$	50,160	$	43	$	—		$	(3,406	)	$	46,797
Other Control Investments
Tectura Corporation⁽⁵⁾	Senior Debt	$	434	$	—	$	9,586	$	—	$	(134	)	$	(1,157	)	$	8,295
	Preferred Stock		—		—		—		—		—			—			—
	Common Stock		—		—		—		—		—			—			—
Total Other Control Investments		$	434	$	—	$	9,586	$	—	$	(134	)	$	(1,157	)	$	8,295
Total Control Investments		$	2,117	$	—	$	59,746	$	43	$	(134	)	$	(4,563	)	$	55,092

Affiliate Investments
Optiscan BioMedical, Corp.	Convertible Debt	$	13	$	—	$	—	$	408	$	—		$	(408	)	$	—
	Preferred Warrants		—		—		209		—		—			(209	)		—
	Preferred Stock		—		—		8,984		—		—			(8,984	)		-
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.) ⁽⁶⁾	Senior Debt		596		—		12,615		—		—			(2,815	)		9,800
	Common Stock		—		—		—		—		—			—			—
Total Affiliate Investments		$	609	$	—	$	21,808	$	408	$	—		$	(12,416	)	$	9,800
Total Control and Affiliate Investments		$	2,726	$	—	$	81,554	$	451	$	(134	)	$	(16,979	)	$	64,892

Portfolio Company	Industry	Type of Investment ⁽¹⁾	Maturity Date	Interest Rate and Floor	Principal or Shares		Cost		Value ⁽²⁾
Control Investments
Majority Owned Control Investments
Gibraltar Business Capital, LLC	Diversified Financial Services	Unsecured Debt	March 2023	Interest rate FIXED 14.50%	$	15,000	$	14,823	$	14,947
	Diversified Financial Services	Preferred Series A Equity				10,602,752		26,122		29,707
	Diversified Financial Services	Common Stock				830,000		1,884		2,143
Total Gibraltar Business Capital, LLC							$	42,829	$	46,797
Total Majority Owned Control Investments (3.99%)*							$	42,829	$	46,797
Other Control Investments
Tectura Corporation	Internet Consumer & Business Services	Senior Secured Debt	June 2021	PIK Interest 5.00%	$	10,680	$	240	$	—
	Internet Consumer & Business Services	Senior Secured Debt	June 2021	Interest rate FIXED 8.25%	$	8,250		8,250		8,250
	Internet Consumer & Business Services	Senior Secured Debt	June 2021	PIK Interest 5.00%	$	13,023		13,023		45
	Internet Consumer & Business Services	Preferred Series BB Equity				1,000,000		—		—
	Internet Consumer & Business Services	Common Stock				414,994,863		900		—
Total Tectura Corporation							$	22,413	$	8,295
Total Other Control Investments (0.71%)*							$	22,413	$	8,295
Total Control Investments (4.70%)*							$	65,242	$	55,092

Affiliate Investments
Optiscan BioMedical, Corp.	Medical Devices & Equipment	Convertible Debt	July 2021	Interest rate FIXED 8.00%		408	$	408	$	—
	Medical Devices & Equipment	Preferred Series B Equity				61,855		3,000		—
	Medical Devices & Equipment	Preferred Series C Equity				19,273		655		—
	Medical Devices & Equipment	Preferred Series D Equity				551,038		5,257		—
	Medical Devices & Equipment	Preferred Series E Equity				507,103		4,240		—
	Medical Devices & Equipment	Preferred Series E Warrants				74,424		572		—
Total Optiscan BioMedical, Corp.							$	14,132	$	-
Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)	Sustainable and Renewable Technology	Senior Secured Debt	January 2021	Interest rate FIXED 6.48%, PIK Interest 6.48%, 6.67% Exit Fee	$	10,000	$	10,775	$	8,308
	Sustainable and Renewable Technology	Senior Secured Debt	January 2021	PIK Interest 10.00%	$	683		683		—
	Sustainable and Renewable Technology	Senior Secured Debt	January 2021	Interest rate FIXED 8.85%, PIK Interest 8.85%	$	1,492		1,492		1,492
	Sustainable and Renewable Technology	Common Stock				488		61,502		—
	Sustainable and Renewable Technology	Class A Warrants				1		—		—
Total Solar Spectrum Holdings LLC (p.k.a. Sungevity, Inc.)							$	74,452	$	9,800
Total Affiliate Investments (0.84%)*							$	88,584	$	9,800
Total Control and Affiliate Investments (5.53%)*							$	153,826	$	64,892

Pursuant to the requirements of the Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

Maryland		74-3113410
(State or Jurisdiction of Incorporation or Organization)		(IRS Employer Identification Number)
400 Hamilton Ave., Suite 310 Palo Alto, California (Address of Principal Executive Offices)		94301 (Zip Code)
		94301 (Zip Code)

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Shares, par value $0.001 per share	HTGC	New York Stock Exchange
5.25% Notes due 2025	HCXZ	New York Stock Exchange
6.25% Notes due 2033	HCXY	New York Stock Exchange

PART I. FINANCIAL INFORMATION		3
Item 1.	Consolidated Financial Statements	3
	Consolidated Statements of Assets and Liabilities as of September 30, 2020 and December 31, 2019 (unaudited)	3
	Consolidated Statements of Operations for the three and nine months ended September 30, 2020 and 2019 (unaudited)	5
	Consolidated Statements of Changes in Net Assets for the three and nine months ended September 30, 2020 and 2019 (unaudited)	6
	Consolidated Statements of Cash Flows for the nine months ended September 30, 2020 and 2019 (unaudited)	7
	Consolidated Schedule of Investments as of September 30, 2020 (unaudited)	9
	Consolidated Schedule of Investments as of December 31, 2019 (unaudited)	20
	Notes to Consolidated Financial Statements (unaudited)	30
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	64
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	83
Item 4.	Controls and Procedures	84
PART II. OTHER INFORMATION		85
Item 1.	Legal Proceedings	85
Item 1A.	Risk Factors	85
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	87
Item 3.	Defaults Upon Senior Securities	87
Item 4.	Mine Safety Disclosures	87
Item 5.	Other Information	87
Item 6.	Exhibits and Financial Statement Schedules	88
SIGNATURES		91

(in thousands) Issuance/Pooling Date	Maturity Date	Interest Rate ⁽¹⁾	September 30, 2020		December 31, 2019
September 22, 2010	September 1, 2020	3.50%	$	—	$	10,000
March 29, 2011	March 1, 2021	4.37%		—		28,750
September 21, 2011	September 1, 2021	3.16%		25,000		25,000
March 21, 2012	March 1, 2022	3.28%		25,000		25,000
March 21, 2012	March 1, 2022	3.05%		—		11,250
September 19, 2012	September 1, 2022	3.05%		24,250		24,250
March 27, 2013	March 1, 2023	3.16%		24,750		24,750
Total SBA Debentures			$	99,000	$	149,000

Large accelerated filer	☒	Accelerated filer	☐
Non-accelerated filer	☐	Smaller reporting company	☐
Emerging growth company	☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with a new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.			☐

(Dollars in thousands)	September 30, 2020		December 31, 2019
Assets
Restricted Cash		20,507	$	50,603
2027 Asset-Backed Notes, investments in securities, at value (cost of $300,671 and $283,891, respectively)		300,402		283,658
2028 Asset-Backed Notes, investments in securities, at value (cost of $364,022 and $347,295, respectively)		364,948		347,929
Total assets	$	685,857	$	682,190

Liabilities
2027 Asset-Backed Notes, net (principal of $200,000 and $200,000, respectively)⁽¹⁾	$	197,521	$	197,312
2028 Asset-Backed Notes, net (principal of $250,000 and $250,000, respectively) ⁽¹⁾		247,579		247,395
Total liabilities	$	445,100	$	444,707

(in thousands)
Portfolio Company	Unfunded Commitments ⁽¹⁾
Chemocentryx, Inc.	$	35,000
The Wing		30,000
memsql, Inc.		25,000
Bicycle Therapeutics PLC		15,000
Udacity, Inc.		15,000
Eidos Therapeutics, Inc.		11,250
Axsome Therapeutics, Inc.		10,000
Antares Pharma Inc.		10,000
G1 Therapeutics, Inc.		10,000
Replimune Group, Inc.		10,000
Dashlane, Inc.		9,700
Clarabridge, Inc.		7,500
Geron Corporation		6,500
Businessolver.com, Inc.		6,375
3GTMS, LLC.		5,036
CloudBolt Software Inc.		5,000
Albireo Pharma, Inc.		5,000
Nuvolo Technologies Corporation		5,000
Nextroll, Inc.		5,000
Reltio, Inc.		5,000
Campaign Monitor Limited		2,979
Varsity Tutors LLC		2,000
ThreatConnect, Inc.		1,800
Greenphire, Inc.		1,280
Ikon Science Limited		1,050
The CM Group LLC		750
Yipit, LLC		425
Mobile Solutions Services		367
ePayPolicy Holdings, LLC		250
Cytracom Holdings LLC		250
Total	$	242,512

	Payments due by period (in thousands)
Contractual Obligations ⁽¹⁾	Total		Less than 1 year		1 - 3 years		3 - 5 years		After 5 years
Borrowings ⁽²⁾⁽³⁾	$	1,306,492	$	25,000	$	454,000	$	337,492	$	490,000
Lease and License Obligations ⁽⁴⁾		11,135		3,000		5,776		1,581		778
Total	$	1,317,627	$	28,000	$	459,776	$	339,073	$	490,778

(in thousands)	Three Months Ended September 30, 2020		Nine Months Ended September 30, 2020
Total operating lease cost	$	735	$	2,205
Cash paid for amounts included in the measurement of lease liabilities	$	562	$	2,223

	As of September 30, 2020
Weighted-average remaining lease term (in years)		4.28
Weighted-average discount rate		5.45	%

(in thousands)
Remainder of 2020	$	573
2021		2,903
2022		3,002
2023		2,293
2024		693
Thereafter		1,511
Total lease payments		10,975
Less: imputed interest		(1,222	)
Total operating lease liability	$	9,753

(in millions)	September 30, 2020		December 31, 2019
Debt Commitments ⁽¹⁾
New portfolio company	$	744.5	$	1,101.3
Existing portfolio company		290.8		355.8
Total	$	1,035.3	$	1,457.1
Funded and Restructured Debt Investments⁽²⁾
New portfolio company	$	348.0	$	640.6
Existing portfolio company		281.4		367.3
Total	$	629.4	$	1,007.9
Funded Equity Investments
New portfolio company	$	—	$	6.1
Existing portfolio company		2.0		11.7
Total	$	2.0	$	17.8
Unfunded Contractual Commitments ⁽³⁾
Total	$	242.5	$	133.7
Non-Binding Term Sheets
New portfolio company	$	77.5	$	50.0
Existing portfolio company		20.4		144.0
Total	$	97.9	$	194.0

	September 30, 2020
(in thousands)	Fair Value		Percentage of Net Assets
BridgeBio Pharma LLC	$	84,861		7.2	%
EverFi, Inc.		83,753		7.1	%
Tricida, Inc.		78,508		6.7	%
Businessolver.com, Inc.		65,397		5.6	%
Delphix Corp.		61,131		5.2	%
Paratek Pharmaceuticals, Inc.		60,802		5.2	%
SeatGeek, Inc.		58,680		5.0	%

Exhibit Number	Description

10.1	Equity Distribution Agreement, dated July 2, 2020, between Hercules Capital, Inc. and JMP Securities, LLC.⁽¹⁾

31.1*	Chief Executive Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

31.2*	Chief Financial Officer Certification Pursuant to Exchange Act Rule 13a-14(a), as adopted pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.

32.1*	Chief Executive Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

32.2*	Chief Financial Officer Certification pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

		HERCULES CAPITAL, INC. (Registrant)

Dated: October 29, 2020		/S/ SCOTT BLUESTEIN
		Scott Bluestein
		President, Chief Executive Officer, and Chief Investment Officer

Dated: October 29, 2020		/S/ SETH H. MEYER
		Seth H. Meyer
		Chief Financial Officer, and Chief Accounting Officer